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 ABSTRACT 
  
Numerous pharmaceutical solid dosage form manufacturing techniques have emerged over 
the years and among them, 3D-Printing (3DP) has emerged as a highly attractive and 
versatile approach. 3DP is a cutting edge technology set to expand and revolutionize tablet 
manufacturing among various other applications in industry. The study reported in this thesis 
focuses on developing a humic acid-polyquaternium-10 (HA-PQ10) 3D-Printable ink for the 
delivery of three anti-HIV bioactives, efavirenz (EFV), tenofovir (TDF) and emtricitabine 
(FTC). HA was strategically employed based on its capability of entrapping both hydrophilic 
and hydrophobic drugs. PQ10 contributed towards the system’s swellability in aqueous 
media. The HA-PQ10 PEC was responsible for retarding drug release therefore it behaved 
as a drug reservoir. Validation of HA-PQ10 complexation was carried out by synthesizing the 
HA-PQ10 polyelectrolyte complex (PEC) in aqueous media at pH 6, 7 and 8. The 
complexation yielded fibrilla and porous PECs. The PEC formation was attributed to ionic 
interactions between the quaternary ammonium centres (PQ10) and carboxylic groups (HA). 
The PECs were determined to be amorphous in nature and exhibited good biocompatibility 
when tested for cytotoxicity in human adenocarcinoma cell line (Caco2). The model drug, 
efavirenz (EFV) was loaded into HA-PQ10 using the complexation-precipitation (C-P) 
technique. The resultant EFV-loaded HA-PQ10 was compared to benchtop extrudates 
manufactured using the extrusion-spheronization (E-S) process.  Assessment of the EFV 
saturation solubility and intestinal permeability showed EFV solubility and permeability 
enhancement of 14.14±2.81% and 61.24±6.92% respectively. The properties were 
compared to those of a marketed comparator product. Loading RTV into the optimized HA-
PQ10 further validated the solubility and permeability enhancing properties in the BCS class 
IV drug as well. The extrudates performed superiorly compared to the formulation 
synthesized by C-P. The E-S technique was utilized to optimize HA-PQ10 based on drug 
release and intestinal permeation enhancement. The optimal HA-PQ10 was employed for 
3DP of EFV-loaded HA-PQ10 into an oral tablet formulation. It was imperative to add 
cellulose acetate phthalate (CAP) to enhance the 3D-Printability of the HA-PQ10. CAP made 
the synthesized delivery system pH responsive and drug release results showed that most of 
the release occurred under intestinal conditions. The EFV-loaded 3DP tablet was compared 
to a tablet synthesized by direct compression. 3DP was more porous, less dense and more 
swellable than the direct compression tablet. These remarkable differences were attributed 
to the tableting method. 3DP leads to the formation of solid bridges between particles as the 
sludge (ink) undergoes extrusion and drying process. The direct compression technique 
involves axial powder compaction at high pressures which force particles to interact through 
Van der Waals forces or hydrogen bond formation. High drug loading of EFV was achieved 
and the tablet was further optimized to manufacture the ‘controlled release tritherapeutic 
tablet’, CRTT, a fixed dose combination (FDC) consisting of EFV, TDF and FTC. In vivo 
studies were conducted in large white pigs and CRTT absorption was compared to a 
marketed FDC, Atripla®. There was sustained release of EFV, TDF and FTC from CRTT 
and this was validated by the long residence times determined from pharmacokinetic 
analysis. EFV was maintained within the therapeutic index of the drug during the 24 hour 
study. Through this study, 3DP proved to be a technology with potential for manufacturing 
novel formulations. As more research is underway in the 3DP field, it can only be 
appreciated that its scope of use will continue to grow and restructure pharmaceutical 
manufacturing processes. 
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CHAPTER 1  
 
INTRODUCTION AND MOTIVATION FOR THE STUDY 
  
1.1. BACKGROUND TO THE STUDY 
Polyelectrolyte complexes (PECs) are increasingly being used to advance drug delivery. 
Their significant swellability in aqueous medium provides controlled drug release. PECs are 
formed by strong, but reversible ionic interactions between a cationic and anionic polymer 
(Lankalapalli and Kolapalli, 2009). Formation of PECs and their stability is determined by 
factors such as the polymer concentration, molecular weight, mixing ratio, nature of ionic 
groups, as well as temperature and pH of the reaction medium. The mechanism of drug 
release from PECs encompasses solution equilibration, ion exchange, charge interaction, 
gradual decomplexation or breakdown and dissolution (Moustafine et al., 2008). The benefits 
of using PECs include protection of the drug from degradation in the gastrointestinal tract 
(GIT), reduced frequency of dosing due to controlled drug release, improved bioavailability of 
poorly soluble drugs and a subsequent reduction of both drug toxicity and side-effects. 
Controlled release of drug provides a steady plasma drug concentration which is essential to 
patients, reducing frequency of dosing improving patient compliance with least drug related 
toxicity.   
 
Various polymers have been used to date, to manipulate the release kinetics of drug-loaded 
systems. However, it is more prudent to use PECs to achieve this since the properties of 
PECs have greater advantage over those of native polymers. For example, with a chitosan 
and polyacrylic acid (Carbopol®) complex, the presence of ammonium ion in the chitosan 
enables the formation of a PEC. Polyacrylic acid has limited use as a controlled release 
polymer due to its sensitivity to ionic environments and high water solubility while chitosan 
has rapid gastric acid dissolution. These challenges can be resolved when two polymers are 
combined to form a PEC (Sabar et al., 2011). Polymeric drug delivery systems also prevent 
the crystallization of drugs within their matrices. This property is particularly essential for 
solid dispersions where the amorphous form of the drug is liable to recrystallization over 
time, thus reducing the solubility of the drug (Qian and Bogner, 2012). 
 
PECs may be synthesised by the titration method. However, the main drawback is the 
dilution of the solution into which the other polymer is titrated, therefore changing the 
concentration of the solution. Another method that has been used is jet mixing where the jet 
mixer generates two opposing jets which collide in a mixing chamber at high velocity and 
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pressure resulting in brief mixing times (Ankerfors et al., 2010). Drug-loaded PECs can also 
be prepared by extrusion where pressure and agitation are applied that mixes the materials 
by forcing them through a die (Wilson and Williams, 2012).  This process has been used to 
improve the solubility of drugs through the formation of amorphous or crystalline dispersions. 
After extrusion, drug particle size is reduced which leads to faster dissolution rate. Extrusion 
can also be combined with heating, resulting in melt extrusion technique (Shah et al., 2012).  
 
The solvent evaporation method is a highly attractive method employed for preparing drug-
loaded solid dispersions. The drug and polymers are dissolved in a common solvent which is 
then evaporated leaving a homogenous solid dispersion of the drug in the polymeric matrix. 
Allowing the continuous evaporation of the common solvent, maximizes the drug loading 
efficiency due to the elimination of drug-solvent interaction which could be stronger than 
drug-polymer interaction (Preisig et al., 2014). This method has successfully been used to 
synthesize PECs due to the ionization of individual polymers in the selected common solvent 
(Yusif et al., 2014; Zhao et al., 2011). 
 
The Biopharmaceutics Classification System (BCS) is used to classify drugs based on their 
aqueous solubility and intestinal permeability. It is used to set drug product dissolution 
standards so as to determine any in vitro-in vivo correlations (IVIVC).  Class I drugs have 
high solubility and permeability, class II drugs exhibit low solubility and high permeability, 
class III drugs exhibit high solubility but poor permeability while class IV drugs have both 
poor solubility and permeability (FDA, 2000). Examples of drugs within this class (class IV) 
include anti-HIV drugs, specifically protease inhibitors (PIs) and non-nucleoside reverse 
transcriptase inhibitors (NNRTIs) (Breckenridge, 2005). Some of the novel drug delivery 
approaches developed to improve the delivery of BCS class II and IV anti-HIV drugs are 
slow release, bio-adhesive and enteric coated systems (Ojewole et al., 2008).  
 
This study utilized the PEC system that enhances the solubility and permeability of drugs to 
synthesize a 3D-Printed (3DP) tablet containing a fixed dose combination (FDC) of anti-HIV 
drugs with the aid of 3D Bioplotter® (EnvisionTEC GmbH, Gladbeck, Germany). FDCs are 
one of the contemporary principal ways that have been implemented to simplify as well as to 
improve the effectiveness of anti-HIV regimens. FDCs offer advantages such as improved 
patient compliance to medication, lower medication costs, the circumvention of inaccurate 
dosing by patients, and reduced risks of side-effects (Chrysant, 2008). Application of the 
humic acid/ polyquaternium-10 polyelectrolyte complex (HA-PQ10 PEC) will be extended to 
drugs falling within any BCS class. 
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3DP is a recent revolutionary and advanced rapid prototyping technique which is highly 
beneficial to the pharmaceutical industry. It produces solid three dimensional objects such as 
tablets of any shape using additive layer manufacturing instructed by computer aided design 
(CAD) (Goyanes et al., 2015; Wu et al., 2009). Drawing on this technology leads to 
simplified, yet improved quality of drug formulations that are manufactured at increased 
speed and lower costs. Figure 1.1 depicts the manufacture of a 3DP tablet using an 
extrusion based 3D-Bioplotter®. 
 
 
Figure 1.1: Schematic representation of 3DP process 
 
1.2. RATIONALE AND MOTIVATION FOR THE STUDY 
FDC drugs presently available have eliminated the pill burden associated with the oral 
administration of anti-HIV drugs (Nachega et al., 2014). However, there are still challenges 
associated with these drugs, and these include: 1) the drugs in the FDC which fall in BCS 
class II, III and IV exhibit poor bioavailability due to poor solubility and/or permeability, 2) 
patients experience difficulties in swallowing the single dose tablet due to the size of the 
formulation, 3) formulations with ideal solubility and permeability properties (BCS class I 
drugs) still present with short half-lives and require multiple daily dosing and 4) there is 
3DP tablet manufacture by sludge extrusion from cartridge onto the 
build platform
Compressed air
Polyethylene cartridge
Injection nozzle
3DP tablet
Printing ‘ink’
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degradation and less than optimal absorption of the anti-HIV drugs exposed to the gastric 
environment. The complexation-precipitation and extrusion-spheronization methods were 
utilized to synthesize the drug-loaded HA-PQ10 complex. However, a feasible technique 
which further reduced the unnecessary use of excipients and yet maintained enhanced drug 
solubility and permeation while supporting the use of natural polymers had to be 
implemented hence the use of the 3D Bioplotter®. The 3D Controlled Release Tritherapeutic 
Tablet (3D-CRTT) led to the fabrication of a novel system with the following applications: 
 Effective delivery of drugs with poor solubility and poor permeability and therefore 
increasing their bioavailability. 
 Effective treatment of chronic conditions such as HIV where reduced dosing frequency 
encourages patient compliance. 
 Formulation of multiple drugs into one delivery system. 
 Lowering the pill burden by combining a multi-drug regimen into an FDC. 
 Effective delivery of drugs, regardless of BCS classification which leads to reduced 
toxicity due to the administration of lower drug concentrations in vivo. 
 Facilitating the stability of solid dispersions. 
 Site-specific delivery of gastro-sensitive drugs including proteins and peptides. 
 Fabrication of a delivery system that will provide sustained drug release; this is beneficial 
in preventing subtherapeutic drug levels as well as toxicity from drugs with a narrow 
therapeutic index. 
 
Two polymers of opposite net charges were utilized to fabricate a PEC in order to investigate 
the possibility of superior controlled release of the drug molecules. It was imperative to 
select polymers that would improve drug wettability therefore increasing drug solubility 
(Conte et al., 2005; Hossel et al., 2000). Both hydrophilic and hydrophobic drugs were 
loaded into the novel complex due to the presence of a hydrophilic PQ10 and amphiphilic 
HA. Entrapment of the drugs would occur in the hydrophobic core of HA. PQ10, being more 
hydrophilic attracted more fluid to the system therefore creating a microenvironment that 
enhanced the solubility of the molecularly dispersed drugs. Entrapment of the drugs in the 
aromatic core of HA would improve their permeation across the pig intestinal tissue when 
undertaking animal studies.  
 
3DP of HA-PQ10 targeted at designing a delivery system which would successfully 
encapsulate drugs from all the BCS classes. The extended release of BCS class III drugs is 
a challenge due to poor permeability (Chakraborti et al., 2014). Unlike conventional methods 
which offer a singular drug release profile, 3DP allows for the formulation of various 
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polymeric systems with sophisticated and reproducible drug release profiles with the benefit 
of reduced risk of inter-subject variation. It offers flexible tabletting with customized shapes 
according to the desired design making it ideal for purposes such as chronotherapy. Precise 
location, distribution and dosage of the desired drug can be achieved. 3DP facilitates the 
synthesis of a multilayered formulation which is resistant to delamination. The production 
steps can be consolidated into one technique and enteric polymers included into the outer 
layer of the tablet eliminating procedures such as coating (Yu et al., 2008). The novel 
aspects of this study are as follows: 
1. The system was formulated using a novel polyelectrolyte complex of two natural and 
cost-effective polymers. 
2. Drug-loaded HA-PQ10 PEC has proven its effectiveness in enhancing aqueous solubility 
and intestinal permeability of BCS class II and IV drugs. The PECs will cause the same 
effect on drugs in BCS class I and III.  
3. The use of heat is not necessary with the bioplotter. This makes it possible to synthesize 
delivery systems with HA-PQ10 PEC which are natural polymers. These polymers melt 
at very high temperatures and are unsuitable for methods requiring heat. Thermolabile 
drugs may be safely formulated. 
4. Utilizing the unique pharmacotechnical properties of 3DP will allow for the formulation of 
an FDC, regardless of drug compatibilities, with each drug loaded into a separate layer. 
An FDC that will be explored includes tenofovir (BCS class III) /emtricitabine (BCS class 
I)/ efavirenz (BCS class II).  
5. An additional polymer, cellulose acetate phthalate (CAP) was included to facilitate the 
3DP process. This thermoplastic and enteric polymer has good mechanical compatibility 
with natural polymers.  
6. Incorporating a ‘smart’ polymer such as CAP served the purpose of making a viscous 
binder paste of the materials for printing. The polymer facilitates gastroprotection and 
enteric release of the drugs. 
7. The tablet mainly released the drugs in the small intestine, the largest portion for 
effective drug absorption. 
 
1.3. OUTLINE OF THE SYSTEM 
The anti-HIV drugs, EFV, TDF and FTC were combined into an FDC and formulated as a 
3DP tablet. Figure 1.2 depicts the mechanism of action of CRTT. This was achieved by 
synthesizing a sludge which made the drug-loaded HA-PQ10 PEC 3D-Printable. The sludge 
was a smooth homogenous consistency capable of being extruded out of the sample holder. 
The optimized tablet shape and design took into consideration the loading capacity of the 
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drugs encapsulated and the ability to contain pores for ease of significant fluid ingress. The 
3DP tablet remained structurally intact with minimal swelling and drug release in gastric 
conditions. This property was attributed to the inclusion of a smart polymer, CAP which is an 
enteric polymer. Drugs were protected from gastric degradation and most of the release 
occurred in the small intestine, the site for maximum absorption. Once the system reached 
the small intestine, CAP allowed more fluid into the system hence increasing wettability of 
drugs and leading to increase in solubility and consequently enhancing drug bioavailability. 
Use of HA-PQ10 PEC ensured that the drugs are released in a controlled manner, a highly 
attractive feature for drugs falling in BCS class I and class III. The selected polymers, HA 
and PQ10 contributed to enhancing the bioavailability by increasing the permeability of the 
drugs.  
                       
      
 
 
 
 
Figure 1.2: Schematic depicting the behaviour of CRTT in gastric and intestinal 
environments  
 
1.4. AIM AND OBJECTIVES OF THE STUDY 
The aim of this study was to develop a 3DP Controlled Release Tritherapeutic Tablet (3D-
CRTT), synthesized with a novel polyelectrolyte complex to achieve programmed and 
targeted enteric release of an anti-HIV FDC over 24 hours. The system was capable of 
extending the stability of the drugs embodied in the solid dispersions and enhancing their 
bioavailability as an FDC. 
Objectives achieved: 
METCT remains intact with minimal
swelling and drug release GI fluid
Stomach (pH 1.2) Small intestine (pH 6.8)
CAP immediately absorbs SIF 
and causes CRTT to swell 
Intestinal fluid ingress followed by slow and
sustained release of EFV, TDF and FTC from
CRTT
Mechanism of action of CRTT: CRTT will pass through the stomach intact due to gastroprotection 
from the pH-sensitive CAP. Increase in pH as the tablet enters the small intestine leads to more 
intestinal fluid entering the tablet and causing swelling. Efavirenz (EFV), tenofovir (TDF) and 
emtricitabine (FTC) will simultaneously be gradually released from the drug-loaded HA-PQ10. The 
presence of pores included in the tablet design will lead to greater contact of the delivery system 
with enteric fluid. 
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1. Determination of the elemental composition of the individual polymers and the PECs. 
The complex was expected to contain elements from both polymers; however, the 
complexation process was affected by the pH of the surrounding medium with alkaline 
media being the ideal one for complexation. Implementation of 3DP for formulating 
CRTT provided for exposure of the PEC in enteric fluid. 
2. Validation of the complexation process by determining dissolution of the complexes in 
various solvents. Stoichiometric PECs do not easily dissolve in solvents therefore the 
different types of solvents were tested to validate that a stoichiometric PEC had been 
synthesized. 
3. Selection of appropriate polymers (HA and PQ10) of opposite charges that could form a 
polyelectrolyte complex as well enhance the solubility and permeability of drugs. 
4. Determination of an ideal technique for synthesizing the FDC. Different methods of 
fabricating a drug-loaded PEC were explored such as complexation-precipitation 
technique and benchtop extrusion-spheronization. 3DP emerged superior to all these 
methods and was therefore utilized to formulate the FDC. 
5. Determination of appropriate thermoplastic polymer and solvents as well their quantities 
to be used as the 3D-Printable biomaterial. Ideal parameters such as speed and 
pressure of extrusion were determined. 
6. Design of CRTT shape and dimensions considering doses of the three drugs as well as 
desired release pattern. 
7. Characterization of the 3DP tablets employing tests such as the determination of 
electrostatic interactions (FTIR), mechanical tensile strength (BioTester), Magnetic 
Resonance Imaging (MRI), surface morphological properties (SEM), thermal and 
thermodynamic properties (DSC and TGA), tablet hardness (Textural profiling),  and 
presence and quantity of pores on tablets (Porosity analysis).  
8. Conduction of in vitro drug release studies in biorelevant media to assess the controlled 
release behaviour of HA-PQ10 PEC. 
9. Undertaking in vivo studies using a pig model to ascertain the pharmacokinetic and 
pharmacodynamic properties of the drug delivery system. 
10. Ascertaining in vitro-in vivo (IVIVC) correlation of the drug release profiles utilizing 
statistical analysis to determine the predictable release characteristics of HA-PQ10.  
 
1.5. OVERVIEW OF THESIS 
Chapter One of this thesis highlights the background of the study and rationale. The aim 
and objectives of the study are discussed in detail. 
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Chapter Two is a detailed literature review of the synthesis and applications of 
polyelectrolyte complexes (PECs) in drug delivery. The review provides a background to 
classification of PECs and an insight to common methods and polymers used in their 
synthesis. The advantages and disadvantages of utilizing these methods are also 
highlighted. There is an in-depth explanation of the formation of PECs and important factors 
that should be present for this process to take place. The mechanism of drug release and 
bioavailability enhancing techniques of PECs are further highlighted. 
 
Chapter Three is a preformulation study focussing on the validation of complexation 
between humic acid and polyquaternium-10. The complexation-precipitation method is 
discussed with reference to the concentrations of the polymers required for stoichiometric 
complexation. The biocompatibility of the system was ascertained using Caco2 cell line. 
Drug release evaluation of the PEC was tested utilizing efavirenz as a model drug. 
 
Chapter Four explores another complexation technique, the benchtop extrusion-
spheronization. The outcome from the extrusion process was compared to the complexation-
precipitation method. The extrusion method gave superior results and was selected for 
optimization implementing a Box-Benkehn design of experiments (DoE). 
 
Chapter Five outlines procedures undertaken for synthesis of 3DP HA-PQ10 tablet. This 
chapter emphasizes on various parameters for EFV-loaded HA-PQ10 3DP. A list of 
unsuccessful formulations is also provided. The 3DP tablets are further compared to tablets 
synthesized by a traditional method, direct compression to ascertain any need for 3DP. The 
superior nature of 3DP is discussed. 
 
Chapter Six underscores the design and fabrication of the fixed dose combination.  This 
chapter provides a prediction of the mechanical properties of the tablet in vivo. The in vitro 
performance of the tablet in comparison to a similar commercial product is also discussed. 
 
Chapter Seven focusses on the in vivo study of CRTT in comparison to a marketed FDC 
with the same drug combination. A pig model was selected for this study describing 
pharmacokinetic and pharmacodynamic properties of the CRTT. Pharmacokinetic modelling 
analysis and (IVIVC) correlation of the results are further provided in this chapter. 
 
Chapter Eight is a conclusion to the study. Future recommendations based on findings of 
this study are highlighted. 
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CHAPTER 2  
 
A REVIEW: OVERVIEW OF NOVEL POLYELECTROLYTE COMPLEXES AS 
PROSPECTIVE DRUG BIOAVAILABILITY ENHANCERS 
  
2.1. INTRODUCTION 
Polymeric materials which are sensitive to specific conditions such pH, temperature, 
magnetic and electric fields have become highly attractive in the field of drug delivery 
(Liechty and Kryscio, 2010; Torchilin 2009). These transitions are primarily due to the 
alterations in the charged groups by the interaction of oppositely charged polymers, changes 
in the efficiency of hydrogen bonding at higher temperature or ionic strength, etc., and they 
lead to the development of a new pharmaceutical platform with improved physico-chemical 
properties. The interaction of two oppositely charged polymers leads to the formation of a 
complex system, generally called a polyelectrolyte complex (PEC).  
  
In PEC formation, strong electrostatic attractions occur without the aid of reaction initiators, 
catalysts or crosslinkers. The elimination of these additives renders most PECs non-toxic 
and easy to make and this lowers the cost in research and development of drug formulations 
(Lee et al., 1999). Furthermore, some polymers cannot be effectively used for drug delivery 
unless they form a complex. For example, the use of a polyacrylic acid matrix usually results 
in immediate drug release and this property is attributed to its sensitivity to ionic 
environments and high water solubility. Chitosan is another polymer which has fast gastric 
acid dissolution. However, these challenges are resolved when the two polymers form a 
PEC. The presence of the positively charged ammonium ions in chitosan facilitates the 
formation of the PEC (Sabar et al., 2011; Chen et al., 2010; Risbud et al., 2000). 
 
In recent years, polyelectrolyte complexes have obtained considerable attention in the field 
of drug delivery because of their biocompatibility, biodegradability and their ability to improve 
the bioavailability of the active molecule (Heinen et al., 2013). In situ, PECs are hydrogel in 
nature and this property closely resembles biological tissue hence their safety in vivo (Chang 
et al., 2014; Calija et al., 2013). Plasma drug concentrations can be increased thereby 
improving the cost–effectiveness of drugs and it will also become possible to administer 
lower doses of drugs (Thanou et al., 2001).  
 
There are various types of polyelectrolyte complexes such as, but are not limited to, 
polymer-polymer, polymer-drug, polymer-drug-polymer and polymer-protein complexes 
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(Petzold and Simona, 2014). In order to form the complex, one component has to be 
positively charged while the other is negatively charged. PECs are generally classified based 
on origin, composition and molecular architecture as shown in Figure 2.1 (Lankalapalli and 
Kolapalli, 2009).  
 
 
Figure 2.1: Classification of polyelectrolyte complexes based on molecular architecture, 
composition and origin 
 
Polymer-drug together with polymer-drug-polymer complexes have been used to improve 
the encapsulation efficiency of drugs as well as to control the rate of drug release due to the 
bonds that form between the polymer and the drug (Cheow and Hadinoto, 2012). High 
encapsulation efficiency will lower the amount of excipients required in a formulation. 
Polymers are being widely used in drug delivery since they can achieve drug delivery at the 
intended site thus reducing unwanted side effects (Soppimath et al., 2001). On the other 
hand, proteins can form strong electrostatic bonds with polymers regardless of their 
isoelectric point and they form either soluble, insoluble or amorphous complexes (Vries et 
al., 2003). These complexes are useful for purposes such as protein separation, 
immobilization or enzyme stabilization (Xu et al., 2011). 
 
The aim of this review is to report on the vast research in literature that has been carried out 
and which centres on PECs formed by means of self-assembly between oppositely charged 
polymers and their contribution towards enhancing the bioavailability of drugs. The specific 
mechanism of drug release by PECs will also be highlighted. An increase in the amount of 
drug reaching the systemic circulation in systems utilizing PECs has been noted and this 
article seeks to clarify whether this increase is entirely as a result of encapsulating the drug 
in PECs or whether it is also due to any other mechanisms present in the system.  
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2.1.1. Polymeric polyelectrolyte complexes 
PECs generally present with the advantage of combining unique physicochemical properties 
from the polymers involved and this property attributes to their novelty. Consequently, they 
form delivery systems with gradual drug release and good swelling capacity (Argin-Soysal et 
al., 2009). It has been stipulated that the high pH-sensitive swelling of PECs renders them 
applicable for oral drug delivery (Li et al., 2013). Polymeric PECs have biomedical 
applications as powders, membranes, sponges, spheres, fibers, gels or in solution 
depending on their intended use (Bernabe et al., 2005).  
 
2.2. METHODS OF SYNTHESIS OF POLYMERIC POLYELECTROLYTE COMPLEXES 
2.2.1. The solution method 
This is a widely used method of PEC synthesis where the polymers are completely dissolved 
in solvents or water before they are mixed together. In most cases, water is the solvent of 
choice and minimizing the use of organic solvents gives impetus for using PECs in 
pharmaceutical industries. The polymers have to be charged in order to facilitate PEC 
formation which occurs by the electrostatic interaction between oppositely charged polyions 
in solution. Incorporation of the drug into a PEC may occur by one of the following ways: 
 
1) Adding the drug as the PEC precipitates out of the solution 
2) Addition of the drug into the PEC that has already formed 
3) Addition of the drug to either of the polymers with the same charge before the PEC 
forms (Lankalapalli and Kolapalli, 2009). 
 
Drug entrapment is influenced by the polymer ratios or whether the resulting PEC is loosely 
or tightly clustered (Vries et al., 2003). Figure 2.2 below illustrates how an active 
pharmaceutical ingredient (API) can be incorporated into a PEC. The PEC can be solubilized 
by the presence of an electrolyte (sodium chloride) in solution. 
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Figure 2.2: Schematic representation of drug loading in a PEC and instability as a result of 
the presence of electrolytes (Kindermann et al., 2011) 
 
2.2.2. Melt extrusion  
Melt extrusion involves the use of an extruder that melts and mixes the polymers and 
excipients together using heat, pressure and agitation. This mixture is then forced out 
through a die in the form of soft rods. The drug, polymers and other excipients are mixed 
physically before being loaded into the extruder. This is illustrated in Figures 2.3(a) and (b) 
below. This method does not require the use of solvents to make the complexes containing 
the drug. The drug is molecularly dispersed within the polymers and this leads to the 
enhancement of its solubilization since the crystal lattice does not need to be broken 
(Kindermann 2012; Vasconcelos et al., 2007). Miscibility of the drug with the polymers 
determines the extent of the formation of intermolecular interactions. It has been noted that 
the melt extrusion process leads to an increase in the bioavailability of drugs since it forms 
amorphous and stable solid dispersions of the drug within a polymer matrix. Controlled 
release together with improved solubility of the drug can be achieved (Janssens and Van 
den Mooter, 2009). 
 
2.2.3. Layer-by-layer self-assembly  
With this method, successive layers of cationic and anionic polymers are deposited onto a 
solid substrate such as silica particles (Mihai et al., 2013). The multilayers are therefore 
stabilized by the electrostatic forces in the PEC. Charged compounds such as drugs and 
proteins can be incorporated in the multilayers which are amorphous in nature. Antunes and 
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co-workers (2011) successfully demonstrated formation of the PEC of chitosan and poly (γ-
glutamic acid) by layer-by-layer assembly (Figure 2.3(c)). 
 
 
Figure 2.3: Schematic representation of a) PEC formation in solution from oppositely 
charged polymers b) Melt extrusion and c) Layer-by- layer self-assembly 
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Based on the description of the methods given above, Table 2.1 below highlights the 
advantages and disadvantages of implementing these methods for PEC synthesis. 
 
Table 2.1: Advantages and disadvantages of the methods of polyelectrolyte complex 
synthesis 
Method of synthesis Advantage  Disadvantage  
Solution  Ease of synthesis and collection 
due to the PEC precipitating out 
immediately after formation 
(Lankalapalli and Kolapalli, 2009; 
Vries et al., 2003). 
 
Some of the polymers and 
drug are lost in supernatant 
solution during synthesis 
(Lankalapalli and Kolapalli, 
2009; Vries et al., 2003). 
Melt extrusion Synthesis is continuous and does 
not require addition of solvents 
(Kindermann 2012; Vasconcelos 
et al., 2007). 
 
Generally its use requires the 
polymers with low melting 
points (Janssens and Van 
den Mooter, 2009).  
Layer-by-layer Stable PECs are formed and 
application of the layers includes 
coating substances (Antunes et 
al., 2011). 
Slow process and a uniform 
surface is needed for the 
deposition of the next 
polymer layer (Mihai et al., 
2013; Antunes et al., 2011). 
 
2.3. FORMATION OF POLYELECTROLYTE COMPLEXES 
In PEC formation, there is initially the formation of a random primary complex which might 
either become an ordered complex or form fibrils but that is not constant (Dakhara and 
Anajwala, 2010). PECs can form within the pH range where both the cationic and the anionic 
polymers are charged (Boddohi et al., 2009). This is the pH around their pKa values 
(Cranford et al 2010; Sarmento et al., 2007). However, monitoring the pH value is vital for 
polymers possessing a weak charge density otherwise those with a strong charge density 
maintain their charges regardless of the pH of the reaction medium (Mihai et al., 2011). 
PECs have been renowned for their ability to maintain the stability of polymers. Generally, 
polymers are not easily dissolved in water due to their low entropy values (Feng et al., 2007; 
Jintapattanakit et al., 2007). The addition of chitosan to alginate in making a carboplatin-
containing PEC stabilizes the alginate pre-gel nucleus which then forms nanoparticles 
(Nanjwade et al., 2011). Similarly, the stability of theophylline and alginate beads was 
enhanced by the electrostatic interactions between the alginate and chitosan. The two 
polymers formed a PEC by the coating of alginate with chitosan (Colinet et al., 2011).  
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Various parameters affecting PEC formation include:  
 pH of the reaction medium 
 ionic strength of the reaction medium  
 density of the charges   
 charge distribution over the polymers 
 mixing ratio of the polymers 
 order of mixing  
 duration of the interaction  
 the position of the ionic groups on the polymer 
 degree of ionization  
 polymer chain flexibility (Hamman, 2010; Dinu et al., 2010; Petrov et al., 2003). 
Polyelectrolyte complexes can be formed using either the stoichiometric or non-
stoichiometric polymer ratios. These ratios influence the polycationic and polyanionic 
densities and they determine the physicochemical properties of the complexes that are 
formed (Le Cerf et al., 2014; Petrov et al., 2003). Table 2.2 below provides examples of 
stoichiometric and non-stoichiometric PECs from studies previously conducted by various 
groups.  
 
2.3.1. Stoichiometric complexes 
Stoichiometric ratios of polymers yield PECs that are electroneutral and they usually 
precipitate out of solution. Their formation is characterized by the strong electrostatic forces 
between the polymers which are in a 1:1 molar ratio (Vasconcelos et al., 2007; Berger et al., 
2004). The complexes do not dissolve in water and organic solvents but are capable of 
swelling in water. Their rigidity and hydrophobic nature is attributed to their lack of free 
charges (Kabanov and Zezin, 1984). There has been intensive research in the use of PECs 
as matrices that slowly release the API over time. Tapia and co-workers (2004) developed 
and characterized chitosan–alginate and chitosan–carrageenan matrices for the prolonged 
release of diltiazem clorhydrate. The amounts of polymers were varied in order to ascertain 
how much of each polymer was required to obtain a complete reaction and therefore the 
synthesis of stoichiometric PECs. They concluded that the chitosan-alginate matrix 
performed better since it resulted in prolonged release of the drug at lower polymeric ratios 
(Tapia et al., 2004). According to a study conducted by Ngwuluka et al. (2013) computational 
as well as in vitro data validated the formation of an interpolyelectrolyte complex in 
stoichiometric ratios between methacrylate copolymer and sodium carboxymethylcellulose. 
This has the potential to be employed in controlled drug delivery (Ngwuluka et al., 2013). 
The use of stoichiometric complexes is limited in fields such as biomimetic mineralization 
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where the PEC would act as a template with free charges that can bind to minerals such as 
Ca2+ in order to form crystals. These crystals lead to the formation of hybrids with unique 
properties. However, non-stoichiometric PECs are eligible for this application but their use 
has not been explored much. Figure 2.4 illustrates the formation of a BSA entrapped in 
carboxymethyl cellulose and chitosan polyelectrolyte hydrogel and its use in biomimetic 
mineralization. The PEC acts as a template by providing carboxylate ions for the calcium 
ions to attach and therefore making a biodegradable scaffold that can be utilized in tissue 
engineering. Sustained release of the BSA also shows that the PEC has drug delivery 
applications (Salama and El-Sakhawy, 2014). 
 
 
Figure 2.4: Carboxymethylcellulose and chitosan polyelectrolyte hydrogel and calcium 
phosphate biomimetic mineralization (Rodríguez et al., 2011). 
 
2.3.2. Non-stoichiometric complexes 
Non-stoichiometric ratios of polymers result in the formation of water soluble complexes and 
the level of turbidity determines the concentration of the PEC in the solution (Kramarenko et 
al., 2006; Kabanov and Zezin, 1984). Formation of this type of PEC is facilitated by the 
presence of a ‘host’ and a ‘guest’ polymer. The ‘host’ polymer possesses a longer chain and 
has to be present in larger amounts compared to the ‘guest’ polymer. The excess charges 
which are not participating in the complex formation therefore interact with the aqueous 
medium and are responsible for the stability of the complex as well as its net charge. The 
resulting PEC is homogenously dispersed in the aqueous solution and its formation is 
 19 
 
reversible. Other factors leading to the formation of hydrophilic PECs are differences in 
molecular weights between the participating polymers and the presence of salt and weak 
ionic groups in the polymers. However, if the conditions of formation are not maintained by 
decreasing the amount or the level of ionization of the host polymer, clustering of complexes 
occurs. This may eventually lead to the formation of stoichiometric complexes (Shovsky et 
al., 2009; Sotiropoulou et al., 2004; Kabanov and Zezin, 1984). Shovsky et al., (2009) noted 
that the formation of non-stoichiometric PECs between block ionomers and enzymes or 
oligonucleotides is beneficial in drug delivery for purposes such as enzyme entrapment or 
gene therapy. They reported on the effect of adding poly [ethylene oxide] ether methacrylate, 
(poly [PEO MEMA]), a non-ionic compound, to a cation, poly 
(methacryloxyethyltrimethylammonium) chloride (poly [METAC]). The poly [METAC] formed 
a water soluble PEC with poly sodium styrene sulfonate (NaPSS) at both stoichiometric and 
non-stoichiometric ratios. Both ratios yielded colloidal dispersions that did not precipitate in 
5mM of sodium chloride. The PECs were able to form aqueous dispersions due to the steric 
hindrance caused by the presence of at least 25% poly (METAC) (Polexe and Delair, 2013) 
PECs that form in non-stoichiometric ratios can form colloids which exhibit the Tyndall effect. 
Recently, Polexe and Delair (2013) effectively entrapped an antibody (anti-ovalbumin) onto 
chitosan and hyaluronic acid colloidal PEC nanoparticles. These PECs maintained their 
colloidal stability. 
 
Moreover, there is a group of PECs that forms regardless of the nature of the polymeric 
ratios and coacervates fall into this category. Being fluid in nature, their formation can be 
reversed. The polyelectrolyte complex-rich fluid is immiscible with the supernatant but it does 
not precipitate out of the solution and can be collected by further centrifugation (Berger et al., 
2009; Bohida 2008). It has been noted that non-stoichiometric, water-soluble PECs can 
eventually form coacervates if the charge density of the polymers increases. The highest 
yield of coacervates is achieved at or near their stoichiometric ratios (Kizilay et al., 2011). 
Agu¨ero and co-workers (2013) provided an example of biomedical application of 
coacervates where they reported the potential of using drug loaded poly(acryloxyethyl-
trimethylammonium chloride–co–2–hydroxyethyl methacrylate) copolymer (poly(Q–co–H)) 
and alginate PEC as a scaffold for effective oral drug delivery. 
 
There are theories that have been proposed to explain how coacervation in PEC formation 
occurs and these include but are not limited to the Overbeek-Voorn, Veis-Aranyi and 
Tainaka theories. These theories have been adequately reviewed by Burgess (1990). 
According to the Overbeek-Voorn theory, the level of clustering is minimized when the 
concentration of salt ions is increased in the polyelectrolyte solution. The salt ions would 
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neutralize the charges and thus lower the charge density. Minimization of clustering also 
occurs when non-stoichiometric binding occurs between the molecules involved (Dinu et al., 
2010; Burgess 1990). In the case of the Veis-Aranyi model, the first step towards co-
acervation is the self-assembly of molecules which is then followed by the slow 
rearrangement of co-acervates. As re-arrangement takes place, entropy value increases. 
The Tainaka theory is based on how the respective negatively and positively charged 
molecules initially assemble without any charge interactions between them. These 
aggregates will then precipitate out due to the attractive forces between them thereby 
forming co-acervates. Higher molecular weights lead to better precipitate formation and the 
ionic interaction then occurs in the precipitate to form PECs (Dinu et al., 2010; Burgess 
1990).  
 
Table 2.2: Examples of stoichiometric and non-stoichiometric polyelectrolyte complexes 
from previous studies 
Stoichiometric PECs Non-stoichiometric PECs 
chitosan–alginate and chitosan–
carrageenan (Tapia et al., 2004) 
poly(methacrylic acid) and poly(N-ethyl-4-
vinyl-pyridinium bromide) (Dainiak et al., 
1998-1999)  
 
methacrylate copolymer and sodium 
carboxymethylcellulose (Ngwuluka et al., 
2013) 
chloride–co–2–hydroxyethyl methacrylate) 
copolymer (poly(Q–co–H)) and alginate 
(Agu¨ero et al., 2013) 
 
carboxymethyl cellulose and chitosan 
(Salama and El-Sakhawy 2014) 
polyvinylsulfate and poly- 
diallyldimethylammonium chloride (Chen et 
al., 2003) 
 
Na-carboxymethyl cellulose and chitosan 
hydrochloride (Shtompel et al., 2011) 
carboxymethylcellulose and N-methylated 
poly(2-vinylpyridine) (Vishalakshi and Ghosh, 
2003)  
 
poly(styrenesulfonate) and 
poly(diallyldimethylammonium) (Wang and 
Schlenoff, 2014)  
chitosan with poly(sodium 2-acrylamido-2-
methylpropanesulfonate) (Mihai and Dragan, 
2009)  
 
Eudragit E PO kappa-carrageenan (Prado 
et al., 2008) 
chitosan and hyaluronic acid (Polexe and 
Delair, 2013)  
 
2.4. POLYMERS USED IN POLYELECTROLYTE COMPLEXATION 
Generally, polymers can be classified according to their source, charge, aqueous solubility 
and bioadhesive properties as illustrated in (Figure 2.5) (Majumdar et al 2010; Roy and 
Prabhakar, 2010; Chickering et al., 1996). In order to form a PEC, the constituent polymers 
should be charged enough to form ionic interactions between the polymers. Polymers used 
for PEC synthesis are either natural, synthetic or chemically modified polymers or a 
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combination of different types of polymers. These three types of polymers may be in various 
forms such as linear, branched, crosslinked, polyacids, polybases, polyampholytes and 
copolymers (Lankalapalli and Kolapalli, 2009). Advantages of using natural polymers are 
that they are biocompatible, biodegradable, cheap and ubiquitous in nature. Synthetic 
polymers present with the advantage of thermal stability due to their strong mechanical 
properties as well as minimal batch to batch variations (Dang and Leong, 2006). This 
stability would make them more suitable for use in methods such as melt extrusion. They are 
polymers of choice for applications such as implants. The natural and synthetic polymers 
can be modified to achieve a desired outcome which in most cases is the optimization of a 
specific property. This will expand the applicability of polymers. Chemical surface treatments 
are implemented in order to alter the charge density, the pH or hydrophilicity/hydrophobicity 
of the polymer (Hoffman 1995). A comparative study on insulin-loaded chitosan/γ-poly 
(glutamic acid) and trimethyl chitosan (TMC-chemically modified form of chitosan)/ γ-poly 
(glutamic acid) nanoparticles for the stability of drug molecule reported that TMC-containing 
PEC had a significantly superior stability across a wider pH range compared to the chitosan-
containing PEC (Mi et al., 2008). Examples of cationic polymers that have been explored for 
complexation include chitosan, poly (ethyleneimine), and poly-L-(lysine). Anionic polymers 
include carboxymethyl cellulose, alginate, dextran sulfate and poly acrylic acid. Some of the 
charged polymers exhibit additional beneficial properties such penetration enhancing effects 
and pH-specific disintegration. Polymers such as chitosan and alginate improve the 
residence time of the system thus improving drug permeation at the site of action (Arora et 
al., 2011). Chitosan retains its bioadhesive properties even after the PEC has disintegrated. 
Polymer disintegration under a certain pH facilitates targeted drug release. For example, 
Eudragit L100-55 and Eudragit L-100 are insoluble in acidic pH but soluble in alkaline pH 
and this makes it suitable for targeted drug delivery to the small intestines (Cetin et al., 
2010). 
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Figure 2.5: Illustrates classification of polymers based on source, charge, aqueous solubility 
and bio-adhesive force 
 
2.5. MECHANISM OF DRUG RELEASE BY PECS 
The use of PECs provides controlled release of the drug with spatial and temporal 
distribution. This changes the pharmacokinetic and pharmacodynamic properties of the drug. 
PECs are also known to retain a large amount of water and therefore have a good swelling 
capacity which helps with the mechanism of drug release (Kim et al., 2004; Tapia et al., 
2004). Drug release is generally by means of diffusion (if PECs have a porous structure) and 
degradation. The degradation of the PEC structure leads to swelling as free charges become 
available for interaction with water. Swelling is caused by the charge repulsion within the 
PEC and also by the neutralisation of free charges by water and other counter ions. The 
degree of swelling is dependent on the flexibility of the PEC (Berger et al., 2004). 
Alternatively, drug release may occur by pH-sensitive shrinking. In this case, the maximum 
level of swelling is reached then shrinkage occurs as the inter-polyelectrolyte reaction is 
completed. The release of dextran from dextran sulfate/chitosan PEC was observed at 
neutral pH when the PEC shrunk (Berger et al., 2004; Sakiyama et al., 2001). The swelling 
or shrinking is therefore responsible for the diffusion of the drug out of the matrix (Alba et al., 
2014; Ngwuluka et al., 2013). Drug release by hydrolysis of the PECs occurs to a very small 
extent (Hamman 2010). However, with regards to PECs having a high water absorption 
capacity, drug release occurs by means of disintegration of the polymer, instead of swelling 
(Tapia et al., 2004). Upon dissolution, a viscous solution of the PEC will form and this helps 
in extending the drug release. In addition, polymers such as poly-L-lysine and 
polyethyleneimine can be used to block the pores in gel networks and thereby retarding the 
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drug release. Alginate-Polyethyleneimine complex led to prolonged release of furosemide, a 
hydrophobic drug. The extra alginate layer helped achieve controlled release by blocking the 
matrix pores. PEC formation delayed the swelling of the system (Mallikarjuna et al., 2005). 
(Figure 2.6) shows the timed-release of the drug profile by the chitosan/ghatti gum PEC in 
comparison to the individual polymers, chitosan and ghatti gum (Reddy et al., 2011). 
 
 
Figure 2.6: Profile illustrating the drug release profile of Chitosan, Ghatti gum and 
Chitosan/Ghatti gum PEC (Reddy et al., 2011) 
 
The controlled release mechanism includes extended release where a certain predetermined 
amount of drug is released at a certain time and sustained release where an unpredictable 
amount of drug is slowly released to maintain plasma concentrations. Polyelectrolyte 
complexes, unlike polymer blends, provide a modified drug release profile. This mechanism 
is believed to facilitate the accumulation of higher drug levels at the site of action (Bani-Jaber 
et al., 2011). This accumulation leads to a higher saturation solubility which leads to 
enhanced drug absorption (Martinez and Amidon, 2002). This type of drug release facilitates 
continuous treatment particularly in the nocturnal phase and it helps to improve the stability 
of the drug (Bani-Jaber et al., 2011; Ahn et al., 2002). The accumulation of toxic amounts of 
the drug in the body is therefore prevented as well as the accumulation of sub-therapeutic 
levels of the drug which may result in the emergence of resistance to treatment (Shu et al., 
2009; Liao et al., 2005). In addition, the drugs possessing a short in vivo half-life may 
become long acting drugs after being incorporated into PECs. Sufficient maintenance of 
plasma drug levels is achieved. Attempts to obtain gradual release of ibuprofen have been 
made by embedding the drug within a Eudragit E 100/Eudragit L 100 polyelectrolyte complex 
(Moustafine et al., 2006). This was successfully achieved. A similar effect on ibuprofen was 
seen with Eudragit EPO/Eudragit L 100-55 complex. The drug was embedded within the 
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matrix without any drug-polymer covalent interactions (Moustafine et al., 2006). Studies 
conducted by Prado and co-workers showed the different polyelectrolyte complexes that can 
be used to achieve the slow release of ibuprofen over time. Cationized starch/К-
carrageenan, Polysiphonia nigrescens and cationized agaroses/Eudragit E and Eudragit E/ 
К-carrageenan complexes gave zero order release kinetic with Fickian diffusion (Prado et 
al., 2012, 2009, 2008).  
 
Lipophilic drugs pose the challenge of poor plasma drug concentrations due to their low 
aqueous solubility. Ai and co-workers (2003), demonstrated the enhanced bioavailability of 
furosemide, when incorporated in the layer-by-layer PEC of polystyrene sulfonate and poly 
(dimethyldiallyl ammonium chloride) in the form of drug loaded gelatin microcrystals (Ai et 
al., 2003). The use of PECs as bioenhancers of active pharmaceutical agents is not only 
limited to hydrophobic substances. A hydrophilic moiety such as fluorescein isothiocyanate 
conjugate bovine serum albumin was embedded into a chondroitin sulfate/chitosan 
nanoparticle complex with significant improvement in the amount of drug that reached the 
target site (Yeh et al., 2011). Another example is of a study conducted by Bawa et al., (2011) 
who investigated the use of a PEC (pectin, chitosan and hydrolyzed polyacrylamide) to 
modify the release of diphenhydramine, a highly water-soluble API. They concluded that the 
delivery system is applicable for targeted release specifically to the small intestines and the 
colon because of its pH-sensitivity. PECs also exhibit a potential in gastroprotection and 
sustaining the release of bioactives that are prone to degradation such as proteins. Liao et 
al. (2005) investigated the ability of interfacial chitosan/alginate polyelectrolyte complexation 
for high drug encapsulation efficiency, sustained release kinetics, and capacity to retain the 
bioactivity of bovine serum albumin (BSA), dexamethasone, platelet derived growth factor 
(PDGF) and avidin. This study achieved the successful incorporation of positively charged 
(PDGF and avidin), negatively charged (BSA) and neutral (dexamethasone) molecules in a 
PEC. It was stipulated that the PEC has the potential for releasing the active ingredient 
slowly over time while retaining the activity (Liao et al., 2005). 
 
The rate of extended drug release is directly proportional to the strength of the PEC. For 
example with the chitosan/pectin PEC loaded with resveratrol, formation of the PEC in low 
pH results in a strong complex which exhibits little swelling and erosion thus retarding drug 
release until it reaches the colon. In the colon, enzymes are responsible for breaking down 
the complex. In-vivo studies in rats revealed that little amounts of resveratrol were detected 
in the plasma in the first 5 hours and these amounts gradually increased with time (Das et 
al., 2011). 
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2.6. BIOAVAILABILITY ENHANCING TECHNIQUES ASSOCIATED WITH PECS 
Numerous studies have been carried out to enhance the bioactivity of drugs by incorporating 
them into polymers (Table 2.3). Making use of PECS is one of the ways that this has been 
done with the ultimate result being the formation of a modified release system which can 
combat the problem of short duration of action of drugs. The drug is either imbedded within 
the complex or it interacts with either of the polymers in the complex (Martinez and Amidon, 
2002). The controlled release mechanism has been explained previously. Other methods of 
enhancing bioavailability such as, the use of nanoparticles or microparticles may also be 
used together with the PECs. The steps involved as well as the suggested ways to improve 
each step for the solid dosage form to reach the systemic circulation are shown in (Figure 
2.7). 
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Table 2.3: Previous studies on drug-loaded polyelectrolyte complexes and their effect on 
drug release 
Polymers  MOS*
1 
Drug LE*
2 
EODS*
3 
 
N-Trimethyl chitosan 
and poly (γ-glutamic 
acid) nanoparticles   
 
Ionic-gelation  
 
Insulin 
 
73.8 ± 2.9% 
 
Sustained release along the entire 
intestinal tract (Mi et al., 2008). 
Alginate-
Polyethyleneimine 
beads  
Solution and 
incubation 
Furosemide  97.16%- 
100.49%, 
Sustained release of the drug with 
reduced initial swelling and erosion of the 
complex (Mallikarjuna et al., 2005). 
Polystyrene 
sulfonate and poly 
(dimethyldiallyl 
ammonium chloride)  
Layer-by-layer 
assembly  
Furosemide  - Sustained release of furosemide (Ai et al., 
2003). 
Dextran sulfate and 
chitosan 
nanoparticles  
Solution Curcumin  ᷉ 74% The drug release pattern showed a burst 
release in the first 3 h followed by a 
controlled release over a period of one 
week (Anitha et al., 2011). 
Eudragit E and 
carrageenan  
Solution Metronidazole  - Less than 9% burst release followed by 
controlled release over 10 hours (Bani-
Jaber et al., 2011). 
Chitosan and gum 
kondagogu  
Solution Diclofenac sodium 64.40- 
85.71% 
5.3 to 5.8 times increase compared to the 
free drug (Naidu et al., 2009). 
Chitosan and poly (γ-
glutamic acid) 
nanoparticles  
Ionic-gelation Insulin  71.8 % Significant increase in bioavailability 
compared to the free insulin 15.1% 
(Sonaje et al., 2009). 
Chitosan and 
alginate microsphere 
beads  
Solution Anti-tuberculosis 
drugs (rifampicin, 
isoniazid and 
pyrazinamide) 
65 - 85% Increase in bioavailability attributed to 
increase in the half life and mean 
residence time of the drugs (Pandey and 
Khuller, 2004).  
Chitosan and dextran 
sulfate microspheres  
Solution Ibuprofen  At least 80% Expected increase in bioavailability since 
solubility of the drug was enhanced by 
colon specific drug delivery (Lin et al., 
2005). 
Chitosan and 
alginate-g-PCL/Ca2+  
 
Coating Theophylline  87-91% Stable in gastric conditions and achieved 
controlled release of the drug over 7 
hours (Colinet et al., 2010). 
Chitosan and pectin 
microparticles  
Solution Resveratrol  >97% Steady increase in blood drug 
concentrations after 5 hours (Das et al., 
2011). 
 Chitosan and 
xanthan gum 
Extrusion Chlorpheniramine 
maleate 
100% Controlled release due to the formation of 
a hydrogel upon dissolution (Fukuda et 
al., 2006). 
Polydiallyldimethyla
mmonium chloride 
(PDADMAC ) and 
polystyrene sulfonate 
Layer-by-layer  Daunorubicin  88.3%-
93.95% 
Higher drug release in alkaline pH with an 
initial burst release of 65% in the first hour 
followed by sustained release 
(Kainourgios et al., 2013). 
 
*
1 
MOS: method of synthesis 
*2
 LE: loading efficiency 
*
3 
EODS: effect on drug release 
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Figure 2.7: Showing schematic representation of different steps involved in achieving 
bioavailability of a solid dosage form 
 
2.6.1. Techniques implemented to improve bioavailability 
Different approaches that exploit polyelectrolyte complexes and are believed to enhance the 
amount of drugs reaching their intended sites of action include permeation enhancers, 
nanoparticles, microparticles and gastroretentive systems, etc. These techniques are further 
described below and the examples given are mainly of PECs containing chitosan and its 
derivatives. There are replete studies in literature based on chitosan and its derivatives and 
their use in PEC synthesis. Chitosan PECs shrink in acidic pH but start to swell in alkaline 
pH and therefore drug release starts to occur. This is opposed to the use of chitosan alone 
which is readily soluble in gastric pH. Naidu et al, (2009) concluded that gum kondagogu and 
chitosan polyelectrolyte complex led to an increase in relative bioavailability of diclofenac 
sodium by 5.3 to 5.8 times compared to the free drug. The study was conducted in rats 
where, modified drug release was achieved and the PEC was a barrier to gastric drug 
release (Naidu et al., 2009). Diclofenac sodium served as an ideal model because it is 
associated with drawbacks such as poor solubility, short duration of action and liability to be 
degraded in the gastrointestinal tract (GIT). Use of the PEC resolved these limitations. Other 
polymers have been utilized for PEC formation without the inclusion of chitosan. When 
metronidazole was loaded into eudragit E and carrageenan IPEC, the gastric residence time 
was prolonged by use of the floating matrix tablet and this property was attributed to 
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controlled release. There was an increase in the amount of metronidazole absorbed in the 
GIT (Bani-Jaber et al., 2011). As mentioned earlier, furosemide loaded in calcium alginate 
and polyethyleneimine (Arora et al., 2011) as well as the polystyrene sulfonate and poly 
(dimethyldiallyl ammonium chloride) PECs (Ai et al., 2003) led to the fulfilment of retarded 
drug release. 
 
2.6.1.1. Permeation enhancers 
Lipophilic molecules can cross the intestinal wall down a concentration gradient in contrast 
to hydrophilic ones which require a selective transport system such as the active transport or 
facilitated diffusion in order for them to cross the wall. The integrity of the wall along the GIT 
may be breached to enhance permeation of molecules. However, there is a risk of toxicity 
when unwanted pathogens enter through the intestinal wall. It is believed that some of these 
permeation enhancers cause irritation to the gastrointestinal (GI) wall (Muheem et al., 2011; 
Gaucher et al., 2010). Generally, polymeric permeation enhancers are hydrophilic in nature 
and are therefore not absorbed. Thiolates and polyacrylates are examples of polymers that 
can be used for permeation enhancement (Bernkop-Schnurch, 2009). Chitosan and its 
derivatives have known excellent bioadhesive properties and therefore increase the 
residence time of substances in the GIT. It is stipulated that chitosan binds to the mucin on 
the mucosa thus facilitating permeation of substances across the wall (Balabushevich et al., 
2011). Protonated chitosan interacts with the tight junctions found on the intestinal wall thus 
facilitating paracellular permeation of macromolecular drugs (Figure 2.8). It has been noted 
that chitosan has minimal effects on the integrity of the cells of the intestinal wall (Zakhem et 
al., 2012). This makes it ideal for enhancing the permeation of drugs. In addition, it is broken 
down by the enzyme beta-glucosidase and therefore is useful in targeted colon delivery of 
drugs. For example, the targeted delivery of vancomycin to the colon was achieved using a 
chitosan/pectin PEC (Pendekal and Tegginamat, 2013). Similarly, Moodley and co-workers 
(2011) formulated the same PEC for colonic delivery of mesalamine. PECs can help solve 
the problem associated with colonic drug delivery due to its distal position in the 
gastrointestinal tract (Moodley et al., 2011). Enhanced permeation and prolonged release of 
5-Fluorouracil was achieved by incorporating it in chitosan and alginate inter-polyelectrolyte 
complex (IPEC). The mucoadhesive nature of chitosan might prevent the presystemic 
metabolism of molecules such as peptides thus enhancing their oral absorption (Pendekal 
and Tegginamat, 2013).  
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Figure 2.8: Schematic illustrations of the presumed mechanism of the paracellular transport 
of insulin released from test nanoparticles (Sonaje et al., 2009) 
 
2.6.1.2. Microparticles 
The microparticle size is of great importance in relation to drug release kinetics, where, the 
larger the particle size, the slower the drug release will be. The specific rate of release may 
be controlled by aiming to use a defined range of microsphere size (Yujie and Pack, 2015). 
This drug delivery method has been found to be applicable in insulin delivery where 
gastroprotection is essential as well as the timely release of the drug for effective glucose 
monitoring (Balabushevich et al., 2013). Chitosan crosslinked with tripolyphosphate formed 
microspheres with dextran sulfate for the delayed release of ibuprofen. Almost 100% drug 
release was observed in intestinal fluid within 6 hours (Lin et al., 2005). Chitosan coated 
alginate and dextran sulfate microspheres were used to develop a system that protects 
insulin from gastric degradation. In addition, it reduced the burst release of insulin (Martins et 
al., 2007). Attempts were also made by Mao and co-workers (2005) who encapsulated 
ciprofloxacin hydrochloride into polystyrene sulfonate and poly (allyl amine hydrochloride) 
microcapsule complex for prolonged release. This type of release has been proven to 
improve drug release and therefore preventing toxicity associated with poorly water-soluble 
drugs (Mao et al., 2005). Another application for microparticles was demonstrated when anti-
tuberculosis drugs (rifampicin, isoniazid and pyrazinamide) were encapsulated into 
chitosan/alginate microspheres. Results revealed bioenhancement, increase in half-life by 
threefold and a significant thirteen times elevation in the mean residence time. Furthermore, 
the release of the drugs in the blood plasma of guinea pigs occurred over 7 days. Frequency 
of dosing would have to decrease thus encouraging patient compliance to treatment 
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(Pandey and Khuller, 2004). Good bioavailability of antibiotics through the oral route is 
beneficial for the treatment of local infections in the GIT such as Crohn’s disease besides 
being a more favourable method of drug administration by patients. 
 
2.6.1.3. Nanoparticles 
Nanoparticle-containing PECs are believed to potentially deliver protein and peptide drugs 
orally. The PEC will shield the drug from GI degradation and will eventually undergo 
enzymatic degradation particularly in the colon. This facilitates site-specific drug delivery to 
either the small intestines or the colon (Morishita and Peppas, 2006). The main problem with 
parenteral delivery is that the protein or peptide drug is not efficiently absorbed and hence 
the need to maximize oral delivery of these drugs (Anitha et al., 2011). Nanoparticulate 
carriers that are resistant to gastric degradation have been used to deliver drugs prone to 
chemical degradation before absorption takes place as well as those which are poorly 
permeable across the GI wall (Lopes et al., 2010). When insulin was encapsulated into 
alginate and chitosan nanoparticulate polyelectrolyte complex, efficacy of the bioactive was 
improved threefold compared to that of the free insulin. Permeation through the intestinal 
wall was increased and the drug was shielded from gastric degradation (Morishita and 
Peppas, 2006; Sakiyama et al., 2001). 
 
Nanotechnology has provided an efficient way to enhance bioactivity therefore showing 
significant differences with conventional systems (Sarmento et al., 2007). For example, 
curcumin-loaded nanoparticles of dextran sulphate and chitosan PEC showed better 
controlled drug delivery and bioavailability in comparison to curcumin-loaded O-
carboxymethyl chitosan (Anitha et al., 2011). The advantage of using nanoparticles over 
microparticles is the additional reduction in size which allows for more complete drug 
absorption within the intestinal transit time which is estimated to be 3-4 hours (Porter et al., 
2008). The particles have improved accessibility to most parts of the body. This further 
reduction in particle size also aids in stabilizing the formulation. The residence time of the 
system increases by making use of nanoparticles and this helps in lowering the drug doses 
used.  Permeation of the drug through the GI wall and the duration of drug delivery can be 
enhanced (Wilczewska et al., 2012; Williams et al., 2012). Nanoparticles serve as drug 
reservoirs since they are not easily excreted from the body. They can also access most of 
the body parts (Shu et al., 2009).  However, some studies have reported on the design of 
delivery systems that combine both nanoparticles and microparticles to achieve multiple 
drug release profiles (Lee et al., 2013).  
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Techniques for forming nanoparticles include dispersion into preformed polymers, 
polymerization of monomers and ionic gelation. The chosen method will influence properties 
of the resulting nanoparticles and are therefore selected based on the desired outcome 
(Fasano, 1998). The ionic gelation technique is the most common one and can be achieved 
by solvent evaporation or nanoprecipitation. The technique can be implemented where 
beads result from the reaction of the polyelectrolyte solution and a counterion solution. The 
beads can swell extensively and form a gel in simulated biological fluids thus releasing the 
drug. Nanoparticles range in size from 10 to 1000 nm and have efficient absorption due to 
their size and lipophilicity (Fan et al., 2012). In the case of nanocapsules, the drug is coated 
with the polymer and its release entails diffusion across the polymeric barrier. Drug release 
is expected to be of zero order. Another type of nanoparticles is nanospheres and these are 
formed by the monodispersion of the drug within the matrix (Mora-Huertas et al., 2010). 
Figure 2.9 illustrates the formation of an insulin-containing chitosan and alginate PEC. pH-
sensitive nanoparticles improve the stability of a delivery system since they respond to 
changes in pH. This is beneficial in the delivery of sensitive bioactives such as insulin which 
presents with complexity of absorption of inadequate amounts into the blood stream via the 
oral route (Mudassir et al., 2015). Various studies have explored the delivery of insulin by 
nanocomplexes with successful outcomes. A marked increase in bioavailability was noted 
when it was loaded into poly-γ-glutamic acid and chitosan nanocomplex in the presence of 
magnesium sulfate and tripolyphosphate (Sonaje et al., 2009). It has been observed that the 
nanoencapsulation of insulin in a chitosan/alginate PEC reduces blood glucose by 40% in 
diabetic rats. This occurs 12 hours after administration with a hypoglycemic effect of 45% in 
24 hours whereas; the free form reduced the blood glucose by 15% in 3 hours with a 42% 
hypoglycemic effect (Wilson et al., 2012).  
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Figure 2.9: Schematic representation of Insulin- chitosan PEC (Jintapattanakit et al., 2007) 
 
2.6.1.4. Gastroretentive controlled release systems 
Intragastric floating systems aid in achieving controlled drug release. These systems have a 
lower density compared to the stomach contents and can therefore float in the stomach 
without affecting the gastric motility. The retention of the system is prolonged in the fed state. 
The residence time may be prolonged by bioadhesive systems as well as swelling and 
expanding systems. This will allow for a more targeted drug release (Bani-Jaber et al., 
2011). The intragastric floating system may be used to improve the gastric absorption of 
drugs such as furosemide. 
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Recent studies of a Eudragit E100/Sodium carboxymethylcellulose PEC successfully 
achieved a release-modulating matrix for the delivery of levodopa. Based on the in vitro 
data, such a system is anticipated to be gastroretentive while providing a zero-order and 
controlled release of the drug in vivo. It is believed to have the potential to enhance 
absorption and subsequently the bioavailability of the psychoactive drug. These results have 
therapeutic benefits since the drug is known to possess an inherent narrow therapeutic index 
(Ngwuluka et al., 2013). 
 
2.6.2. Combination systems  
The above mentioned approaches to enhance bioavailability of drugs can also be combined 
with the result of further improving the effectiveness of the PEC-containing delivery system. 
Amoxicillin-loaded chitosan/alginate complex utilized both properties of nanoparticles and 
the penetration enhancing system. The amoxicillin-loaded PEC may be successfully used in 
the eradication of Helicobacter pylori (Arora et al., 2011). 
 
2.7. CONCLUDING REMARKS 
Polyelectrolyte complex-mediated drug delivery befits an imminent area of research in the 
field of pharmaceutics with the aim of developing novel and more effective delivery systems 
for safe, targeted delivery of bioactives in vivo. One major advantage of polyelectrolyte 
complexes is that they can combine properties of different polymers by maintaining their 
individual characteristics. The controlled and site-specific delivery of drugs by PECs is 
attributed to their swelling capability in gastrointestinal fluids as well as their pH dependent 
degradation. From the literature review provided in this chapter, it can be inferred that the 
field of polyelectrolyte complexes can be expanded more by combining systems containing 
the complexes with other bioavailability enhancing techniques such as nanoparticles and 
permeation enhancers for more effective multiple drug delivery applications.   
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CHAPTER 3  
 
A HUMIC ACID-POLYQUATERNIUM-10 STOICHIOMETRIC SELF-ASSEMBLED 
FIBRILLA POLYELECTROLYTE COMPLEX: EFFECT OF PH ON SYNTHESIS, 
CHARACTERIZATION AND DRUG RELEASE 
  
3.1. INTRODUCTION 
Polyelectrolyte complexes (PECs) utilize unique properties of polymers involved in the 
complex and are formed by electrostatic binding between a cation and an anion (Nath et al., 
2015; Ankerfors et al., 2010). As previously reported by our group (Siyawamwaya et al., 
2015), polymers that are readily charged or those that become charged under specific 
conditions such as certain pH values are a prerequisite for PEC formation. This study utilized 
the solution mixing method to investigate the possibility of a stoichiometric PEC formation 
between humic acid (HA) and polyquaternium-10 (PQ10) with emphasis on the effect of pH 
of the solution medium on synthesis. It is a well-known fact that pH of the solution medium is 
one of the parameters which significantly impacts on the PEC formation (Kumar and Ahuja, 
2013; Lin et al., 2005). Stoichiometric polymeric ratios yield insoluble and neutrally charged 
PECs (Tapia et al., 2004; Kabanov and Zezin, 1984). 
 
PQ10 is a cationic cellulose derivative which is also known as quaternized 
hydroxyethylcellulose ethoxylate. It is stipulated that polymers containing quaternary amino 
groups are promising candidates for biomedical applications since they exhibit diverse 
chemical properties (Bierbrauer et al., 2014). They are soluble in both aqueous and 
aqueous-alcoholic media. The ammonium group in PQ10 is situated at the end of the poly 
(ethylene glycol) chains therefore it possesses a very high affinity for negatively charged 
groups . During the aggregation process, as the PEC forms, these hydroxyethyl substituents 
may be included in the complex and thereby contributing to the self-assembly process 
(Rodrı́gueza et al., 2003). 
 
Advantages of using PQ10 include non-toxicity, mucoadhesion, biocompatibility, stability 
against gastrointestinal enzymes and the ability to attain a high viscosity upon swelling 
(Mazoniene et al., 2011). An example of a similar polymer is chitosan by which the cationic 
nature is also attributed to the presence of the ammonium substituents. The ionization of 
PQ10 is pH independent unlike that of chitosan. PQ10 exhibits efficient solubility properties 
in water and upon dissolving, there is thickening of the medium (Rodrı́guez et al., 2003a 
2003b). PQ10 has been known to form stable complexes with anionic surfactants and this 
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combination is believed to possibly enhance the solubility of hydrophobic drugs (Cumming et 
al., 2008; Rodrı́gueza et al., 2003). Additionally, polyquaternium compounds exhibit 
antibacterial properties which are facilitated by their penetration enhancing effects 
(Carmona-Ribeiro and de Melo Carrasco, 2013; Rodrı́gueza et al., 2003). 
 
Humic acid (HA) belongs to a family of humic substances which are weakly acidic and 
heterogeneous compounds. Its acidic behavior is exhibited by the ionization of carboxylic 
and phenolic groups and it has been shown to exhibit good complexing properties with 
cations. HA contains both a supramolecular and macromolecular structure with a significant 
aromatic character. The quantity of the aromatic groups is directly proportional to the more 
carboxylic acid groups present in the HA structure (Baigorri et al., 2009). HA is a mixture of 
different components and therefore it is not associated with a distinct structure. 
 
HAs are partially soluble in water and the solubility increases with increase in pH. The 
alkaline medium will cause deprotonization of some HA molecules and therefore peptization 
occurs as the molecules repel each other (Klučáková and Pekař, 2005). In the study 
undertaken, commercial brown HA was used. The brown colour emanates from the aromatic 
carbon moieties derived from plant precursor materials (Coble et al., 2014). Brown HA is 
known to dissolve in alkaline solution and dissolution is independent of ionic strength unlike 
gray HA which dissolves in low ionic strength. The condensed aromatic structures and 
oxygen containing groups are responsible for the molecular aggregates formed in solution by 
the brown HA as well as its high affinity for hydrophobic substances (Baigorri et al., 2009). 
HA also exhibits amphiphilic properties (Bahvalov et al., 2010). The negative charges take 
part in complex formation with cationic groups and the hydrophobic site becomes exposed 
thus forming a water insoluble complex (Stepanov 2008; Yee et al., 2006). 
 
A HA and PQ10 polyelectrolyte complex was synthesized in aqueous solutions at pH 6.0 
(F1), 7.0 (F2) and 8.0 (F3). To the best of our knowledge, this complex has not been 
reported in literature thus far. The main aim of this study was to confirm formation of the 
novel PEC. Currently, there is extensive research on the use of natural polymers for 
biomedical and industrial application largely due to their biocompatibility, biodegradability 
and ubiquitous availability (Thakur et al., 2016; Thakur and Thakur, 2014; Tsai et al., 2014). 
Additionally, properties such as simulating natural tissues and extemporaneous self-healing 
enable biopolymers to be applicable for properties such as synthesis of hydrogels for 
extended release of bioactives (Thakur and Kessler, 2015; Thakur and Thakur, 2015). A 
lipophilic drug, efavirenz (EFV), was chosen as the model prototype drug to determine the 
drug release profile from this complex. EFV is a long-established drug in HIV treatment due 
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to the fact that at least two mutations are required in the reverse transcription for any drug 
resistance to materialize in patients (Hofman et al., 2004). Figure 3.1 depicts the model 
structures of HA and PQ10. 
 
 
Figure 3.1: (a) Model structure of humic acid as proposed by Stevenson (Peña-Méndez et 
al., 2005) and (b) general structure of polyquaternium-10 (Yang et al., 2008)  
 
3.2. MATERIALS AND METHODS 
3.2.1. Materials 
Brown humic acid, polyquaternium-10 (quaternized hydroxyethylcellulose ethoxylate), methyl 
thiazoyl tetrazolium bromide (MTT) and the solubilizing solution (10% sodium dodecyl sulfate 
in 0.01M hydrochloric acid) were purchased from Sigma-Aldrich® (St. Louis, MO, USA). 
Pure efavirenz powder was purchased from Xingcheng Chemphar Co., Ltd. (Taizhou, 
Zhejiang, China) and was used as received. pH of solutions was adjusted to the desired pH 
using 1M sodium hydroxide (NaOH) solution and 0.1M solution of hydrochloric acid (HCl). 
The Caco2 human adenocarcinoma cell line, Dulbecco’s Modified Eagle’s Medium (DMEM), 
foetal bovine serum and all other cell culture reagents were acquired Promolab Pty Ltd T/A 
Separations (Johannesburg, South Africa).  All other reagents were of analytical grade. 
 
3.2.2. Determination of the humic acid concentration and functional group profiling 
HA (2.3g) was added to 400mL of deionized water and the pH was adjusted accordingly 
using 1M NaOH/HCl to pH 6.0, 7.0 and 8.0. The solution was left to stir for 2 hours after 
which it was filtered using 90mm filter paper. Filtration was repeated to ensure that only the 
dissolved HA remained in the solution (Klučáková and Pekař, 2005). The filtrate (0.5mL) was 
measured out and left to dry overnight. After drying, the samples were re-weighed to 
determine the amount of HA that dissolved in deionized water. The titration method was 
implemented to determine the amount of carboxylic acid groups present in the HA sample. 
(a) (b)
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Titration gave an indication of the exact number of moles of HA that reacted with the PQ10. 
The automatic pipette was used to measure the phenolphthalein and NaOH volumes. Brown 
HA solution (0.5mL) was diluted in 500mL of water and 150µl of phenolphthalein was added 
to the solution. The solution was left to stir for a minute. Titration of the solution was carried 
out by adding a known amount of the NaOH from the micropipette until the end point was 
reached (Klučáková and Pekař, 2005). 
 
3.2.3. Determination of the self-assembly of humic acid and polyquaternium-10 to 
form the fibrilla PEC  
PQ10 powder (600mg) was dissolved in deionized water (100mL). The PQ10 solution was 
slowly titrated into HA solution (100mL) under constant magnetic stirring (Piyakulawat et al., 
2007). The solution was left to stand to allow the supernatant to separate from the PECs. 
The PECs were then soaked in distilled water and filtered using the 90mm filter paper. Drug 
loading in the complexes was conducted by adding the drug solution (200mg of drug 
dissolved in 20mL methanol) to the HA solution prior to adding the PQ10 solution.  The PEC 
strands were filtered as soon as they separated from the supernatant. The PEC was dried in 
an oven at 40ºC for at least 12 hours, when a constant mass was obtained.  The powder 
containing 200mg drug was thereafter filled into hard gelatin capsule shells size 00 for drug 
release studies after determination of percentage drug loading of PECs (Heinen et al., 
2013). 
 
3.2.4. Physicochemical characterization of the PEC and native components 
3.2.4.1. Determination polyquaternium-10 concentration for stoichiometric ratio 
reaction with humic acid 
Rheology was performed to determine the viscosities of the supernatants that separated out 
from the complex. Measurement was conducted with the aid of a Modular Advanced 
Rheometer (ThermoHaake MARS Modular Advanced Rheometer, Thermo Electron, 
Karlsruhe, Germany). Viscosity measurements were taken over 360 seconds at 25ºC.  
 
3.2.4.2. Determination of polyquaternium-10 and humic acid electrostatic interactions  
Intermolecular interactions between HA and PQ10 were determined utilizing a PerkinElmer 
Spectrum 2000 ATR-FTIR (PerkinElmer 100, Llantrisant, Wales, UK). Wavelength for 
analysis ranged from 650 to 4000cm-1 with a resolution of 4cm-1. A direct force of 115N was 
applied and 25 scans/spectrum were taken. 
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3.2.4.3. Assessment of the influence of simulated gastrointestinal fluids on the 
swelling and degradation of the PEC 
Pre-weighed PECs were placed in 100mL of USP buffers at pH 1.2 and 6.8 to mimic 
gastrointestinal conditions. These were incubated in an orbital shaker bath (37ºC, 50rpm) 
and the weights were recorded every 2 hours for 8 hours thereafter, at 24 hours. Percentage 
swelling degree (% SD) was calculated for each PEC using Equation 3.1. Any changes to 
the initial structures of the PECs were determined by conducting FTIR on PECs that had 
been left to dry in an oven at 50ºC until a constant mass was obtained.  
 
    % 𝑆𝐷 =  
𝑊𝑠−  𝑊𝐷
𝑊𝐷
 𝑥 100               
                                                                                                                              Equation 3.1 
Where, Ws is weight of swollen PEC and WD is the weight of the dry PEC.  
 
3.2.4.4. Degree of crystallinity of polyquaternium-10, humic acid and the PEC 
Dried and powdered samples of the PECs were analysed using a powder X-Ray 
diffractometer (Rigaku Miniflex 600 XRD) (Rigaku Corporation, Tokyo, Japan) to compare 
the crystallinity of the PECs to that of the native polymers. Measurements were taken from 
0º-90º at 10º/min. The incident and receiving slits were both at 2.5º. No monochromator was 
used during the analysis process. Operation of the XRD was done at 40kV and 15mA. 
 
3.2.4.5. Determination of thermodynamic properties of the PEC 
Differential scanning calorimetry (DSC) was conducted for the determination of the thermal 
behavior of HA, PQ10 and PECs. A Mettler-Toledo TC15, TA controller System (Mettler 
Toledo, DSC1, STARe System, Schwerzenback, Switzerland) was utilized. A maximum of 
10mg of sample was filled into each pan which was then closed and perforated. 
Temperature was set at 10ºC-300ºC with a heating rate of 10ºC/min. Thermal degradation 
was carried out using thermogravimetric analysis, Perkin Elmer TGA 4000, (Perkin Elmer 
Inc. Waltham, USA). The heating range utilized was 30ºC–900ºC with a 10ºC/min heating 
rate. 
 
3.2.4.6. Analysis of the surface morphology and elemental quantification of the PEC 
and native components 
Surface morphology was analysed with the aid of a scanning electron microscope. FEI Nova 
NanoLabTM 600 DualBeam (FEI, Hillsboro, OR, USA) was used. Preparation of samples was 
undertaken by sputter coating them with gold and palladium using the SPI-Module Sputter 
coater (Structure Probe Inc. West Chester, USA). Scanning was conducted under 30kV with 
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a beam current of 0.63nA. The working distance was set at 5mm and a dwell time of 3µs 
was utilized. Compositions of the samples were determined using Energy Dispersive X-ray 
spectroscopy which is installed as part of the FIB/SEM. Element mapping was conducted 
with an accelerating voltage of 30kV and an image resolution of 512µm x 448µm. EDS 
utilizes a focused beam of electrons to measure X-ray emissions from charged particles of a 
solid sample. 
 
3.2.4.7. In vitro drug release studies and drug loading capacity of the PEC 
Acetonitrile (50%, 80mL) was added to a 100mg powder sample of the PECs. The amount of 
drug in the sample was determined using a calibration curve constructed using an ultraviolet 
(UV) spectrophotometer (LAMBDA 25 UV/Vis spectrophotometer, PerkinElmer, MA, USA) at 
248nm. A series of dilutions of EFV in simulated intestinal fluid (SIF) (pH=6.8) with 1% 
sodium lauryl sulfate (SLS) were prepared. Percentage drug loading was calculated using 
Equation 3.2. 
 
 % 𝑑𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 =
𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑖𝑛 100𝑚𝑔 𝑝𝑜𝑤𝑑𝑒𝑟 𝑠𝑎𝑚𝑝𝑙𝑒 
𝑡𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑝𝑜𝑤𝑑𝑒𝑟 𝑠𝑎𝑚𝑝𝑙𝑒
 𝑥 100        
                                                                                                                              Equation 3.2 
 
Drug release studies were conducted utilizing the USP apparatus II paddle stirrer (Erweka 
DT 700, Erweka GmbH, Heusenstamm, Germany) with a rotation of 50rpm (Ngwuluka et al., 
2012). Temperature was set at 37ºC and 900mL of simulated gastric fluid at pH 1.2 and 
intestinal fluid at pH 6.8 were used respectively. SLS was added to the dissolution media 
due to the low solubility of EFV. Sample aliquots (5mL) were collected and immediately 
replaced with fresh buffer at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7 and 8 hours. Quantification of the drug 
was carried out after drying the samples and reconstituting the dry powder with acetonitrile. 
Preliminary studies showed that the polymers potentially interfered with UV analysis. Dilution 
of the samples was done separately with deionized water before filtration and UV analysis at 
248nm. All data was obtained in triplicate. 
 
3.2.4.8. Determination of impact of the PEC on viability of Caco2 cell line 
Ex vivo cytotoxicity of HA-PQ10 PEC was conducted on the human colorectal 
adenocarcinoma (Caco2) cell line. The growth medium consisted of Dulbecco’s Modified 
Eagle’s Medium (DMEM) with 4.0mM L-Glutamine and 10% sodium pyruvate foetal bovine 
serum (FBS). Cytotoxicity was measured with the aid of the methyl tetrazolium (MTT) cell 
proliferation assay. The tetrazolium ring of 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl 
tetrazolium bromide is reduced by the cell mitochondrial dehydrogenases yielding MTT 
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formazan crystals which were quantified spectrophotometrically to obtain the optical density 
with the aid of a microplate reader (Power Wave XS, BIO-TEK®, USA) (Palamà et al., 
2011). Caco2 cells (100µl) with a density of (6 x 104)/100µl were seeded in a 96 well plate 
and incubated in a CO2 incubator (RS Biotech Galaxy, Irvine, UK). After 24 hours, 
0.375mg/mL powdered PEC samples (100µl) dispersed in the cell culture medium were 
added to the well plates in triplicate and incubated for another 24 hours. The test solution 
was replaced with culture medium (100µl) and MTT solution (10µl) before incubation for 3 
hours. Solubilization solution was added before absorbance from the wells was measured at 
570nm with a background absorbance of 690nm. Cell viability was calculated using Equation 
3.3. 
 
𝐶𝑒𝑙𝑙 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (%) =  
𝑂𝐷𝑡𝑟𝑒𝑎𝑡𝑒𝑑 
𝑂𝐷𝑐𝑜𝑛𝑡𝑟𝑜𝑙
 𝑥 100 
                                                                                                      Equation 3.3 
Where ODtreated is the optical density of the cells treated with the PEC sample and ODcontrol is 
the optical density of the untreated cells. 
 
3.3. RESULTS AND DISCUSSION 
3.3.1. Self-assembly nature of humic acid and polyquaternium-10 to form a fibrilla PEC  
As the PQ10 solution was slowly added to the HA solution, the PEC was instantly formed 
and it was observed as brown strands that precipitated out and settled at the bottom of the 
beaker. Figure 3.1(a) represents the stages of formation and the strands that formed which 
is generally characteristic to PEC formation. The PECs were synthesized in stoichiometric 
ratios at pH 6.0 (F1), pH 7.0 (F2) and pH 8.0 (F3). When the PECs were soaked in distilled 
water, they did not dissolve but collected at the bottom of the beaker possibly due to the 
intramolecular interactions being more superior to the PEC-water interactions. Upon filtering, 
they were washed with deionized water to ensure that all unentrapped drug was removed 
from the fibrous PEC sample. Complexation between the polycation (PQ10) and the anionic 
amphiphile (HA) transpired through the formation of electrostatic bonds between the 
functional groups. When the PQ10 solution was titrated into the HA solution, the ammonium 
groups bonded with the carboxylic groups therefore exposing the less hydrophilic cellulose 
backbone to the aqueous environment (Figure 3.1(b)). The HA macromolecule was engulfed 
by the PQ10 molecules in a stoichiometric ratio that facilitated the self-assembly of the 
polymers into a strong and stable system, devoid of crosslinking. Drug loading was 
conducted by adding the dissolved drug into the HA solution prior to titration of the PQ10 into 
the solution. EFV was encapsulated into the polymer through hydrophobic interactions with 
the large aromatic core present in HA. 
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Figure 3.2: (a) Digital pictures of the self-assembly of HA and PQ10 and the fibrous PECs 
collected by filtration before drying; (b) a schematic depicting the self-assembly process of 
the HA and PQ10 
 
3.3.2. Evaluation of the humic acid concentration and presence of functional groups 
Since HA is known to dissolve in alkaline conditions, a pH of 7.0 was found to be ideal for 
dissolving the polymer with 100mL of this solution being utilized for PEC formation. 
Preliminary rheology results for HA in solution showed a viscosity of 1.0735mPa.s at pH 6.0, 
1.406mPa.s at pH 7.0 and 1.348mPa.s at pH 8.0. A higher viscosity value indicated an 
increase in the amount of humic acid that completely dissolved in water at that particular pH. 
Consequently, using a pH >8.0 meant that phenolic groups would become ionized as well 
since they possess an estimated pKa of 9. The phenoxide ion is however less stable and 
can therefore easily reform the phenol group unlike the ionized carboxylic group. The 
carboxyl groups are the more dominant ones in number in HA compared to the phenolic 
groups (Ritchie and Perdue, 2003). Re-weighing the dry HA samples indicated that an 
average amount of 2.8mg of HA was present in 0.5mL of HA solution. Concentration of HA 
was determined to be 5.6mg/mL. Six titrations were carried out and an average of 150µl was 
obtained for the complete reaction of 0.5mL of HA. It was thus confirmed that 0.3mmols of 
COO- groups were present in 5.6mg of HA. 
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3.3.3. Analysis of the polyquaternium-10 concentration for stoichiometric reactivity 
with humic acid 
Rheology of supernatants was carried out as a means of quantifying the amount of PQ10 
required to react completely with 25mL (140mg) of HA. The solution containing the PECs 
was allowed to stand for 30 minutes so that the supernatant could be collected after the PEC 
settled. The viscosities steadily decreased as the amount of PQ10 increased from 0.1g. The 
increase was due to a more complete reaction occurring between the polymers. 
Simultaneously, the colour of the supernatants changed and became lighter from a brown 
colour with the decrease in viscosity. Complete reaction was determined after adding 0.141g 
of PQ10 because the viscosity of the supernatant was lowest (1.066mPa.s) at this weight. 
0.141g of PQ10 was required to completely react with 0.140g of HA. Thereafter, the viscosity 
values started increasing when 0.142g or more of PQ10 were added. This increase was 
probably due to the presence of the unreacted PQ10 since complete reaction was achieved 
with 0.141g.  Results from rheology are illustrated in Figure 3.2.  
 
 
Figure 3.3: Viscosities of supernatants from complexes synthesized by adding different 
quantities of PQ10 to HA 
 
3.3.4. Elucidation of the polyquaternium-10 and humic acid electrostatic interactions  
The FTIR spectra for all PECs synthesized at different pH values showed that all the 
samples had the same peaks at similar wavelengths thus implying that they did not possess 
distinct qualitative differences. The main difference was with the percentage transmittances 
(%T) peaks. The FTIR spectra are shown in Figure 3.3(a) and Figure 3.3(b). In comparison 
to the HA spectrum, the F2 spectrum shows a shift in the position of the broad peak at 
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3323.54cm-1 to 3329.63cm-1 as well as a decrease in intensity of absorption. This peak is 
attributed to the free carboxylic acid groups. F3 contained the most of these free groups. 
Two bonds in HA at 1030.28cm-1 and 1008.07cm-1 which correspond to C-O bonds and Si-O 
bonds respectively were destroyed. Between 1080cm-1 and 1300cm-1, the C-O bonds of 
primary alcohols and ether linkages in the PQ10 were destroyed. 
 
  
Figure 3.4: FTIR spectra of (a) F1, F2 and F3 and (b) a comparison of F2 with HA and 
PQ10 
 
The absorption in HA at 1379.59cm-1 is due to the COOH groups and this peak was still 
detected in the PECs though at a much lower absorbance. The shift in the position of the 
unreacted COOH in the PECs at around 1353cm-1 was caused by the changes that occurred 
as complexation took place (Bigucci et al., 2008; Amir et al., 2004). This peak significantly 
decreased in intensity in the complex. Unreacted NH3
+ which is expected to absorb around 
1640cm-1 was not detected in the PECs (Heinen et al., 2013). C-H bonds at 2927.52cm-1 
and 2862.49cm-1 in PQ10 were also present in the PECs at 2924.67cm-1. The analysis 
confirmed formation of a new compound and the region of interaction is depicted by the new 
peak that formed at 1592cm-1 which is present in all the PECs. Detection of the new peak at 
this wavelength is congruous with the FTIR results of chitosan and alginate complexation 
reported by Ribeiro and co-workers (2005). 
 
3.3.5. The influence of simulated gastrointestinal fluid on swelling and degradation of 
the PEC 
Percentage swelling degree (%SD) of the PECs generally increased with time although 
swelling was limited by the lack of or low amounts of free charges within the PECs (Li et al., 
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2009). There was a rapid increase in %SD in the first 2 hours with the PECs swelling most in 
pH 6.8 medium which was followed by a steady increase over time. F1 swelled more in pH 
1.2 medium due to the presence of the free ammonium groups in PQ10. F2 reached 
equilibrium of %SD in both buffers due to the lack of free ions within the PEC. The pH at 
which F2 was synthesized ensured that almost all the charged groups from both polymers 
were exhausted. The complete neutralization of the charges in the polymers resulted in a 
decrease in the internal osmotic pressure of F2. The swelling behaviour was consistent with 
a study conducted by Li et al (2009) in which it was concluded that the chitosan/alginate 
PEC lacking free charged ions would swell the least. F3 exhibited the most %SD after 24 
hours in both simulated media with the most swelling occurring in pH 6.8. The swelling was 
attributed to the abundance of ionized COO- groups and therefore suboptimal reaction with 
the NH3
+ groups at pH 8.0 so that more water could interact with the PEC. The free ions 
were present in the PEC before the experiment was conducted which explains the high %SD 
even in acidic medium. These results are shown in Figure 3.4. FTIR was also utilized to 
determine any pH degradation of the PECs after 24 hours. F1 and F3 formed new bonds at 
912cm-1 (C-H bending) and this bond was already present in F2 before the experiment was 
conducted. The characteristic peak in F2 was altered in both media. F1 and F3 notably had 
this bond (around 1590cm-1) altered in pH 1.2 and this behavior can be attributed to the 
aforementioned fact that there were free ammonium and carboxylic groups in these PECs. 
The behavior of all the PECs signified their potential to interact with the aqueous media and 
their capability of degrading in vivo.  
 
 
 
 
 
 
 
 55 
 
 
 
 
Figure 3.5: PEC degradation and % swelling degree profiles of (a) F1, (b) F2 and (c) F3 in 
SGF and SIF 
 
3.3.6. Degree of crystallinity of polyquaternium-10, humic acid and the PEC 
PQ10 exhibited a strong and broad reflection at about 22º which signified the amorphous 
nature of the polymer (Figure 3.5). The presence of minerals such as calcium, aluminium 
and sodium in the polymers are responsible for lowering the intensities of the XRD spectra 
for the native polymers. These elements scatter the X-rays thus leading to a reduction in 
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their absorption by the samples (Rupiasih and Vidyasagar, 2009). This reflection is present 
in all the PEC formulations which are largely amorphous. The intensities of the formulations 
are reduced in comparison to the polymers and F2 exhibits the least value in this regard. 
The differences between the PECs and native polymers validate the formation of a new 
complex.  
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: Powder X-Ray diffraction patterns for (a) F1, F2 and F3 and (b) a comparison of 
F2 with HA and PQ10 
 
From the results in Table 3.1, it can be noted that all the formulations were amorphous with 
no trace of crystallinity. F2 lacked any significant peaks that could be detected while the 
ones in F1 and F3 fell in similar positions and corresponded to some of the peaks in the 
individual polymers (2θ = 20 for PQ10 and 2θ = 24 for HA). The lack of crystallinity in F1, F2 
and F3 signifies good compatibility between the polymers at these pH values. The diffraction 
pattern of HA was similar to that reported by Mirza and co-workers (2011) in being largely 
amorphous although showing a few crystalline peaks. 
 
Table 3.1: 2θ positions and % crystallinity obtained from XRD 
Polymer/PEC 2θ positions % Crystallinity 
F1 
F2 
F3 
PQ10 
HA 
19.54º; 23.8º 
- 
20.68º; 23.7º 
20.06º; 31.37º; 45.14º; 76.19º; 80.60º 
12.18º; 20.69º; 24.64º; 26.462º 
0 
0 
0 
3.5 
0 
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3.3.7. Analysis of the thermodynamic properties of the PEC 
All the PECs (F1, F2, F3) had single broad peak melting points which fell between 60ºC and 
80ºC (Figure 3.6(a)).  These endothermic peaks were followed by another set of endothermic 
peaks. The onset of the second endothermic event was at 188.10ºC and 220ºC for F2 and 
F3 PECs respectively. F1 showed this change at 244.50ºC. The onsets of these peaks are 
an indication of the stability of the compounds analyzed, where early onset reflects 
instability. It therefore can be concluded that F2, the most amorphous formulation of the 
three formulations, was most stable. Compared to those of HA and PQ10, the thermal 
behavior of the PEC did not correspond to that of either HA or PQ10 (Figure 3.6(b)). A single 
melting point was obtained for all the PECs and these were lower than those of HA (91ºC) 
and PQ10 (80.25ºC). PQ10 had a second endothermic peak at 264.73ºC. This reflects the 
formation of a single new complex different to either of the individual polymers and whose 
melting point is a contribution of the polymers (HA and PQ10). All the thermograms for the 
individual polymers as well as for F1, F2 and F3 showed broad peaks which are 
characteristic of macromolecules. The second endothermic event falls between 150ºC and 
290ºC and this finding is compliant with the DSC results on a chitosan and sodium alginate 
PEC from a study conducted by Shao and co-workers (2015). Similar to the HA-PQ10 PEC, 
the chitosan/sodium alginate PEC is formed by electrostatic bonds between ammonium 
groups in chitosan and carboxylic acid groups in the alginate salt. The bizarre-shaped peak 
shown by HA between 40ºC and 140ºC in Figure 3.6(b) was due to its macromolecular 
nature. 
 
Figure 3.7: DSC thermograms for (a) F1, F2 and F3 and (b) a comparison of F2, HA and 
PQ10 
 
TGA analysis revealed that the PECs were characterized by some initial weight loss 
beginning around 30ºC which was probably caused by dehydration of the samples as they 
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were heating up. The thermal degradation behavior of the PECs is shown as inserts in the 
graphs in Figure 3.7. The PECs showed one degradation event; however, the first derivative 
revealed that the degradation was a two-step process in which the first step occurred at a 
temperature range of 300ºC-350ºC and the second step at 400ºC-550ºC. F2 degrades first 
at 506.13ºC followed by F1 at 529.91ºC and lastly F3 at 542.51ºC. Mass loss was more than 
90% for all the PECs with F2 exhibiting the most mass loss and F3 the least loss.  Total 
degradation of HA and PQ10 did not occur within the 30ºC–700ºC range. The PECs 
degraded at lower temperatures than the two polymers. The mass loss for PQ10 and HA 
was about 4% and 30% respectively. The degradation results from TGA are similar to the 
DSC ones where F2 melts and degrades first followed by F1 and F3. Both sets of results 
suggest loss of organisation within the PECs due to the complexation process as similarly 
observed by Pandey et al (2013) in the study of a chitosan/pectin PEC. These differences 
are as a result of the effect of pH on PEC formation. The degradation of the PECs at lower 
temperatures can also be attributed to this loss of organization.  
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Figure 3.8: TGA thermograms for (a) F1, F2 and F3 and (b) a comparison of F2, HA and 
PQ10 
 
3.3.8. Assessment of the surface morphology and elemental quantification 
The physical structures of the PECs were different to those of the individual polymers as 
shown by the images in Figure 3.8 where HA and PQ10 are different to F1, F2 and F3. The 
images reveal that the surface of PQ10 is characterized by ridges and that of HA is compact 
and speckled by smaller crystals. SEM images of the PECs showed self-assembled fibrils. 
F1 PEC had fewer and smaller pores while F2 and F3 had larger and more numerous pores. 
Increase in pH of synthesis resulted in PECs which were more porous. With regards to the 
use of PECs in drug delivery, pore diameter and number has an influence on the rate of drug 
release (Bawa et al., 2011). It is apparent from the SEM images below that complexation 
occurred because the “fibrilla” appearance of the PECs does not resemble the appearances 
of the individual polymers.  
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Figure 3.9: SEM images of (a) HA, (b) PQ10, (c) F1, (d) F2, (e) F3 at 2000x magnification 
 
The quantitative results of PQ10 and HA were compared to those of all the PECs and these 
are shown in Figure 3.9. F1 has the least elements while F2 contains the most. Both F2 and 
F3 exhibit a mixture of elements in PQ10 and HA. This finding is consistent with SEM results 
where F2 and F3 are more porous than F1 containing the least elements. 
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Figure 3.10: Elemental composition of (a) F1, (b) F2 and (c) F3 in comparison to HA and 
PQ10 
 
3.3.9. Evaluation of in vitro drug release and drug-loading within the PEC 
The calibration curve in Figure 3.10 was determined spectrophotometrically at 248nm. A 
stock solution of 0.3mg/mL was used from which a series of dilutions were prepared. 
SigmaPlot 12.0 (Systat Software Inc, San Jose, California, USA) was employed to plot a 
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liner curve of the UV absorbance of EFV as the dependent variable against the drug 
concentration. The R2 value obtained was 0.99.  
 
 
Figure 3.11: EFV calibration curve 
 
The percentage drug loading (%DL) had to be determined prior to filling capsules for use in 
the drug release studies. Huang and Dai (2014) have noted that the ideal %DL should be 
>20% and F1 showed the ideal %DL of 23.91% while F2 and F3 had %DLs of 14.27% and 
11.9% respectively. The decrease in %DL with increase in pH of synthesis can be attributed 
to the presence of COO- ions which reduced the hydrophobicity of the HA. A high %DL will 
lower the amount of matrix materials to be included in a formulation. On the other hand, very 
high quantities of the drug in the dissolution medium could lead to recrystallization due to the 
thermodynamic instability of the drug in such quantities. The lack of protection from the 
polymeric matrix causes this instability (Six et al., 2004). With the solution mixing method, 
the %DL depends on the self-assembly that occurs when the dissolved polymers and the 
drug are mixed together. Percentage DL can be affected by the inevitable loss of some of 
the polymers and drug in solution during PEC synthesis. 
 
According to the release profiles in Figure 3.11, F2 and F3 exhibited immediate drug release 
over the 2 hours in SGF while a slower drug release pattern was achieved in SIF. The 
release pattern of F1 was different from F2 and F3 in that only 20% of the drug was released 
in SGF while at least 85% was released in SIF over the test period. F1 contained excess 
NH3
+ ions and in SGF charge repulsion might have occurred therefore limiting the swelling 
ability of the PEC and decreasing the rate of drug release in acidic media. This behaviour 
was due to the ability of the PEC to control the drug release in its swollen state as also 
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reported by Saleem and co-workers (2012) on CMe3
+ and COO- interactions. In SIF, the 
excess charge increased the charge density in the PEC leading to faster drug dissolution.  
 
F2 and F3 showed similar drug release profiles in both SGF and SIF. Both PECs exhibit low 
charge densities in acidic medium therefore they are liable to rearrangement leading to 
breakages of the complexes and rapid drug release. However it must be noted that EFV 
dissolves better in acidic SGF compared to the alkaline SIF (Singh et al., 2013) and this 
might have contributed to the faster release rate from F2 and F3 in SGF. F3 contained 
excess ions (COO-) in SIF which retarded PEC swelling due to charge repulsion. 
 
The drug was released from the PECs when the complexes interacted with the aqueous 
environment leading to the gradual breakage of the electrostatic bonds between HA and 
PQ10. The hydrophilic polymer, PQ10, would form a layer rich with the aqueous medium 
around the drug-loaded HA thus enhancing the wetting of the amphiphile, HA, which 
ultimately leads to better wetting of the drug entrapped in the hydrophobic core of HA (De 
Paolis and Kukkonen, 1997). The PEC therefore serves as a drug reservoir. This PEC may 
be utilized for drug delivery with the release pattern being programmed to a desired profile 
such as once daily dosing. This is beneficial for HIV patients so as to improve their 
compliance to medication as well as provide them with more effective treatment.  
 
 
 
 
 
 
 
 
 
 
Figure 3.12: Drug release profiles of EFV-loaded F1, F2 and F3 in (a) SGF and (b) SIF 
 
3.3.10. Elucidation of the impact of HA, PQ10 and PEC on viability of Caco2 cells 
The optical densities of cells treated with the PECs and native polymers were compared to 
the optical density of the untreated cells. The PEC concentration utilized was similar to the 
one implemented in the drug release studies. All the polymer and PEC samples yielded cell 
viabilities above 90% (Table 3.2). Palamà and co-workers (2011) established that cell 
viabilities above 90% indicated non-cytotoxicity. Complexation did not drastically alter the 
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non-cytotoxicity of the biopolymers therefore the native polymers and the PEC were 
biocompatible with the Caco2 cells. The least value (96.8%) was noted for both F2 and F3 
and this decrease in viability was probably due to the presence of excess COO- ions in the 
PECs. These findings validate that the polymers and PEC possess the potential for safe in 
vivo drug delivery application. 
 
Table 3.2: Viability of Caco2 cells treated with PECs and native polymers 
Sample Cell viability (%) 
HA 100 
PQ10 98.4 
F1 98.9 
F2 96.8 
F3 96.8 
 
3.4. CONCLUDING REMARKS 
This study corroborated the formation of a novel polyelectrolyte complex between the HA 
and PQ10. The complexation ability of the two polymers can be attributed to their 
complementary charges that facilitated spontaneous formation of the electrostatic bonds 
between quaternary amino groups in PQ10 and carboxylic groups in the HA leading to the 
formation of a self-assembled “fibrilla” architecture. The use of both polymers has been 
previously established to be safe and HA and PQ10 are readily available at low costs. 
Characterization of the mechanical properties of these biomaterials was essential to validate 
if they are possible candidates for use in drug delivery. Generally, polyelectrolyte complex 
use can be implemented for purposes such as drug delivery particularly to achieve controlled 
drug release. This was validated by the drug release studies and for future uses, different 
polymer ratios or changes in drug loading can be explored in order to achieve a specific 
desired outcome in drug delivery. pH degradation studies revealed the possibility of 
biodegradation of the PECs and also drug release as these PECs break down upon 
interaction with simulated gastrointestinal fluid. This system has significant potential in the 
field of drug delivery for its application in the delivery of lipophilic drugs such as EFV and 
therefore improving the effectiveness of anti-HIV drugs. Other pharmaceutical methods of 
HA-PQ10 complexation will be explored. 
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CHAPTER 4  
 
SYNTHESIS, COMPARISON AND OPTIMIZATION OF A HUMIC ACID-QUAT10 
POLYELECTROLYTE COMPLEX BY COMPLEXATION-PRECIPITATION VS. 
EXTRUSION-SPHERONIZATION 
  
4.1. INTRODUCTION 
The humic acid (HA) and polyquaternium-10 (PQ10) polyelectrolyte complex (PEC) was 
explored in order to benefit from the synergistic effect of using a polymeric complex contrary 
to the individual polymers. The novel HA-PQ10 PEC, previously reported (Siyawamwaya et 
al., 2016), was investigated further for the purposes of comparing properties of the 
complexes synthesized by two different methods. The high affinity for negatively charged 
groups that is exhibited by PQ10 can be attributed to the presence of the quaternary amino 
groups. Our previous study revealed that this molecule formed a polyelectrolyte complex 
with HA, a macromolecule which is classified as an anionic polyelectrolyte. In this study, 
commercial brown HA and PQ10 of 656.1g/mol were utilized (Siyawamwaya et al., 2016). It 
is essential to identify a simplified and cost-effective method of PEC fabrication applicable to 
contemporary dosage form design. Solid dispersions were synthesized using the 
complexation-precipitation (C-P) and extrusion-spheronization (E-S) approaches. Solid 
dispersions have been known to enhance the bioavailability of drugs (Kim et al., 2009). 
Dispersion of the drug within a matrix prevents agglomeration of the drug while encouraging 
its solubility. These dispersions are also responsible for increasing the surface area of the 
drug therefore enhancing the wettability of the bioactive (Singh et al., 2016). However, the 
main drawback of solid dispersions is the tendency of the drug to recrystallize due to the 
metastable properties of the amorphous formulation (Serajuddin 1999; Shergill et al., 2016).  
 
The aqueous solubility and intestinal tissue permeability of efavirenz (EFV) were measured 
and any differences to a selected marketed formulation were noted. Poor solubility occurs 
when the drug solubilization rate is slower than the rate of its passage in the gastrointestinal 
tract (GIT) (Kim et al., 2009). Various methods of improving the hydro-solubility of drugs 
have been employed and these include, but are not limited to, the addition of surfactants into 
formulations, the reduction of drug particle size, delivery of the drug in emulsion vehicles and 
the use of solid dispersions (Usach et al., 2013; Siyawamwaya et al., 2015). The 
permeability of such drugs can also be enhanced by utilizing polymeric delivery systems that 
increase the residence time of the drugs or by encapsulating the drugs in microspheres 
and/or nanoparticles that have a high surface area to volume ratio.  
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The model anti-HIV drug, EFV, was loaded into HA-PQ10 PEC fabricated by the 
complexation-precipitation and the extrusion-spheronization techniques. According to the 
Biopharmaceutics Classification System (BCS), EFV is categorized in Class II (Fandaruff et 
al., 2015). It is a non-nucleoside reverse transcriptase inhibitor (NNRTI) with a bioavailability 
estimated to be between 40-45% and a solubility of 3-9µg/mL (Rao and Shirsath 2016; Six 
et al., 2004). Any drug with a solubility <10µg/mL is regarded as poorly soluble. NNRTIs bind 
to the reverse transcriptase in a non-competitive manner. RTV was added to the optimized 
PEC in order to validate applicability of the complex to BCS class IV drugs which exhibit both 
poor solubility and poor permeability. RTV is classified as a PI which inhibits the formation of 
mature infectious virions. It possesses a bioavailability of 5% and an aqueous solubility of 
1.26µg/mL (Dengale et al., 2015). Low aqueous solubility and permeability also results in 
low and variable bioavailability in vivo and consequentially, higher drug doses have to be 
dosed in order to achieve optimal biological effects (Jones et al., 2013).  
 
4.2. MATERIALS AND METHODS 
4.2.1. Materials 
Humic acid (HA) (brown), polyquaternium-10 (PQ10), microcrystalline cellulose (Avicel PH-
101)(MCC) and sodium lauryl sulphate (SLS) were procured from Sigma-Aldrich® (St. Louis, 
MO, USA). Pure efavirenz (EFV) and ritonavir (RTV) powder (99.99% purity) were 
purchased from Xingcheng Chemphar Co., Ltd. (Taizhou, Zhejiang, China) and used as 
received. The commercially available comparator products were Sonke-Efavirenz® 200mg 
and soft elastic capsules of Norvir® 100mg (ritonavir). All other reagents used were of 
analytical grade.  
 
4.2.2. Synthesis of the drug-loaded Polyelectrolyte Complex (PEC) 
4.2.2.1. Complexation-Precipitation (C-P) via solution-blending of HA and PQ10 
Synthesis of the drug-loaded PEC by C-P involved dissolving EFV (200mg) in methanol 
(20mL) prior to titrating one polymer solution into the other. The EFV solution was added to 
the HA solution (100mL of 5.75mg/mL) and agitated for 5 minutes. Thereafter, an aqueous 
solution of PQ10 (235mL of 2.4mg/mL) was slowly titrated into the HA/EFV solution to 
facilitate self-assembly of the drug-loaded PEC (PEC-E(C-P)) within seconds. The precipitate 
was filtered and dried in a vacuum oven at 40ºC for 12 hours after which it was milled and 
filled into hard gelatin capsules.  
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4.2.2.2. Extrusion-spheronization (E-S) via benchtop extruder and spheronizer 
A combination of HA (1400mg), PQ10 (1410mg), EFV (650mg) and microcrystalline 
cellulose (MCC) (1000mg) were blended in a homogenizer for 5 minutes before synthesis of 
the EFV-loaded PEC (PEC-E(E-S)). The same amount of HA and PQ10 used in the C-P 
method were employed in E-S as well. Deionized water was added to form wet granules of 
the powder mass. The homogenous wet granules were transferred into the barrel of a Mini-
Screw Extruder (Caleva Ltd. Sturminster Newton, Dorset, UK) for extrusion at 100rpm. MCC 
absorbed the granulating fluid (water) which was then compressed onto the outer surface of 
the extrudates thus further lubricating the surface to render the extrusion process feasible. 
The extrudates were then collected and immediately spheronized in a Multi-Bowl 
Spheronizer (Caleva Ltd. Sturminster Newton, Dorset, UK).  
 
4.2.3. Physicochemical and mechanical characterization of the drug-free HA-PQ10 
PEC  
4.2.3.1. Assessment of the surface morphology 
SEM (FEI Nova NanoLabTM 600 DualBeam FIB/SEM, Hillsboro, OR, USA) was utilized for 
determining the surface morphology of the PEC samples. Analysis was conducted at 20 kV. 
Prior to mounting samples onto the SEM stage, they were thoroughly dried and sputter 
coated with chromium for 2 minutes. All images were taken at x2000 magnification. 
 
4.2.3.2. Complexation validation via PEC solubility testing in varying solvents 
Complete synthesis of the PECs was evaluated utilizing the solvent test. PECs were 
dispersed separately in ethyl acetate, dimethyl sulfoxide (DMSO), formic acid, ethanol, 
acetone, dichloromethane (DCM) and water at 80ºC for 24 hours under constant stirring. 
The achromatic solutions were observed for any colour changes which would indicate the 
solubility of PECs in the solvent. 
 
4.2.3.4. Determination of polyelectrolyte complex cytotoxicity  
Ex vivo cytotoxicity of drug free HA/PQ-10 PEC was conducted on the human colorectal 
adenocarcinoma (Caco2) cell line. The growth medium consisted of Dulbecco’s Modified 
Eagle’s Medium (DMEM) with 4.0mM L-Glutamine and 10% sodium pyruvate foetal bovine 
serum (FBS). A 25cm2 tissue culture flask was utilized to aseptically culture the cells which 
were placed in an incubator (RS Biotech Galaxy, Irvine, UK) at 37ºC, 95% relative humidity 
and 5% CO2. Culturing was continued until a desired cell density (70-80% confluency) was 
obtained. Cytotoxicity was measured with the aid of the methyl tetrazolium (MTT) cell 
proliferation assay. Caco2 cells (100µL) were cultured in a 96 well plate with a density of (6 x 
104)/100µL and incubated in a CO2 incubator. After 24 hours, serial dilutions of HA, PQ10, 
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PEC(E-S) and PEC(C-P) samples (100µL) were prepared in the well plate in triplicate and 
incubated for 24 hours. The samples were then replaced with 10µL of MTT solution and 
growth medium (100µL) before incubation for 3 hours. Absorbance from the wells was 
measured with the aid of a microplate reader (Power Wave XS, BIO-TEK®, USA) at 570nm 
with a background absorbance of 690nm. The MTT assay was also carried out on cells that 
were treated with the optimized formulation and cell viability was measured after 24 hours. 
Measurement was repeated on cells that were left to recover for a further 24 hours. 
 
4.2.4. Characterization of EFV-loaded HA-PQ10 PECs produced by E-S and C-P 
4.2.4.1. Influence of PEC synthesis method on the interaction of HA and PQ10 
Attenuated Total Reflectance-Fourier Transform Infrared, ATR-FTIR, with a single reflection 
diamond MIRTGS detector (PerkinElmer® Spectrum 100 Series FT-IR Spectrometer 
PerkinElmerLtd., Beaconsfield, UK) was employed to assess the interactions between the 
PEC, pure drug and native polymers. This was conducted over a wavenumber of 6000-
450cm-1 using 25 wavescans per spectrum and a force of 115N. A resolution of 4cm-1 was 
utilized. 
 
4.2.4.2. Determination of the thermal properties of PECs and physical mixture 
Melting points of dry powder samples were comparatively deduced by using differential 
scanning calorimetry (DSC) (Mettler Toledo DSC-1 STARe System, Schwerzenback, ZH, 
Switzerland) over a temperature range of 20ºC–300ºC with a heating rate of 10ºC/min.  
Nitrogen was used as the purge gas to avoid oxidation. A maximum of 10mg sample was 
placed in a 40µL aluminium pan and the lid was crimped and perforated. Analysis of the 
thermograms revealed the specific temperature that the samples melted at and the curves 
were plotted as heat flow (mW) against temperature. 
 
4.2.4.3. Determining the extent of supersaturation and in vitro EFV release 
Drug quantification was conducted utilizing the EFV calibration curve described in Chapter 3 
and the one for RTV had to be constructed as well. Serial dilutions of RTV in simulated 
intestinal fluid (SIF) containing 1% sodium lauryl sulfate (SLS) were utilized. The percentage 
drug-loading (%DL) was ascertained by adding finely ground PEC powder (100mg) into SIF 
(40mL) at pH 6.8 containing SLS (1%) (according to USP monograph, USP 32-NF 27). The 
powders were dispersed in the SIF. After incubation in an orbital shaker bath, samples were 
filtered with a 0.22µm filter and drug concentrations determined spectrophotometrically 
(Lambda 25 UV/Vis spectrophotometer, PerkinElmer, MA, USA) at 247nm for EFV 
(R2=0.9926) and 241nm for RTV (R2=0.9998). The saturation solubilities were determined by 
adding formulations containing 2.5mg/mL of EFV in SIF. This was incubated in an orbital 
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shaker bath for 36 hours and drug concentrations were determined via UV absorbance 
measurements (Mabrouk et al., 2015). Sampling was conducted every 12 hours and the 
highest quantity of drug concentration determined was considered the supersaturation 
amount. The EFV release rate from the capsules was determined using the USP Apparatus 
II paddle stirrer at 50rpm (USP 33) (Erweka DT 700, Erweka GmbH, Heusenstamm, 
Germany). Formulations were placed under a ring-mesh assembly to prevent floatation that 
may lead to unsteady and biased drug release profiles (Viral et al., 2010). The temperature 
was maintained at 37ºC and sample aliquots (5mL) were collected at predetermined times 
over a 24 hour test period. Sink conditions in the dissolution fluid (900mL) were maintained 
by replacing the samples withdrawn immediately with drug-free media. The dissolution 
medium consisted of SIF, which was necessary to perform the studies under physiologically 
relevant conditions since the solubility of poorly aqueous soluble drugs is affected by the 
presence of surfactants. Saturation solubility, EFV release and permeation studies for the 
optimized PEC’s were undertaken in the fed state simulated intestinal fluid (FeSSIF). 
Preparation of FeSSIF comprised dissolving NaOH (20.2g), glacial acetic acid (43.25g) and 
NaCl (59.37g) in deionized water (5L) and thereafter adjusting the pH to 5.0. Native FeSSIF 
(500mL) was used to dissolve sodium taurocholate (59.08g) and 59.08mL of lecithin 
dissolved in methylene chloride (100mg/mL) was added to the blank FeSSIF. The methylene 
chloride was eliminated from the emulsion by evaporation and the volume of the media was 
adjusted to 2L (Sinha et al., 2010). Collected sample aliquots were immediately filtered using 
a 0.22µm filter and diluted appropriately. Equation 4.1 was employed to calculate the %DL. 
 
%𝐷𝐿 =
𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑖𝑛 100𝑚𝑔 𝑝𝑜𝑤𝑑𝑒𝑟 𝑠𝑎𝑚𝑝𝑙𝑒 
𝑡𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑝𝑜𝑤𝑑𝑒𝑟 𝑠𝑎𝑚𝑝𝑙𝑒
 𝑥 100 
                  Equation 4.1 
 
4.2.4.4. Ex vivo permeability studies employing porcine small intestinal tissue 
A Franz Diffusion Cell (FDC) apparatus (PermeGear Inc. Bethlehem, PA, USA) was utilized 
to measure the drug permeation across porcine small intestinal tissue from the PECs across 
a concentration gradient of 4mg/mL. Phosphate buffered saline (PBS) (12mL) at pH 7.4 was 
added to the acceptor compartment. An emulsion of capsule contents (4mg/mL) in SIF and 
FeSSIF for the optimized PECs was added to the donor compartment. The two 
compartments were separated by a portion of excised porcine small intestinal tissue (ileum). 
The intestinal tissue was freshly obtained from a large white pig and immediately snap-
frozen for preservation. Prior to the permeation experiment, the tissue was thawed and 
allowed to equilibrate on the acceptor compartment to 37ºC for 20 minutes. The adipose and 
muscular layers were carefully excised. The study was performed over a 24 hour period at 
 74 
 
37ºC. Sample aliquots (0.5 mL) were withdrawn and replaced by PBS of equal volume. The 
mean values of the quantity of EFV that permeated were used to compute the flux (J) and 
permeability coefficient (P) of the drug according to Equation 4.2 and Equation 4.3. Flux is 
the quantity of drug transported across the membrane over a certain period of time and was 
determined employing Equation 4.2.  
 
𝐽 =  
𝑀
𝐴𝑡
 
                  Equation 4.2 
 
Where, M is the mass of EFV present in the acceptor compartment at time t and A is the 
area available for permeation (Tang et al., 2005). Permeability can be defined as the rate of 
EFV permeation per unit concentration (Dezani et al., 2013) and the permeability coefficient 
was calculated according to Fick’s first law. 
 
𝑃 =  
𝐶2  ×  𝑉
𝐴 ×  𝑡 ×  𝐶1
 
                  Equation 4.3 
 
Where: P (cm.h-1) is the permeability coefficient; V (mL) is the volume of the acceptor 
compartment (12mL); A (cm2) is the effective permeation area (1.767cm2); t (h) is the time 
interval; C1 (mg.mL
-1) is the concentration in donor compartment and C2 (mg.mL
-1) is the 
concentration in the acceptor compartment (Lavon et al., 2005). The transepithelial electrical 
resistance (TEER) of the porcine tissue was measured using a SevenMulti™ dual meter 
pH/conductivity (Mettler Toledo, Zurich, Switzerland) at 25ºC to confirm tissue integrity. 
           
4.2.5. PEC optimization via a Design of Experiments (DoE) approach 
4.2.5.1. Implementation of a randomized Box-Benkehn experimental design 
A series of PEC formulations were synthesized using a 2-factor, 2 tier Box-Benkehn 
statistical design. Minitab® V16 software (Minitab Inc. PA, USA) was used to generate the 
experimental design template constituting 13 formulations, 5 centre-points and 1 replicate 
with the ratio of HA:PQ10 and the quantity of granulation fluid (deionized water) being the 
independent variables as shown in Table 4.1. The mean dissolution time (MDT) from the 
drug release studies and the drug flux from porcine intestinal tissue permeability studies over 
24 hours were the responses that were considered and maximized to obtain an optimized 
PEC formulation with enhanced solubility and permeability of the encapsulated drug. 
Maximum speeds of extrusion and spheronization were set as constants based on results 
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from preliminary studies that showed that maximum speeds were ideal to facilitate the 
required extrusion and spheronization. EFV was used as the model drug for the 
experimental design phase of this study. 
 
4.2.5.2. Evaluation of extrudate flow properties of the HA-PQ10 PEC 
The Hausner Ratio (HR) was calculated to determine the flow properties of the extrudates 
that were then encapsulated into gelatin capsules. In order to measure the bulk and tapped 
densities, initial and final volumes of specific extrudate weight was recorded. The volume 
was at least 60% of the cylinder volume (Method 1 -section 2.9.34 European 
Pharmacopoeia (EP8.0, 2014). The final volume was measured after tapping a 50mL glass 
cylinder onto a hard wood surface from a 20mm height (Jan et al., 2015). Bulk density, 
tapped density and the HR were calculated according to Equations 4.4, 4.5 and 4.6. 
 
𝐵𝑢𝑙𝑘 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 =  
𝑤
𝑣𝑜
 
                  Equation 4.4 
𝑇𝑎𝑝𝑝𝑒𝑑 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 =  
𝑤
𝑣𝑓
 
                             Equation 4.5 
𝐻𝑅 =  
𝑇𝑎𝑝𝑝𝑒𝑑 𝑑𝑒𝑛𝑠𝑖𝑡𝑦
𝐵𝑢𝑙𝑘 𝑑𝑒𝑛𝑠𝑖𝑡𝑦
 
                  Equation 4.6 
Where w is the weight of the extrudates (g), vo is the initial volume of extrudates (mL) and vf 
is the final volume of the extrudates (mL). 
 
4.2.5.3. Establishing the surface morphology and porosity of the optimized PEC 
Surface morphologies of the optimized formulations were determined by SEM as explained 
in 2.3.1. The porosity was measured using BET isotherms of nitrogen on a Porosity Analyzer 
(ASAP 2020, Micromeritics Instrument Co., GA, USA) (Kondiah et al., 2013). The extrudates 
were degassed to remove surface moisture and impurities. In order to measure the surface 
area, pore size and pore volume of the samples, unspheronized pieces of extrudates which 
were at least 100mg in weight were analysed.  Analysis involved two phases, the evacuation 
phase and the heating phase. Parameters for the evacuation phase included a temperature 
ramp rate of 10ºC/min with a target temperature of 40ºC and an evacuation rate of 
50mmHg/sec. The temperature ramp rate for the heating phase was 10ºC/min with a 30ºC 
hold time. The analyzer generated the Brunauer-Emmett-Teller (BET) and Barrett-Joyner-
Halenda (BJH) nitrogen adsorption and desorption analysis. BET analysis provided surface 
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area analysis while BJH provided pore size and pore volume analysis. Equations 4.7 and 4.8 
were implemented for BET surface area determination.  
 
𝐴𝑠(𝐵𝐸𝑇) =  𝑛𝑚
𝑎  𝑥 𝐿 𝑥 𝑎𝑚 
                  Equation 4.7 
𝑎𝑠(𝐵𝐸𝑇) =  
𝐴𝑠(𝐵𝐸𝑇)
𝑚
 
                      Equation 4.8 
 
Where, As(BET) is the total surface area and as(BET) is the specific surface area of the 
adsorbent mass (m). L is the Avogadro constant (Kondiah et al., 2013). 
 
4.3. RESULTS AND DISCUSSION  
4.3.1. Outcome of PEC synthesis and physical variances between PEC(E-S) and 
PEC(C-P) 
Synthesis of the PECs was successful using either the C-P or E-S approaches. With the C-P 
technique, complexation occurred instantaneously when the PQ10 solution was added to the 
HA drug solution. This was evidenced by the formation of strand-like precipitates as a result 
of the complexation process. Self-assembly of the polymers produced a dense supernatant 
that presented a challenge in filtration. For the E-S technique, it was imperative to add 
excipients that facilitated extrusion and subsequent spheronization.  
 
4.3.1.1. Analysis of surface morphology of the PEC in compacted and powdered form 
Scanning electron microscopy (SEM) images of the PECs synthesized by the two methods 
revealed that they notably differed morphologically (Figure 4.1). The compact PEC(E-S) 
(Figure 4.1(b)) displayed an irregular surface devoid of the large pores associated with the 
PEC(C-P) fibres. Powdered PEC(C-P) maintained its fibrous nature while the surface of PEC(E-S) 
was tightly packed together in the powdered form. Surface morphology may be utilized in 
predicting drug dissolution properties which are dependent on surface area (DiNunzio et al., 
2008). From the SEM images, the pores on the PEC(C-P) may facilitate faster interaction of 
the PEC with the dissolution fluid, thus enhancing solubility and the rate of drug release. 
However, PEC(E-S) would be expected to have a more extended drug release pattern.  
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Figure 4.1: SEM images of drug-free PECs (a) PEC(E-S), (b) PEC(E-S) (powdered), (c) PEC(C-
P) and (d) PEC(C-P) (powdered) at x2000 magnification 
 
4.3.1.2. Validation of drug-free PEC complexation via solubility testing in varying 
solvents media 
Stoichiometric PECs are generally insoluble in any known solvent (Shovsky et al., 2009). 
The PECs were insoluble in all the representative solvents; ethyl acetate (electron donor), 
DMSO (electron acceptor), formic acid (proton donor), ethanol (proton donor), acetone 
(proton acceptor), DCM (dipole-dipole interaction) and deionized water (neutral). The slight 
solubility of PEC(E-S) in water was attributed to the partial complexation from E-S which 
resulted in the presence of uncomplexed polymers that were readily soluble in the water. 
Formic acid was included to validate the typical behaviour of PECs containing cellulose 
based polymers which dissolve completely in the acid (Ito et al., 1986). Both formulations 
completely dissolved in formic acid. 
 
4.3.1.3. Assessment of the cytotoxicity of the PEC  
The MTT assay utilizes the reduction of the tetrazolium ring of 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyl tetrazolium bromide by the cell mitochondrial dehydrogenases yielding MTT 
formazan crystals which were then quantified spectrophotometrically with the aid of a 
microplate reader. This reduction of the tetrazolium ring is directly proportional to cell 
metabolism (Coimbra et al., 2011). Studies previously conducted revealed that HA, PQ10 
and PEC(C-P) were non-cytotoxic to Caco2 cells at 0.375mg/mL (Siyawamwaya et al., 2016). 
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The assay in this study was conducted to ascertain the impact of each complexation 
technique on the cell viability and therefore biocompatibility of the PECs over 24 hours. 
According to the data presented in Figure 4.2 all the samples for the PECs and polymers 
exhibited non-cytotoxic behaviour (cell viability >90%) at all test concentrations barring 
PEC(C-P) at 1.5mg/mL which revealed slight cytotoxicity (cell viability = 89±2.01%). It can be 
inferred that PEC(E-S) in comparison to PEC(C-P) is less likely to induce acute cytotoxicity at 
higher concentrations (1.5mg/mL). 
 
 
Figure 4.2: Cell viability analysis of HA, PQ10 and drug-free PECs 
 
4.3.2. Characterization of EFV-loaded PEC synthesized by C-P and E-S 
4.3.2.1. The influence of complexation method on EFV, HA and PQ10 interactions 
The FTIR spectra (Figure 4.3) revealed that the dominant bond (C=O cyclic, 1700cm-1) from 
EFV was present in both PECs and the physical mixture (pE), with its position remaining 
constant in all formulations. However, its intensity was diminished significantly in the PECs 
and pE compared to the pure drug. Another EFV bond expressed in PEC-E(E-S), PEC-E(C-P) 
and pE was the exocyclic triple bond stretching (2248cm-1). These characteristic peaks are 
consistent with the ones reported by da Costa and co-workers (da Costa et al., 2012). 
Exhibition of these bonds in the drug loaded formulations confirmed presence of the 
unaltered drug in the drug/polymer complex or physical blend. The tertiary amide bond in 
EFV (1600cm1) overlaps with the new bond that is expected to form in PECs as previously 
reported (1). This is the point of complexation between NMe3
+ and COO-. Most of the groups 
in EFV are not available for bond formation with the polymers except for the N-H bond. This 
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is detected at 3500cm-1–3100cm-1 and would overlap with the polymeric O-H stretch 
detection at the same wavenumber. The interaction of the N-H bonds with hydrogen donor 
groups on the polymer chains may result in drug/polymer interaction which may improve 
drug entrapment and overall, enhance drug solubility as the bond would easily break in 
aqueous medium. The shape of the bond at 3500cm-1–3100cm-1 was sharper in the drug-
loaded PECs than the drug-free PECs and pE. The resultant band around 3300cm-1 had a 
lower intensity than that of the drug free PEC signifying drug/polymer interaction (Sathigari et 
al., 2012; Pawar et al., 2016). FTIR is a quantitative analysis of the bonds found in the test 
sample, therefore the diminished absorbance of EFV bands in the formulations could have 
resulted from the masking effect of the polymers on the drug due to the high polymer : drug 
ratio. 
 
 
Figure 4.3: FTIR spectra for (a) PEC-E(E-S) and (b) PEC-E(C-P)  
 
4.3.2.2. Elucidation of the thermodynamic properties of the EFV-loaded PEC 
compared to drug-free PEC and physical drug/polymer mixtures 
The DSC thermograms in Figure 4.4 revealed the differences in thermal properties of the 
PECs produced by the two methods, pure EFV and physical blends. The physical blend 
shows various Tm values some of which correspond to the Tm of PEC(E-S),  PEC(C-P) and EFV. 
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As expected, multiple endothermic events were noted for pE and one of them coincides with 
the melting point of pure EFV. The endotherm is reduced compared to that of the pure drug 
due to the high polymer : drug ratio. There was no sharp melting endotherm corresponding 
with that of the crystalline API in both drug-loaded PECs thus signifying the good miscibility 
of the API into the polymeric matrix. According to literature, the disappearance or shifting of 
the endotherm of a pure drug is indicative of lack of defined crystalline arrangements. This 
was probably a result of the API being partially miscible in the matrix and therefore forming a 
mixed solid dispersion system of amorphous and crystalline drug (Koh et al., 2013). This is 
consistent with the FTIR results that revealed that drug/polymer interactions occurred. Ideal 
drug-polymer interactions are vital in order to prevent clumping of drug which is responsible 
for drug polymorphism. It can be inferred that the drug crystallinity was reduced upon 
dispersion into the HA-PQ10 and therefore led to enhanced drug solubility. A similar 
conclusion was reached by Mabrouk and co-workers (2015) who concluded that increase in 
solubility of efavirenz loaded into physically crosslinked hydroxyethylcellulose and polyacrylic 
acid hydrogel was as a result of a decrease in crystallinity of the drug as well as 
drug/polymer interactions. The endothermic peaks from 50ºC-100ºC were attributed to loss 
of moisture from the samples.  
 
The peaks (around 150ºC) adjacent to the one for EFV were attributed to the polymer 
thermal properties, this same peak is exhibited in the drug free extruded sample. This peak 
becomes broader in both complexes thus it can be concluded that the PECs are more 
amorphous in nature compared to the native polymers. PEC(C-P) was expected to undergo 
complete complexation during synthesis in aqueous medium and hence would be more 
amorphous than PEC(E-S). Complexation of PEC(E-S) was probably partial after synthesis and 
only completed in situ during drug release and permeation when the system got in contact 
with the aqueous medium. PECs form in water or under temperatures which would cause 
the polymers to melt and neither of these conditions were met during the E-S process 
(Siyawamwaya et al., 2016). The presence of the drug in the PEC resulted in remarkable 
changes in PEC-E(C-P) which expressed significant endothermic events unlike PEC(C-P) which 
hardly showed any changes during heat absorption. The behaviour of PEC-E(E-S) was 
identical to its drug-free counterpart. 
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Figure 4.4: DSC thermograms for (a) PEC-E(E-S) and (a) PEC-E(C-P)  
 
4.3.2.3. Evaluation of the extent of supersaturation and EFV release 
Both PECs exhibited %DL >14% with PEC-E(C-P) possessing higher EFV-loading 
(20.82±2.03%w/w) than PEC-E(E-S) (14.19±0.49%w/w). This was due to the presence of 
excipients that were pertinent for the E-S process therefore lowering the %DL. The amount 
of MCC required to facilitate the E-S process was directly proportional to the amount of drug 
in the formulation (Kleinebudde 1997). Caution was exercised in determining the ideal drug-
loading in order to avoid leaching of drug from the extrudates. PEC-E(E-S) exhibited superior 
solubility properties (5.1±5.39%) to PEC-E(C-P) (2.83±2.69%) and pE (0.88±2.55%). The 
incorporation of EFV into the HA-PQ10 PEC greatly increased the wettability of EFV. 
Solubility enhancement was attributed to the partial conversion of the crystalline drug to the 
amorphous form which provided better interaction between the drug and dissolution medium 
due to the negation of lattice energy in the system. The PEC, due to the nature of the native 
polymers (HA and PQ10), was able to attract more dissolution medium which was trapped in 
the matrix for prolonged periods of time thus allowing sufficient contact between the drug 
and medium, leading to increase in wettability and consequently higher solubility. For PEC-
E(E-S), the extrusion process led to the dispersion and possible hydrogen bond interactions of 
EFV with the polymeric matrix thus enhancing drug solubility. After 36 hours, PEC-E(E-S) still 
provided a saturated system and this demonstrated that a considerable degree of stability in 
protecting EFV from recrystallization within the dissolution time period was present. PEC-E(C-
P) did not maintain this stability since the highest EFV concentration was detected at the 24 
hour sampling point. Supersaturation of the drug may not occur if an amorphous system 
rapidly reverts to the crystalline state (Prasad et al., 2014). It was imperative to implement 
the additional step of complexation since the physical blend did not result in notable solubility 
amplification of EFV.  
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Figure 4.5(a) depicts the EFV release profiles over a 24 hour period. PEC-E(E-S) and PEC-
E(C-P) both exhibited controlled release of EFV due to the entrapment of the drug in the novel 
complex. For satisfactory comparison of the drug-loaded PECs, MCC was added to the 
PEC-E(C-P) before encapsulation into the hard gelatin capsules. The formulation that yielded 
superior solubility and permeability enhancement was selected for optimization and loading 
of the additional BCS class IV drug, RTV. Since the PECs do not easily dissolve in SIF, they 
were responsible for slowly releasing the drug from the system thus providing a controlled 
release system. Drug release from pE was poor (<40%) and this validated the need for using 
a PEC instead of the physical blend for optimal drug delivery. With the physical blend, upon 
dissolution of the capsule shell, the exposed blend formed a PEC in situ. However, the PEC 
formation occurred on the surface and was not uniformly distributed within the drug/polymer 
blend. Drug release from PECs is affected by the specific chemical structures of the native 
polymers hence different release profiles are expected from different polymer combinations 
(Shao et al., 2015). The amphiphilic HA was responsible for lowering the solid/liquid 
interfacial tension therefore increasing the wettability of the lipophilic EFV which was trapped 
in the hydrophobic core of the polymer. This further prevented the agglomeration of EFV 
particles.  
 
4.3.2.4. Assessment of ex vivo intestinal tissue permeability of EFV from the PEC 
Transmembrane permeability profiles of the PECs were superior to those of the comparator 
products as illustrated in Figure 4.5(b). The constant EFV permeation from the PECs 
revealed that there was no saturation in the intestinal membrane. The permeability 
coefficient for PEC-E(E-S) (0.163±0.043cm
2.h-1) and PEC-E(C-P) (0.232±0.008cm
2.h-1), was 
elevated by the presence of larger amounts of free drug due to supersaturation. EFV-loading 
into the PEC system was responsible for this behavior. The consistent permeation coupled 
with higher permeability coefficients and flux values observed in the PEC-E(C-P) were due to 
faster EFV release. PEC-E(C-P) exhibited the highest flux of 0.054±0.024mg.cm
-2.h-1 while 
PEC-E(E-S) had a flux of 0.033±0.052mg.cm
-2.h-1. The least flux was recorded for pE 
(0.008±0.017mg.cm-2.h-1).  
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Figure 4.5: (a) Drug release profiles and (b) porcine intestinal tissue permeation profiles for 
EFV formulations 
 
Figure 4.6 shows the TEER of the intestinal tissue before and after the permeation studies 
were undertaken. Results demonstrated any changes that might have occurred to the 
integrity of the tissue as a result of drug permeation. Both PECs had an increase in 
membrane charge contrary to pE which exhibited a decrease in membrane charge when 
EFV crossed the small intestinal tissue. It can be deduced that the EFV-loaded PECs did not 
cause any irreversible membrane damage and neither were there any leakages since EFV 
passage was constant. Controlled drug release was also responsible for the constant 
concentration gradient on the membrane. The improved permeation did not compromise the 
tissue viability as evidenced by the reversibility of TEER value after placement in distilled 
water at the end of the study. Permeation enhancement can be attributed to the interaction 
of the mucoadhesive PEC with the intestinal tissue. This led to prolonged duration of the 
drug at the absorption site in high concentrations due to enhanced solubility of the drug. The 
presence of mucus could have enhanced effectiveness of the complex. PEC-E(c-p) did not 
have a stronger interaction with intestinal mucosa compared to the EFV-loaded extrudates. 
Permeation was affected by the PEC delivery system and not the physical mixture implying 
that the mechanism was not tight junction controlled but largely dependent on the resulting 
complex. 
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Figure 4.6: Intestinal integrity analysis of EFV-loaded formulations (TEER in Ω.cm2 x 104) 
 
4.3.3. Analysis of the experimental design and optimized PEC formulations 
4.3.3.1. Analysis of the physical properties of the experimental design formulations 
PEC synthesis by E-S was chosen for optimization purposes since the complex showed 
superior solubility over 24 hours. All design formulations were effectively extruded and 
spheronized. At least 95±0.39% of the extrudates fell within the ideal size range of 500-
1000µm as determined by Singh and co-workers (2012). The optimized PEC formulation 
had a composite desirability of 0.939. Loading of an alternative drug RTV into the optimized 
formulation (resulting in PEC-R(E-S)) did not alter the E-S properties and RTV was also 
soluble in and compatible with the optimized polymer ratio. The HR value measures the 
interparticulate friction between extrudates and the test was implemented to determine 
suitability of the samples for encapsulation in a hard gelatin shell (Shah et al. 2008). The HR 
value was <1.25 (Table 4.1) for all formulations therefore F1-F13 had good flow properties. 
Generally, the smaller the HR value, the better the flow properties of the test sample 
(Shravani et al., 2011; Singh and Kumar 2012). The small difference between the bulk (Da) 
and tapped (Dc) densities further demonstrated that the extrudates had good flow properties. 
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Table 4.1: Flow properties of extrusion and spheronization of experimental design 
formulations 
Formulation HA : PQ10 
molar ratio 
Deionized 
Water 
(drops) 
Bulk Density 
(Da) (g/mL) 
Tapped 
Density (Dc) 
(g/mL) 
Da -Dc (g/mL) Hausner Ratio (HR) 
F1 5:3 4 0.79±0.0004 0.71±0.053 0.08±0.062 0.90±0.023 
F2 5:3 4 0.79±0.019 0.71±0.037 0.08±0.031 0.90±0.092 
F3 5:3 5 0.66±0.040 0.62±0.071 0.04±0.005 0.94±0.034 
F4 1:3 4 0.85±0.073 0.68±0.004 0.17±0.009 0.80±0.003 
F5 1:3 5 0.71±0.009 0.63±0.0009 0.08±0.084 0.89±0.003 
F6 5:3 4 0.79±0.063 0.71±0.008 0.08±0.104 0.90±0.010 
F7 3:1 3 0.79±0.039 0.65±0.083 0.14±0.075 0.82±0.097 
F8 1:3 3 0.75±0.038 0.71±0.028 0.04±0.027 0.95±0.021 
F9 5:3 4 0.79±0.082 0.71±0.026 0.08±0.026 0.90±0.063 
F10 3:1 5 0.68±0.051 0.56±0.012 0.12±0.009 0.82±0.044 
F11 3:1 4 0.80±0.093 0.67±0.014 0.13±0.017 0.84±0.050 
F12 5:3 4 0.79±0.028 0.71±0.019 0.08±0.015 0.90±0.002 
F13 5:3 3 0.73±0.004 0.68±0.049 0.05±0.035 0.93±0.008 
Data expressed as mean (n=3) 
 
Rapid contact of the extrudates with the aqueous medium facilitated the formation of the 
rate-controlling PEC due to in situ complexation. The highest MDTs were recorded for F4, 
F5 and F8 and these formulations contained the most PQ10 (1:3). This finding was due to 
the formation of a hydrated viscous layer around the extrudates as they absorbed the 
dissolution medium and this was consistent with the finding noted by Charoenthai and co-
workers (2007). High molecular weight polymers are associated with sustained drug release 
from a system (Charoenthai et al., 2007). The excess PQ10 provided the charge required for 
interaction with the aqueous environment thus attracting more aqueous fluid around the 
extrudates. It was observed that the extrudates from the formulations containing 5:3 
polymeric ratios (F1-F3, F6, F9, F12 and F13) dissolved as the drug release progressed 
while the rest of the formulations remained intact during the study. For the three groups of 
polymeric ratios, the highest MDTs were noted for the formulations synthesized with 4 drops 
of distilled water for 446mg of drug/polymer powder mass therefore this was the ideal 
amount of granulating fluid for maximizing MDT. The presence of excess HA, a 
macromolecule, resulted in the drug release retardation seen in F7, F10 and F11. The 
amount of drug that permeated across the intestinal tissue was enhanced by the increase in 
the amount of HA in the formulation. The highest amount was recorded for F11 (Table 4.2), 
which was optimal.  
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Table 4.2: Flux and permeability coefficient results of experimental design and optimized 
formulations 
Formulation Flux 
(mg.cm-2.h-1) 
Permeability 
Coefficient 
(cm2.h-1) 
MDT (hours) Extrudates within 
710-1000µm size 
range (%) 
F1 0.05±0.037 0.08±0.055 2.88±1.93 96.66±0.02 
F2 0.05±0.029 0.08±0.059 2.94±5.03 96.66±0.49 
F3 0.08±0.097 0.14±0.096 3.03±9.28 96.84±4.91 
F4 0.01±0.082 0.02±0.016 8.63±0.17 98.92±6.44 
F5 0.02±0.031 0.04±0.014 8.20±0.96 99.32±7.68 
F6 0.05±0.060 0.07±0.032 3.48±0.49 96.66±0.94 
F7 0.04±0.068 0.69±0.049 5.80±2.61 98.52±2.88 
F8 0.04±0.010 0.08±0.087 6.39±7.30 99.22±0.26 
F9 0.05±0.007 0.08±0.082 3.17±5.53 96.66±8.04 
F10 0.09±0.009 0.56±0.035 5.64±8.17 95.50±10.92 
F11 0.10±0.045 0.17±0.0007 5.76±1.16 97.28±1.92 
F12 0.05±0.051 0.08±0.066 3.20±1.58 96.66±1.80 
F13 0.08±0.060 0.15±0.040 3.03±3.37 96.42±4.97 
     
Optimized formulations 
 
Formulation Flux 
(mg.cm-2.h-1) 
Permeability 
Coefficient (cm2.h-1) 
Total Drug Permeability 
(%) 
PEC-E 
cE 
PEC-R 
cR 
0.033±0.040 
0.0078±0.015 
0.019±0.012 
0.086±0.007 
1.85±0.088 
0.00087±0.048 
1.95±0.041 
0.012±0.071 
96.34±0.49 
35.10±0.96 
95.72±7.57 
56.94±3.53 
Data expressed as mean (n=3) 
 
4.3.3.2. Analysis of PEC formulation variables on MDT and ex vivo drug permeability 
The optimal PEC formulation (having the composition of F11) consisted of a 3:1 HA:PQ10 
polymeric ratio and synthesized with 4 drops of granulation fluid. Selection of the optimized 
system was based on the formulation that yielded both maximized MDT and flux values. 
Figure 4.7 is a schematic of the optimization desirability plots as determined by the Box-
Benkehn experimental design. 
 
Analysis of the regression coefficients for MDT revealed that p-values were significant 
(<0.05) therefore depicting good interaction of the polymers and granulating fluid. An R2 of 
97.8% was noted. Similarly, regression coefficients for flux showed significance for the 
interaction of HA and PQ10 with water and an R2 value of 79.7%. The range for the p-values 
was 0,023-0,299. The residual plots for MDT and flux further validated a good fit of the 
model for the data. The plots indicated that there was a correlation between the observed 
and predicted data. The 2D response contour plots generated by Minitab® (Figure 4.8) 
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revealed that utilizing a formulation with either high or low level HA results in high MDT 
values. On the contrary, the use of the mid-level granulating fluid would be recommended to 
enhance the MDT. The contour plot for drug flux depicts that an increase of HA and water 
causes a simultaneous increase in amount of drug that permeated the intestinal tissue. 
 
Figure 4.7: Schematic of the optimization desirability plots 
 
 
Figure 4.8: Contour plots depicting the influence of granulating fluid and HA: PQ10 on (a) 
MDT and (b) flux 
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4.3.4. Characterization of the optimized PEC formulation 
4.3.4.1. Analysis of surface morphology and quantification of porosity of the 
extrudates 
Spherical extrudates were obtained after spheronization as depicted in Figure 4.9. The 
technique was responsible for the smoothing of the extrudates (Figure 4.9(a) and 4.9(d)) 
devoid of the rough surface observed in the cross-sectional images of both PECs (Figure 
4.9(b) and 4.9(e)). PEC-E(E-S) had larger, interconnected and more numerous pores which 
were not observed in PEC-R(E-s). Figure 4.9(c) and (f) are surface morphologies of the 
extrudates after 24 hour drug release studies. Both PECs exhibited a porous surface with 
PEC-R(E-S) revealing larger pores than PEC-E(E-S). It can be inferred that drug release from 
PEC-E(E-S) occurred by diffusion while release from PEC-R(E-S) involved erosion of the matrix. 
 
 
Figure 4.9: Surface morphology images of the EFV (a-c) and RTV (d-f) extrudates 
 
Porosity is a measure of the quantity of nitrogen gas adsorbed onto the sample pores. Pore 
diameter may impact the rate of drug release due to the interaction of the drug-loaded matrix 
with the aqueous dissolution medium (Berger et al., 2004). Evaluation of the BET results 
(Table 4.3) revealed that PEC-E(E-S) had a significantly larger surface area (-249.7811) than 
PEC-R(E-S) (-6.5412). This finding may be correlated with the SEM images, Figure 4.9(b) and 
4.9(e). The BJH findings on pore sizes and volumes also maintained a similar trend of PEC-
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E(E-s) exhibiting a larger intraparticular porosity. Both formulations possessed mesopores 
since their pore sizes fell in the 2-50nm range. 
 
Table 4.3: BET and BJH analysis of optimized PECs 
Parameter PEC-E(E-S) PEC-R(E-S) 
Surface area                                       
BET surface area (m²/g) 
 
-249.78±0.036 
 
-6.54±0.079 
Pore volume                                        
BJH Adsorption cumulative volume of 
pores 
BJH Desorption cumulative volume of 
pores 
 
0.0032±0.0005 
0.00029±0.009 
 
0.00072±0.084 
0.00071±0.007 
Pore size 
BJH adsorption average pore diameter 
 
BJH desorption average pore diameter 
 
103.02±0.023Å 
(10.30nm) 
127.66±0.094Å 
(12.77nm) 
 
30.4±0.506Å 
(3.04nm) 
31.64±0.019Å 
(3.16nm) 
Data presented as mean (n=3) 
 
4.3.4.2. Evaluation of saturation solubility, drug release and permeability of the 
optimized PEC formulation 
Figure 4.10 shows the calibration curve used to quantify RTV. The solubility results revealed 
that both PECs exhibited more superior solubility properties to the commercially available 
comparator products (cE (EFV) and cR (RTV)). PEC-E possessed a much greater increase 
in supersaturation (14.16±2.81%) than PEC-R (4.39±0.57%). cR is a lipid-based formulation 
and such formulations have been the most popular for enhancing drug bioavailability over 
the last two decades (Jannin et al., 2015).  
 
 90 
 
 
Figure 4.10: Calibration curve for RTV 
In vitro dissolution studies were conducted in FeSSIF. The small intestine was selected as 
the target area of interest because most absorption occurs at this point. The upper intestine 
contains more bile salts and lecithin in the fed state therefore making it an important site for 
dissolution of poorly soluble drugs (Viral et al., 2010). Figure 4.11(a) depicts profiles of the 
fractional drug release (FDR) against time for PEC-E(E-S) and PEC-R(E-S) over 24 hours. The 
comparator brands exhibited immediate drug release within 2 hours and the amount of drug 
released remained constant for the remainder of the 24 hours. Drug release for cE was 
incomplete (< 80%) and cR exhibited a total drug release within 2 hours. Solid dispersions 
have been known to prevent crystal growth of drugs as well as reduce the drug particle size 
and this property is responsible for the increase in concentration of the drug that undergoes 
dissolution (Betageri et al., 1995). Solid dispersions are responsible for creating a 
microenvironment that promotes supersaturation of the drug in the dissolution medium 
(Brouwers et al., 2009). These findings may be correlated to the Noyes Whitney equation 
(Equation 4.9) which is used to demonstrate how the dissolution rate of poorly soluble 
compounds may be improved so as to enhance oral bioavailability. 
 
𝑑𝐶
𝑑𝑡
=  
𝐴𝐷(𝐶𝑠 − 𝐶)
ℎ
 
                  Equation 4.9 
 
Where dC/dt is the rate of dissolution, A is the surface area available for dissolution, D is the 
diffusion coefficient of the compound, Cs is the saturation solubility of the compound in the 
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dissolution medium, C is the concentration of drug in the medium at time t and h is the 
thickness of the diffusion boundary layer (Dash et al., 2010).  
 
Loading the drugs into the PECs was beneficial in delaying the occurrence of any 
precipitation which is common in supersaturated solutions. This stability was achieved by the 
physical interaction of the drug with the polymers as validated by the FTIR results. Figure 
4.11(b) highlights the permeability profiles of PEC-E(E-S) and PEC-R(E-S) and their respective 
comparator products. Permeation enhancement for PEC-E(E-S) and PEC-R(E-S) in comparison 
to the marketed formulations was 61.24±6.92% and 38.78±0.50%, respectively. According to 
the collated data, there was a tremendous permeation flux and permeability enhancement of 
the BCS class II/IV drugs which were loaded in the novel PEC when measured against cE 
and cR. This enhancement was more pronounced in PEC-E(E-S) and this may be attributed to 
EFV’s ability to cross the intestinal tissue. The use of HA and PQ10 had a contributory effect 
on the permeation of EFV and RTV as both polymers have previously been reported to 
possess good mucoadhesive properties (Mazoniene et al., 2011; Zhang at al., 2003). A 
study by Mirza and co-workers (2011) revealed that the permeation of carbamazepine 
complexed to HA improved significantly compared to the permeation of the pure drug. This 
enhancement was attributed to HA being amphiphilic and more hydrophobic in aqueous 
media.  
 
 
 
 
 
 
 
 
 
 
Figure 4.11: Graphs depicting (a) drug release profiles of EFV and RTV optimized 
formulations and (b) permeability profiles of EFV and RTV optimized formulations 
 
4.4. CONCLUDING REMARKS  
Extrusion-spheronization and complexation-precipitation techniques were successfully 
implemented for both drug-free and drug-loaded polyelectrolyte complex fabrication. 
Although they enhanced the delivery of the bioactive, synthesis by extrusion-spheronization 
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provided more desirable qualities in the resultant solid dispersions. The use of solid 
dispersions has been widely implemented as a solubilization technique, though there are 
limited studies on their implementation to enhance the solubility and permeability of anti-HIV 
drugs in BCS class II/IV. Solid dispersions of EFV and RTV in the optimized HA-PQ10 PEC 
showed promising results for targeted release to the small intestine and accelerated drug 
solubility and permeability. The formulation constituting the novel HA-PQ10 PEC may also 
be applied for targeted release of highly water soluble drugs. The quantity of HA used in this 
study was below the permissible 512mg/kg reported previously by Mirza and co-workers 
(2011). Therefore the PEC can be safely utilized for drug delivery purposes and the extruded 
PEC formulation was selected for optimization. Overall, these results indicated that the PEC 
enhanced the solubility and permeability of BCS class II/IV drugs that may have a positive 
impact on their bioavailability in a suitable in vivo model. Administration of full doses from the 
extruded PEC, particularly EFV, would result in sizable formulations hence it was imperative 
to further investigate formulation techniques that would allow higher drug loading and 
smaller formulation sizes. 
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CHAPTER 5  
 
SYNTHESIS AND COMPARISON OF HUMIC ACID-POLYQUATERNIUM 10 
TABLETS IMPLEMENTING 3D-PRINTING AND DIRECT TABLET 
COMPRESSION  
  
5.1. INTRODUCTION 
Tablet formulations are the most popular and various techniques of tableting have been 
documented ranging from conventional methods such as direct compression to extensive 
cutting edge methods such as using 3D-Printing (3DP). The traditional approach is feasible 
and reproducible when powder samples have adequate flow and compressibility properties 
(Juban et al., 2016).  
 
3DP is revolutionizing the field of drug delivery. It involves the synthesis of customized and 
digitally controlled tablets in a layer-by-layer manner. Pharmaceutical industry has embraced 
3DP for the synthesis of dosage forms and research is underway to make 3DP viable for 
manufacturing customized medicines. This technique is highly attractive allowing for precise 
and extensive drug-loading capacity (Goyanes et al., 2015).  
 
This study aimed at synthesizing a 3DP oral tablet, consisting of a humic acid (HA)-
polyquaternium-10 (PQ10) polyelectrolyte complex (PEC) and with high drug-loading of 
efavirenz (EFV). To the best of our knowledge, no research has been undertaken on 3DP of 
tablets consisting of HA-PQ10 as the printing ‘ink’. Manufacture of the oral tablet was 
undertaken with the aid of a 3D Bioplotter® (EnvisionTEC GmbH, Gladbeck, Germany) that 
is able to process a wide range of biomaterials such as polymer melts, polymer solutions 
and bioactive polymers (Pfister et al., 2004). 3D bioplotting uses pressure to extrude material 
(API and polymers) from a sample holder in 3D onto a build platform. Each layer must 
solidify in order for the tablet to hold. This may be achieved by extruding molten polymers or 
a sludge that solidify at the build platform or by extruding the API-polymer melt into a liquid 
of equal viscosity (Goyanes et al., 2015). Properties of the 3DP tablets were compared to 
tablets manufactured by direct compression to determine if the 3DP formulation performed 
superiorly. 
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5.2. MATERIALS AND METHODS 
5.2.1. Materials 
Brown humic acid sodium salt (HA), hydroxyethylcellulose ethoxylate, quaternized (PQ10 
Mw=656.1g/mol), cellulose acetate phthalate (CAP Mw=2534.12g/mol), and sodium lauryl 
sulfate (SLS) were purchased from Sigma–Aldrich® (St. Louis, MO, USA). Efavirenz (EFV) 
was procured from Xingcheng Chemphar Co., Ltd. (Taizhou, Zhejiang, China). All other 
chemicals used were of analytical grade. Analytical grade methanol and acetone were used 
as solvents in sludge synthesis as well as to induce rapid solidification of the printed tablet 
due to their volatility. 3D-Printing was undertaken with the aid of a 3D-Bioplotter® 
(Bioplotter®, EnvisionTEC GmbH, Gladbeck, Germany). The sludge was transferred into a 
30mL polyethylene cartridge attached to a 0.61mm cone needle (Nordson EFD, East 
Providence, Rhode Island, USA) on one end, and a feed tube connected to filtered and 
compressed air on the other end. The tablet shape and dimensions were designed with the 
aid of Magics® software Version 18.2 (Materialise, Leuven, Belgium) which created a rapid 
prototyping STereoLithography (.stl) file format with the desired cylindrical shape and 
dimensions (20mm diameter; 10mm thickness). Direct tablet compression was conducted on 
a Mini-Tablet Press (Rimek Minipress- II MT, Karnavati, Gujarat, India). 
 
5.2.2. Preparation and characterization of a 3D-Printable (HA-PQ10)-EFV sludge  
5.2.2.1. Determination of ideal excipients and solvents for 3DP sludge synthesis 
EFV-loaded HA-PQ10 was rendered 3D-Printable by the addition of the enteric polymer and 
binding excipient, cellulose acetate phthalate (CAP) (12%w/v in acetone). Different 
excipients and solvents were explored to assess 3D-Printability of the EFV-loaded HA-PQ10 
and it was determined that the CAP solution (12%w/v in acetone) could be effectively used 
as a binder solution. Preparation of the sludge involved the hydration of PQ10 (750mg) with 
deionized water (3mL). This was left to soak at room temperature for 15 minutes. EFV was 
partially dissolved in methanol (6mL) and the mixture added to the hydrated PQ10. Three 
different amounts of EFV (1500mg, 3000mg and 6000mg) were utilized to formulate sludges 
possessing the HA-PQ10 : EFV ratios  of 1:2, 1:1 and 2:1, respectively. After adequate 
mixing, powdered HA (2250mg) was added followed by the CAP solution (1mL, 12%w/v in 
acetone). Methanol was also responsible for lowering the boiling point of acetone used to 
dissolve the CAP therefore maintaining the viscosity of the sludge while still in the printer 
cartridge, before extrusion. It was therefore determined that the critical material attributes 
(CMAs) for the 3D-Printable sludge were viscosity, printability without clogging the nozzle, 
operating temperature, concentration of CAP in acetone and quantity of methanol. The 
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resultant sludge was tested for 3D-Printability from the low temperature print head (0-70ºC). 
The sludge formulation described yielded 5 tablets. 
 
5.2.2.2. Determination of polymer-drug interactions in EFV and the 3D-Printable 
sludges 
Interactions between the EFV and HA-PQ10 in the sludges were analyzed by Attenuated 
Total Reflectance Fourier Transform Infrared (ATR-FTIR) spectroscopy (PerkinElmer 
Spectrum 100, Llantrisant, Wales, UK). Powdered samples were placed onto an ATR top-
plate containing a diamond crystal. Analysis was conducted within the wavenumber range of 
650-4000cm-1 with a direct contact force of 115N. The spectra from the EFV-loaded sludges 
were compared to the spectra for EFV and EFV-free 3D-Printable sludge (3DPHA-PQ10). 
 
5.2.2.3. Determination of thermal properties of EFV and 3D-Printable sludges 
Thermal behaviour of pure EFV and the sludges was assessed by Differential Scanning 
Calorimetry (DSC, METTLER Toledo DSC1, STARe System, Switzerland). A known amount 
of the test sample was weighed in a 40µl aluminium pan which was sealed and perforated 
before evaluation. The test was conducted at a temperature range of 25–325ºC at 10ºC/min. 
The melting points for each sample were determined and used to assess miscibility between 
EFV and HA-PQ10. 
 
5.2.2.4. Determination of (HA-PQ10)-EFV sludge consistency  
A texture analyzer (TAXT2i, Stable Microsystems Ltd., Surrey, England) equipped with a 
10mm diameter acrylic cylindrical probe was used to infiltrate the sample and the force 
exerted to the probe was recorded. The EFV-loaded sludge was placed in a 30mm canister 
to minimize air exposure while the probe penetrated the sludge to a depth of 20mm. A pre-
test speed of 1mm/s was implemented while a test and post-test speed of 0.5mm/s was set 
and assessment was repeated in triplicate. In order to determine the sludge hardness 
(maximum positive force after deformation) cohesiveness (maximum negative force after 
deformation) and springiness (distance that the sludge extended before separating from the 
probe), the one-deformation test was employed with the parameters being kept constant for 
all test samples (Tai et al., 2014; Yildiz et al., 2013; Sandhu and Singh, 2007).  
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5.2.3. Manufacture and physicochemical characterization of 3DP and direct 
compression tablets 
5.2.3.1. Synthesis of cylindrical tablets using 3DP and direct compression 
Slicing of the tablet had to be carried out in Magics® to ensure that there were no errors in 
the design. The STL file was converted to the BPL file format (Bioplotter RP® Version 3.0) 
which could be used for 3DP in Visual Machine®. The 3DP critical process parameters 
(CPPs) for the EFV-loaded HA-PQ10 sludge were printing speed and extrusion pressure 
and these were controlled and set in Visual Machine®. The pressure and speed tuning 
option on the Visual Machine® software on the 3D Bioplotter® was employed to optimize the 
strand width of the preferred sludge. The extruded sludge successfully formed a cylindrical 
tablet (20mm diameter, 10mm thickness) without layer collapse. The tablets were allowed to 
dry for 12 hours at 20ºC. For direct compression, the sludge was left to dry before producing 
a homogenous powder with the aid of a mortar and pestle. Tablets were compressed on a 
Mini-Tablet Press under a pressure of 3 tonnes. 
 
5.2.3.2. Measurement of mechanical strength and polymer-EFV packing of 3DP and 
direct compression tablets  
The indentation tablet hardness was determined by calculating the Brinell hardness of the 
tablets synthesized from the sludges via 3DP and direct compression. A 3.175mm steel 
indenter was used to apply a 5kg load onto the surface of the tablets. The indenter had a 
maximum displacement of 0.1mm on the flat surface of the tablets. Tablet density was 
calculated to determine the influence of tableting method on the packing of polymer 
networks in the 3DP and direct compression tablets. Equation 5.1 was employed to calculate 
the Brinell Hardness Number (BHN) and Equation 5.2 was used to calculate the tablet 
density. 
𝐵𝐻𝑁 =  
2𝐹
𝜋𝐷(𝐷 − √(𝐷2 − 𝑑2))
 
                  Equation 5.1 
Where, F=load on the indenting tool (kg), D=diameter of the spherical probe indenter 
(3.175mm), and d=diameter at the rim of the impression made (depth 0.1mm) (Busignies et 
al., 2006). 
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𝐷(𝑔/𝑐𝑚3) =  
𝑤
(
𝑚
2 )
2 𝑥 𝜋 𝑥 ℎ
 
                  Equation 5.2 
Where w is the tablet weight (g), m is the tablet diameter (cm) and h is the tablet thickness 
(cm) (Hanif et al., 2014). 
 
5.2.3.3. Porositometric analysis undertaken on the 3DP and direct compression 
tablets 
Porositometric analysis, utilizing Brunauer-Emmet-Teller (BET) and Barrett, Joyner and 
Halenda (BJH) isotherms of nitrogen, was undertaken. The adsorption and desorption 
profiles were generated to determine the surface area, pore diameter, total pore volume, and 
bulk and absolute densities of the 3DP and direct compression tablets. The ASAP 2020 
Porositometer with ASAP 202 V3.01 software (Micromeritics Instrument Corp., Norcross, 
GA, USA) was employed for the analysis. Degassing of weighed samples (>100mg) placed 
in isothermal jackets was conducted for 24 hours before analysis.  
 
5.2.3.4. Mapping of matrix hydration kinetics and gravimetric analysis of the 3DP and 
direct compression tablets 
The dimensional changes associated with hydration kinetics of the 3DP and direct 
compression tablets in SIF were mapped using Magnetic Resonance Imaging (MRI) system 
(Oxford Instruments Magnetic Resonance, Oxon, UK). MRI has an in-line dissolution flow 
through cell (USP apparatus 4). SIF was circulated continuously at 4mL/min and a total of 64 
scans were used. The physical properties of the 3DP tablet were compared to those of the 
direct compression tablet with the exact same (HA-PQ10)-EFV compositions. Gravimetric 
analysis was conducted to quantify the amount of moisture absorption and mass loss of the 
3DP and direct compression tablets in SIF over 8 hours.  
 
5.2.3.5. Analysis of in vitro drug release of 3DP and direct compression tablets 
A USP 33 type II dissolution apparatus (Erweka DT 700, Erweka GmbH, Heusenstamm, 
Germany) was used to assess drug release profiles from 3DP and direct compression 
tablets. The test was conducted for 8 hours in 900 mL simulated intestinal fluid (SIF) 
(pH=6.8; 37ºC; 50rpm) with 1% SLS. The small intestine, being the site of maximal 
absorption, was the target site for the delivery of EFV. At preset intervals, 5mL of the SIF 
was sampled and analyzed by ultraviolet (UV) spectrophotometer (LAMBDA 25 UV/Vis 
spectrophotometer, PerkinElmer, MA, USA).  
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5.3. RESULTS AND DISCUSSION 
5.3.1. Analysis of the synthesized 3D-Printable (HA-PQ10)-EFV sludge 
5.3.1.1. Assessment of the synthesis of a 3D-Printable sludge 
Different excipients and solvents were explored to produce an EFV-loaded 3DP ink. Table 
5.1 shows the results obtained from various printing ink screening formulations. 
 
It was determined that CAP solution (12%w/v in acetone) adequately plasticized the (HA-
PQ10)-EFV sludge. Preparation of the sludge involved the hydration of 750mg of PQ10 by 
adding 3mL of distilled water. This was left to soak at room temperature for 15 minutes. EFV 
was partially dissolved in 6mL of methanol and the mixture added to the hydrated PQ10. 
Three different amounts of EFV (1500mg, 3000mg and 6000mg) were utilized to make 
sludges containing different (HA-PQ10):EFV ratios (1:2, 1:1 and 2:1). After adequate mixing, 
powdered HA (2250mg) was added followed by the CAP solution (1mL, 12%w/v in acetone). 
CAP plasticized the sludge and provided enteric release properties (Asghar et al., 2008). 
The extruded sludge successfully formed a cylindrical tablet (20mm diameter, 10mm 
thickness) without layer collapse (Figure 5.1).  
 
 
Figure 5.1: 3D-Printing of HA-PQ10 sludge using the 3D-Bioplotter® 
 
Minimal amount of methanol (1mL/500mg) was added to EFV to facilitate its dispersion in 
PQ10. Methanol was also responsible for lowering the boiling point of acetone used to 
dissolve the CAP therefore the sludge remained in a molten state while still in the printer 
cartridge, before extrusion. Limitations associated with 3DP are clogging of the sludge in the 
nozzle thus disturbing the extrusion process. In some cases, the surface of the printed 
product presents with imperfections, something which is uncommon in conventional tableting 
(Alhnan et al., 2016).  
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Table 5.1: screening formulation template for 3D-Printable sludge  
Polymer ink  Extrusion 
pressure 
(bar) 
Printing 
speed 
(mm/s) 
Injection 
nozzle (mm) 
Result 
PEI; lactose; methanol:water 
(1:1) 
3 20 0.840 
 
PTBEM; PEI; 
methanol:chloroform (1:1) 
1 30 0.610 
 
Eudragit L-55; PEGME; 
methanol:water (1:1) 
1.5 30 0.610 
 
PEI:acetonitrile (1:5) 2 25 0.840 
 
Eudragit L-55; 
triacetin:methanol:water 
(1:4:5) 
0.5 5 0.610 
 
Eudragit L-55; 
methanol:water (1:1) 
 
0.4 5 0.610 
 
PEI; methanol:chloroform 
(1:1) 
1.7 30 0.610 
 
MCC; PEI (5% in water); 
methanol:chloroform (1:1) 
 
1.5 30 0.610 
 
MCC; PEI (5% in water); 
methanol:chloroform (1:1) 
 
2.5 20 1.370 
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5.3.1.1. Assessment of chemical and physical interactions in (HA-PQ10)-EFV sludge 
The EFV functional groups were expressed in all the formulations and these included C-F 
stretch (1493cm-1), tertiary amide (1601cm-1), C=O cyclic (1742cm-1), typical exocyclic triple 
bond stretching (2248cm-1) and N-H stretching (3312cm-1) (Figure 5.2). These peaks were 
similar with previously reported analysis by Alves and co-workers (2014). The addition of 
HA-PQ10 and CAP to EFV during sludge formation did not shift the skeleton stretching 
bands therefore (HA-PQ10)-EFV chemical interactions were not notable. The FTIR spectra 
for the 3DP2:1 and 3DP1:1 exhibited broad peaks corresponding with the EFV N-H stretching 
vibrations (3500-3200cm-1). The N-H stretching absorbance is lower in 3DP2:1 (0.07) and 
remained unchanged in 3DP1:1 (0.1) compared to the absorbance of the same band in pure 
EFV (0.1). These observations are indicative of hydrogen bonding between the H donating 
groups in the N-H bands of EFV and H accepting groups in the O-H bands of 3DPHA-PQ10 
(Sathigari et al., 2012). The interaction was more pronounced in 3DP2:1 which had a 
decrease in the N-H peak absorbance in addition to peak broadening. 3DP2:1 possessed a 
higher HA-PQ10 concentration than 3DP1:1 and the presence of more numerous O-H groups 
led to higher chances of (HA-PQ10)-EFV H-bond formation. The broad peak exhibited in 
3DPHA-PQ10 at 3380cm
-1 was attributed to the water absorption band (Fule and Amin, 2014). 
The increase in absorbance of the 3DP1:1 tertiary amide band at 1601cm
-1 suggests an 
elevation in the band vibrations at that (HA-PQ10)-EFV ratio.  
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Figure 5.2: FTIR spectra depicting (HA-PQ10)-EFV interactions in 3D-Printable sludges at 
(HA-PQ10) : EFV ratios of 1:2, 1:1 and 2:1 
 
5.3.1.2. Analysis of thermodynamic properties of (HA-PQ10)-EFV sludge 
Figure 5.3 depicts the thermograms for EFV and the 3DP sludges at different (HA-PQ10) : 
EFV ratios. The broad endotherm at 75ºC exhibited by 3DPHA-PQ10 was associated with water 
absorption as also is depicted in the 3DPHA-PQ10 FTIR spectrum (Fule and Amin, 2014). The 
endotherms for 3DP2:1 showed a disappearance of the EFV melting endotherm and this 
indicated that EFV was totally miscible in HA-PQ10 at this ratio. Two endotherms were 
shown for the 3DP1:1 formulation with the one occurring at 100ºC being ascribed to loss of 
water. The EFV melting peak area was reduced in 3DP1:1 indicating partial conversion of the 
EFV to the amorphous state. A fraction of the drug was transformed from the crystalline to 
the amorphous state as it became miscible into the polymeric matrix (Alhijjaj et al., 2016).  
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Figure 5.3: DSC thermograms of 3D-Printable sludges at (HA-PQ10) : EFV ratios of 1:2, 1:1 
and 2:1 
 
5.3.1.3. Assessment of the (HA-PQ10)-EFV sludge consistency 
The hardness of the sludges was determined by recording the maximum force of 
deformation after the probe was applied. Figure 5.4 shows that 3DP1:2 sludge recorded the 
highest maximum force. During 3D-Printing, 3DP1:2 required the highest extrusion pressure 
and it was liable to clogging the injection nozzle. During texture analysis, 3DP1:2 sludge left a 
residue on the probe after deformation. The thick consistency was influenced by the high 
EFV concentration in the sludge. The increase in EFV concentration was also accompanied 
by an increase in cohesiveness. 3DP1:1 and 3DP2:1 recorded maximum negative forces of -
0.054N and -0.04N respectively therefore indicating that 3DP1:1 and 3DP2:1 had similar 
cohesiveness. Sandhu and Singh (2007) reported that hardness can be impacted by the 
structure of the polymer in the substance tested. The 3DP2:1 was harder than 3DP1:1 
exhibiting a higher value for maximum positive force of 0.122N while maximum positive force 
for 3DP1:1 was 0.12N. 3DP2:1 contained a higher concentration of the macromolecular HA-
PQ10 (Siyawamwaya et al., 2016). Springiness was directly proportional to the length of time 
taken to return to the original force (0N) after deformation. 3DP2:1 produced a tailing curve 
which took the longest to return to zero (>20s) and this was suggestive of superior 
springiness compared to 3DP1:2 and 3DP1:1. 3DP2:1 exhibited the largest springiness due to 
an increase in concentration of the macromolecular polymers (Mua and Jackson 1998).  
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Figure 5.4: Graphs depicting one-deformation tests of sludges (a) 3DP1:2, (b) 3DP1:1 and (c) 
3DP2:1 
 
5.3.2. Analysis of the tablet manufacturing process and physicochemical 
characterization of 3DP and direct compression tablets 
5.3.2.1. Determination of the tableting parameters for 3DP and direct compression 
The preferred sludge for 3DP was determined to be 3DP1:1 after the assessment of FTIR, 
DSC and texture analysis results. 3DP1:1 contained equal proportions of HA-PQ10 and EFV. 
To maximize stability and uniformity throughout the 3DP process with this sludge, the 
printing speed and extrusion tuning option on Visual Machine® was employed (Figure 5.5). 
This function allowed for measurement of the strand widths at the respective extrusion 
pressure and printing speed. Optimal 3DP parameters (pressure=2bars and speed=25mm/s) 
were selected based on a strand width closer to the size of the injection nozzle as this was 
indicative of strands that would assemble a good solid object. The extrusion pressure and 
print speed were further validated in Visual Machine® by testing them at the ink purge 
station. Direct compression tablets were synthesized by compacting the dried sludge under 
3 tonnes without additional excipients. The average tablet weights were 1085.7±2.81mg and 
1571.5±3.7mg for 3DP and direct compression tablets respectively. The small variability in 
both tablets implies good reproducibility with either method of tableting. 
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Figure 5.5: Printing speed and extrusion pressure tuning to detect strand width using a 
0.61mm injection nozzle 
 
5.3.2.2. Assessment of mechanical strength and (HA-PQ10)-EFV packing in 3DP and 
direct compression tablets  
Assessment of the Brinell hardness test revealed that the direct compression tablets were 
significantly harder than the corresponding 3DP tablets. The calculated BHN numbers of 
3DP tablet and direct compression tablet at the same ratio were 129.79N/mm2 and 
158.72N/mm2 respectively. The measured tablet hardness is a reflection of the force exerted 
on the sludge or powder mass during tableting and the obtained values show that there was 
a greater force exerted onto the direct compression tablets than the 3DP tablets. Calculation 
of the tablet densities revealed that 3DP tablet was less dense (0.346g/cm3) compared to 
direct compression tablet (0.500g/cm3). The differences in BHN and tablet densities was due 
to the tableting technique used where axial forces were exerted on the powder for the direct 
compression tablet by the upper and lower dies of the tablet press. Powder compaction 
shifted intermolecular bonds (hydrogen and Van der Waals bonds) within the compressed 
(HA-PQ10)-EFV mass thus storing some energy within the tablet (Muley et al., 2016). 3DP 
was subjected to restricted compression forces.  
 
5.3.2.3. Assessment of porositometric analysis of the 3DP and direct compression 
tablets 
This test provided a mechanistic understanding of the void spaces in the 3DP and direct 
compression tablets. 3DP tablets exhibited a higher surface area and pore volume than 
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direct compression tablets of the same composition (Table 5.2). The contrasting 
observations were due to the different intermolecular forces created within the internal tablet 
structure. Direct compression tablets were subjected to axial compression forces during 
synthesis and these were responsible for the significant reduction in the void spaces thus 
creating a continuous and dense (HA-PQ10)-EFV network (Andrews et al., 2008 
;Westermarck et al., 1998). This is congruent with the calculated density values in section 
5.3.2.2. The degree of pores is expected to determine the extent of interaction of the matrix 
with the dissolution medium (Gonzalez et al., 2013). It is worthwhile to note that correlation 
of pore surface and dissolution may not always be accurate due to the fact that porosity 
analysis relies on high pressure N2 being forced into the pores of the sample whereas 
dissolution is dependent on tablet surface properties (Riippi et al., 1998). 
 
Table 5.2: Pore volume and BET surface areas of 3DP and direct compression formulations 
Parameter 3DP tablet Direct compression 
tablet 
Surface area BET Surface Area 
 
3.0141m²/g 2.1084m²/g   
 Adsorption average pore 
width (4V/A by BET) 
 
97.6188Å 51.0291Å   
Pore volume   BJH Adsorption average 
pore diameter (4V/A):     
 
125.343Å 85.614Å 
   BJH Desorption average 
pore diameter (4V/A):     
93.275Å 68.910Å    
 
Assessment of the shapes of the isotherms revealed that the branches are mostly in a 
horizontal alignment and it can be deduced that all formulations exhibited type II isotherms 
characterized by H3 hysteresis loops. Figure 5.6 depicts the isotherms with the quantity of 
nitrogen adsorbed (cm3/g STP) plotted against relative pressure (P/Pº). The increase in 
adsorption towards P/Pº=1 is indicative of presence of pores in both tablets. Both tablets had 
an adsorption average pore width 2–50nm therefore this can be interpreted as that the 
formulations contained mesopores (Sing 1985). Mesoporous surfaces provide a large 
surface area to volume ratio that enhances wettability of the encapsulated drug. Such a 
surface is able to retain high drug doses in the pores for long periods thus they are beneficial 
in manufacturing controlled release formulations (Santos et al., 2011). 
Analysis of the microstructural images from SEM (Figure 5.6) revealed that the 3DP and 
direct compression tablets exhibited different surface features. The 3DP tablet had a smooth 
surface compared to direct compression tablet. 3D-Printing resulted in the formation of 
interconnected fibrils and pores (red circles) dispersed on the tablet surface. The features on 
 110 
 
the direct compression tablet suggested that it had a more compact microstructure with a 
loose mesh of fibrils. These findings corroborated with the porositometric analysis which 
showed that 3DP was characterized by the presence of more numerous pores than the 
direct compression tablet.  
 
 
 
 
Figure 5.6: Isotherm linear plots of (a) 3DP1:1 tablet and (b) direct compression tablet 
depicting N2 adsorption (blue) and desorption (red) with inserts of SEM micrographs of 
tablets at x2000 magnification 
 
5.3.2.4. MRI mapping and gravimetric analysis of the 3DP and direct compression 
tablets 
MRI was employed to map solvent mobility in 3DP and direct compression tablet. This 
approach highlighted the difference in hydration dynamics of the 3DP tablet with the direct 
compression tablet in situ. Fluid penetration into the matrix resulted in changes in the proton 
signal of the MRI which caused increase in tablet brightness (Shapiro et al., 1996). 
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Observations similar to those made Kulinowski and co-workers (2011) were made where the 
uncompressed tablet (3DP tablet) swelled longitudinally and did not disintegrate in contrast 
to the compressed tablet (direct compression tablet) which formed voids as the study 
progressed.  
 
Figure 5.7 shows that the 3DP tablet underwent gradual and homogenous hydration to form 
a hydrogel structure. The tablet swelled and maintained its dimensional integrity throughout 
the test period. With the progression of time, it formed a gel layer due to the absorption of 
SIF and consequent relaxation of the polymer network, thus allowing the release of EFV. 
Upon contact with SIF, the direct compression tablet was hydrated accompanied by tablet 
fragmentation which formed the free polymer layer. 3DP exhibited 3 phases of hydration 
kinetics characterized by the dry core, interface layer and gel layer. The direct compression 
tablet had an additional moiety, the free polymer chains layer (outermost layer), thus making 
it exhibit 4 phases of hydration kinetics. The dry core is the innermost part of the tablet with 
limited fluid mobility and this core was no longer visible after 2 hours in 3DP tablet and after 
4 hours in the direct compression tablet. 
 
Figure 5.7: MRI coronal plane imaging of (a) 3DP tablet and (b) direct compression tablet in 
SIF over 8 hours 
 
Although both tablets consisted of the same (HA-PQ10) : EFV compositions, striking 
differences were visualized between them with the 3DP tablet swelling, floating and 
remaining intact while the direct compression tablet also swelled to a limited extent but 
fragmented. Figure 5.8 shows differences in tablets before and after MRI was conducted. 
The 3DP tablet showed significant increase in size after the study thus confirming its 
swellability in SIF. 
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Figure 5.8: Digital images of the dry 3DP and direct compression tablets before MRI and the 
hydrated tablets after MRI analysis 
 
Equations 5.3 was employed to calculate the total equilibrium swelling front as well as the 
dry mass loss at a particular time (t) and at the onset of the experiment (0) (Ali et al., 2017). 
 
𝑊𝑎𝑡𝑒𝑟 𝑐𝑜𝑛𝑡𝑒𝑛𝑡(%)(𝑡) =
𝑤𝑒𝑡 𝑚𝑎𝑠𝑠(𝑡) − 𝑑𝑟𝑦 𝑚𝑎𝑠𝑠(𝑡)
𝑤𝑒𝑡 𝑚𝑎𝑠𝑠(𝑡)
𝑥100 
                  Equation 5.3 
 
Gravimetric analysis in SIF revealed that SIF permeated into both 3DP and direct 
compression matrices leading to 57.7±0.15% and 44.8±0.89% fluid absorption respectively. 
Visual analysis of the medium in which this analysis was conducted (Figure 5.9), revealed 
that direct compression tablet lost fragments of the tablet during the study, something which 
was not observed with the 3DP tablet.  
 
3DP tablet before MRI 3DP tablet after MRI
Direct compression tablet before 
MRI
Direct compression tablet after 
MRI
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Figure 5.9: Gravimetric analysis of (a) 3DP and (b) direct compression tablets in SIF 
 
5.3.2.5. In vitro drug release profiles  
The rate of EFV release from the 3DP tablet was slightly higher than that of the direct 
compression tablet likely due to the rapid fluid ingress which caused loosening of the matrix 
(Figure 5.10). Hydrophilic polymers are known to retard drug release through formation of 
viscous gel barriers around the tablet (Ali et al., 2017). EFV release was reduced by the CAP 
gel layer that formed at the tablet-dissolution fluid interface in SIF. Both 3DP and 
compressed tablets were expected to swell due to the presence of the enteric-responsive 
CAP which is known to swell upon exposure to SIF (Asghar and Mantha, 2008). Swelling 
was more significant in the 3DP tablet which served to impede drug release. The method of 
manufacture influenced the tablet formed, based on the pressure or compression applied 
(Moritz and Łaniecki, 2012). 3DP utilized pressure to force the sludge out of the sample 
holder with complete drying of the tablet to constant weight occurring over a 12 hour period. 
According to a study conducted by Markl and co-workers (2016) the particles are not 
distorted before interparticular interactions occur as is the case in direct compression of 
tablets, therefore drug release profiles for direct compression tablets cannot be expected to 
be similar to the 3DP tablets consisting of the same components.  
 
The drug release profiles obtained in this study are inconsistent with the findings reported by 
Crowley and co-workers (2003) who showed that tablets from direct compression had a 
faster drug release than tablets that underwent extrusion during manufacture. (HA-PQ10)-
EFV hydrogen bond interactions that occurred in the sludge as discovered in FTIR in section 
5.3.1.1.  From the MRI mapping analysis (section 5.3.2.4) and the presence of more pores, 
as shown in porositometric analysis (5.3.2.3), one would expect an immediate and faster 
release compared to that exhibited by the direct compression tablets. The HA-PQ10 
electrostatic bonds would be expected to undergo hydrolysis leading to cleavage 
(Windheuser et al., 1963). However, in this case the matrix was a PEC (HA-PQ10) which 
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behaved as an EFV reservoir, as expected, and that resulted in a robust 3D-Printed tablet 
slowly releasing the encapsulated drug as demonstrated by the release profiles 
(Siyawamwaya et al., 2016). The DSC results in section 5.3.1.2 show that increasing HA-
PQ10 amounts in the sludges resulted in enhanced (HA-PQ10)-EFV miscibility thus 
promoting the conversion of the crystalline EFV to the more soluble amorphous state. In 
order to control and extend the release of the encapsulated drug, the presence of both 
amorphous and crystalline forms of the drug in one formulation is beneficial (Al-Hamidi et al., 
2010). Furthermore, the large volume of pores in 3DP facilitated higher dissolution. Mixing 
and partial solubilization of EFV in methanol during the sludge synthesis contributed to 
solubility enhancement (Savjani et al., 2012).  
 
Exploring different shapes has proven to be one approach to tailoring drug release profiles. 
By modifying the structural patterns or strand widths printed, the porosity of the tablet may 
be changed and this may consequently be used to customize the drug release profiles 
(Goole and Amighi, 2016). A 3D-Bioplotter® offers the flexibility of using either a low (0-
70ºC) or high (30-250ºC) temperature printing head. This allows for one tool to be employed 
in the manufacture of diverse formulations consisting of a wide range of materials. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10: Drug release profiles of 3DP tablet and direct compression tablet in 900mL SIF 
at 37ºC over 8 hours 
 
Based on the findings in this study, the differences between 3DP and direct compression 
tablets are attributed to the arrangement of particles during tableting as illustrated in Figure 
5.11. 3DP was undertaken on a wet sludge and drying occurred gradually over 12 hours 
after the tablet was synthesized. On the other hand, direct compression was carried out on 
the dried powder mass of the sludge. The two processes also apply pressure differently 
during the tableting process. 3DP utilized extrusion of the sludge while shaping it into the 
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predetermined cylindrical shape. With direct compression, the distortion observed with tablet 
hydration was caused by loose packing of the compressed material at the lateral surface of 
the tablet. Direct compression of solid materials is expected to result in the development of a 
lower perpendicular force in the die compared to the force applied on the material (Klose et 
al., 2006). Keleb and co-workers (2001) reported that during cold extrusion process, solid 
bridges form between tablet particles as they dry and these are responsible for the higher 
porosity in extruded tablets than direct compression tablets. Since the direct compression 
tablet exhibited a higher BHN, the intermolecular forces created by compaction are more 
numerous than the solid bridges that formed in the 3DP tablet. These findings can be 
correlated with the porosity data that confirmed that the 3DP tablet had a larger number of 
pores than the direct compression tablet. 
 
Figure 5.11: Proposed EFV-polymer particle arrangement in 3DP tablet and direct 
compression tablet 
 
5.4. CONCLUDING REMARKS 
The optimal sludge, 3DP1:1, was selected based on its ease of printing and polymer-EFV 
interactions and miscibility noted in the FTIR and DSC findings. FTIR results revealed that 
there were (HA-PQ10)-EFV hydrogen bond interactions with 3DP1:1 and this makes it more 
attractive for enhancing drug solubility. Although both 3DP and direction compression are 
physical tableting methods, remarkable differences were seen in the manufactured tablets.  
Direct compression tableting method was responsible for the formation of denser and 
therefore more mechanically resilient tablets. The (HA-PQ10)-EFV mixture was subjected to 
particulate interactions during compaction and this contributed to the increase in tablet 
strength. The compaction force impacts on the strength of tablets synthesized. The 3DP 
tablet swelled more and released more EFV during drug release compared to the direct 
compression tablet. The implementation of 3DP offers flexibility in the design of formulations 
which is not restricted to the structure of moulds as is the case in conventional tableting. HA-
PQ10 PEC has proved to be a flexible composite material with potential for the controlled 
oral delivery of drugs. 
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CHAPTER 6  
 
FORMULATION AND EVALUATION OF AN ANTI-HIV 3D-PRINTED 
‘CONTROLLED RELEASE TRITHERAPEUTIC TABLET’ 
  
6.1. INTRODUCTION 
The major recurrent challenge faced with the enteral administration of drugs falling in the 
Biopharmaceutics Classification System (BCS) class I and class III is that they behave like 
liquid formulations in vivo. They rapidly dissolve at a faster rate than the gastric emptying 
time (Tsume and Amidon, 2010). One of the solutions to the problem is to formulate 
controlled release preparations. This ensures that therapeutic levels in the body can be 
maintained while unpleasant side effects associated with the drugs are prevented. However, 
for BCS class III active pharmaceutical ingredients, poor intestinal tissue permeation further 
limits their optimal bioavailability.  
 
This study focused on the design, characterization and evaluation of a novel 3D-Printed 
Fixed-Dose Combination (FDC) tablet comprising a humic acid-polyquaternium 10 complex 
(HA-PQ10) as the ‘pharma-ink’ to achieve controlled release of three drugs namely efavirenz 
(EFV), tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) as the model drug 
regimen. The previously reported unique ‘printable’ properties of HA and PQ10 inspired the 
use of this complex for designing the 3DP FDC tablet in this study (Siyawamwaya et al., 
2016, 2015). It is crucial to control the release of these highly hydrophilic drugs (TDF and 
FTC) to circumvent their dose dependent toxicity in the human body as well as to maximize 
their absorption into the systemic circulation. Additionally, they are associated with short 
half-lives therefore making frequent administration of the drugs imperative in order to 
maintain the required plasma drug levels. The aim was to prolong their release beyond 
immediate and intermediate drug release. TDF is a fumarate salt of the 
bisisopropoxycarbonyloxymethyl ester derivative of tenofovir which has been shown to be 
more effective than other tenofovir derivatives. FTC is used for the prevention of perinatal 
HIV-1 reverse transcriptase. Both TDF and FTC are nucleoside reverse transcriptase 
inhibitors (NRTIs). EFV falls under the non-nucleoside reverse transcriptase inhibitor 
(NNRTI) group for HIV-1 drugs (Ray et al., 2016).  
 
Therefore this study aimed to utilize a single-step 3DP as an alternative manufacturing 
technique to produce a controlled release FDC tablet using pre-blended and partially self-
assembled HA and PQ10 as the polyelectrolyte framework to control the release of EFV, 
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TDF and FTC as the recommended first-line treatment drugs for HIV-1 (Lamorde et al., 
2012). These drugs are also listed within different classes of the Biopharmaceutics 
Classification System (BCS) (EFV=class II, TDF=class III and FTC=class I) and thus useful 
to test the feasibility of the 3DP tablet to control the release of hydrophilic and lipophilic drug 
molecules. In vitro dissolution performance of CRTT was measured against that of Atripla® 
(Merck, Sharp & Dohme Corp, Kenilworth, NJ, US), a prescription FDC tablet currently 
available on the market. This combination of drugs was first approved in 2006, after showing 
evidence of bioequivalence with the individual drug (Lamorde et al., 2012). FDCs, in 
comparison to monotherapy, offer benefits of encouraging patient adherence to treatment. 
The HA-PQ10 PEC was utilized to formulate an oral FDC which circumvents some of the 
rate limiting steps to effective drug absorption.  
 
6.2. MATERIALS AND METHODS 
6.2.1. Materials 
Brown humic acid sodium salt (HA), hydroxyethylcellulose ethoxylate, quaternized (PQ10 
Mw~656.1g/mol) and cellulose acetate phthalate (CAP Mw=2534.12g/mol) were purchased 
from Sigma-Aldrich® Inc. (St. Louis, Mo, USA). Efavirenz (EFV) (Wenzhou Zhongtai 
Chemical Co., Ltd, Wenzhou, China), tenofovir disoproxil fumarate (TDF) (Changzhou 
Yongrui Chemical Research Institute Co., Ltd, Jiangsu, China) and emtricitabine (FTC) 
(Beijing Zhongshuo Pharmaceutical Technology Development Co., Ltd, Beijing, China) were 
the model drugs used. UPLC grade water was purified by Milli-Q® gradient water purification 
system (Millipore SAS, Molsheim, France). Analytical grade methanol and acetone were 
used as solvents for the sludge synthesis. 3DP of the sludge was undertaken using a 3D-
Bioplotter® (EnvisionTEC GmbH, Gladbeck, Germany) equipped with polyethylene 
cartridges. 
 
6.2.2. Synthesis of 3DP fixed dose combination tablet 
The optimal shape of the tablet was determined by printing various tablet shapes and 
ascertaining the shape that yielded better prototyping. The tablet shapes explored included, 
cylindrical, donut-shape, elliptical, cuboid and a rectangular prism (rounded box). Computer-
aided design of these shapes was undertaken using the Magics® software. Afterwards, two 
strategies of printing a single tablet containing the three actives, EFV, TDF and FTC were 
investigated. These included 3DP of the sludge with all the drugs mixed in their respective 
proportions and the second method involved 3DP of each individual drug in its own sludge, 
in layers. For the second method, the initial layers consisted of EFV, followed by FTC and 
the top most layers would consist of TDF. All the sludges comprised of optimal HA-PQ10 : 
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drug ratios yielding 50% drug loading as determined in Chapter 5 section 5.3.7. A 0.61mm 
injection nozzle was utilized for all formulations. Printing parameters had to be slightly 
adjusted from those previously determined in Chapter 5 section 5.3.1 to suit the sludge 
consistency. 
 
6.2.3. Determination of electrostatic stability between formulation components 
The test for electrostatic interaction was undertaken to measure the extent of 
electromagnetic radiation absorption and vibrations resulting from chemical bonds between 
the drug molecules EFV/TDF/FTC and HA-PQ10 during the 3DP process. Powdered 
samples of the formulation components were placed on a diamond crystal of an Attenuated 
Total Reflectance-Fourier Transform Infrared (ATR-FTIR) spectrophotometer equipped with 
a single reflection diamond MIRTGS detector (PerkinElmer® Spectrum 100 Series FT-IR 
Spectrometer PerkinElmerLtd., Beaconsfield, UK). Analysis was conducted over a 
wavenumber of 6000cm-1-450cm-1. 
 
6.2.4. Surface morphology characterization of 3DP tablet 
The surface morphology of the tablets was characterized with the aid of scanning electron 
microscopy (SEM) (FEI Nova NanoLabTM 600 DualBeam FIB/SEM, Hillsboro, OR, USA). 
The samples were coated with 10nm of carbon followed by 5nm of gold-palladium coating 
prior to mounting them on a double-sided carbon tape. The parameters employed were 30kV 
at 30µs. Scanning of the samples provided insight into the exact strand widths and pore 
sizes created employing a 0.61mm injection nozzle at 60º and 90º angle inner structure 
pattern when 3D bioplotting.  
 
6.2.5. Prediction of tablet matrix strength in simulated gastric and intestinal fluid 
CRTT tablets were mounted on the BioTester 5000 test system (CellScale Biomaterials 
Testing, Waterloo, Ontario) using the BioRake tines (1.3mm tine spacing). The tablets were 
first hydrated in simulated gastric fluid (SGF, pH=1.2) and simulated intestinal fluid (SIF, 
pH=6.8) for 30 minutes to facilitate the mounting onto the BioRakes. The test was conducted 
to predict any remarkable changes in the tensile modulus of CRTT in vivo (Yin et al., 2015). 
Samples were tested while submerged in the respective fluid, SGF or SIF, at 37ºC. Y-axis 
uniaxial stretching was conducted with the BioRakes 2500µm apart. A load cell of 5N was 
utilized taking into account gastric mechanical destructive forces (1.9N fed state) as well as 
the intestinal force of 1.2N (Ali et al., 2017).  The image tracking tool was used to quantify in-
plane motions and to directly measure the resultant strains that took place during the test. 
Parameters used for the displacement test included applying a stretch magnitude of 40% for 
20 seconds and repeating the cycles 3 times. The data collated was utilized to construct 
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stress-strain curves and the initial linear portion was used to determine the Young’s modulus 
in both SGF and SIF (Sriamornsak et al., 2007). Stress is the force exerted per unit area and 
strain is the deformation observed due to the stress. 
 
6.2.6. Determination of drug loading and the in vitro dissolution of CRTT and the 
conventional tablet 
Calibration curves were prepared by making serial dilutions of the standard solutions for EFV 
(0.67mg/mL), TDF (1mg/mL) and FTC (1mg/mL. Drug loading was determined by printing 
two tablet layers which were then crushed, placed in 50mL of SIF and left in the orbital 
shaker bath for 24 hours to ensure complete drug release. Drug quantification was carried 
out with the aid of the UV spectrophotometer (LAMBDA 25 UV/Vis spectrophotometer, 
PerkinElmer, MA, USA). 
 
 Dissolution studies were carried out in a USP 33 type II apparatus (Erweka DT 700, Erweka 
GmbH, Heusenstamm, Germany) which was operated at 50rpm and 37ºC over the 24 hour 
test period. For the first 2 hours, the test was run in 500mL fed state simulated gastric fluid 
(FeSSGF), pH 1.2 and this was changed to 900mL fed state simulated intestinal fluid (SIF), 
pH 6.8 for the rest of the study. Preparation of FeSSIF comprised of dissolving NaOH 
(20.2g), glacial acetic acid (43.25g) and NaCl (59.37g) in deionized water (5L) and thereafter 
adjusting the pH to 5.0. Native FeSSIF (500mL) was used to dissolve sodium taurocholate 
(59.08g) and 59.08mL of lecithin dissolved in methylene chloride (100mg/mL) was added to 
the blank FeSSIF. The methylene chloride was eliminated from the emulsion by evaporation 
and the volume of the media was adjusted to 2L (Viral et al., 2010). Middle stage simulated 
gastric fluid was prepared by mixing 500mL of ultra high temperature milk (UHT-milk) with 
480mL of acetate buffer. The solution was adjusted to pH 5.0 before adding the acetate 
buffer to 1L (Jantratid et al., 2008). Sample aliquots (5mL) were withdrawn at predetermined 
times and these were filtered then dried before reconstituting them with methanol. Drug 
release was measured with the aid of a UV spectrophotometer at the respective 
wavenumbers for each drug (EFV=247nm, TDF=262nm and FTC=281nm).  
 
6.3. RESULTS AND DISCUSSION 
6.3.1. Assessment of synthesis of the 3DP tablet 
One of the aims of this study was to improve 3DP of the drug loaded HA-PQ10 from Chapter 
5. Different pharmaceutical materials give different results with the selected shapes and it 
was imperative to determine the optimal tablet shape that was most ideal for the selected 
materials. It was concluded that the rectangular prism shape worked best with the drug-
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loaded HA-PQ10. Figure 6.1 shows digital images of CRTT obtained from printing using the 
two different designs and containing the same dosages. Printing the three drugs in separate 
layers is advantageous in customizing the release patterns for each drug. However, in this 
study separating the drug layers increased the formulation size. 3DP of the sludge 
containing a blend of EFV/TDF/FTC yielded reproducible tablets. The printing of TDF-loaded 
HA-PQ10 sludge distorted the overall shape and appearance of the tablet (Figure 6.1). 
Sludge modifications such as adding more polymers would be required to enhance the 3D-
Printability of TDF-loaded HA-PQ10. Ultimately, this would increase the size of the tablet 
thus negatively impacting on patient compliance (Jimmy and Jose, 2011).  
 
 
Figure 6.1: Digital images of results from two design attempts implemented 
 
The optimal CRTT design was the rectangular prism which was manufactured from the ink 
containing EFV, TDF and FTC. Printing parameters for the FDC were an extrusion pressure 
of 1.3bars, at a print speed of 37mm/s. The addition of TDF and FTC to the EFV-loaded HA-
PQ10 had an additional plasticizing effect on the sludge therefore lowering the extrusion 
pressure to that determine in Chapter 5. Pre and post flow delays of 0.05s were 
implemented and the wait time between layers was 30s. The inner pattern comprised of a 
strand distance of 1.2mm and to further optimize the formulation, 60º and 90º angles 
between each layer were explored. 
 
6.3.2. Analysis of any electrostatic interactions between the HA-PQ10 and the drugs 
Analysis of FTIR spectra (Figure 6.2) revealed that there was no evident interaction between 
the drugs and HA-PQ10. Due to its predominance, EFV displayed some of its dominant peak 
in CRTT while TDF and FTC bands were masked. The peaks from EFV (exocyclic triple 
bond=2278cm-1, C=O cyclic bond=1742cm-1 and tertiary amide=1601cm-1) expressed in 
CRTT did not shifted but their absorbances were diminished due to the presence of the other 
drugs and polymers in the system. The formation of the two new peaks in the wavenumber 
region of 3250-3300cm-1 in CRTT suggests that hydrogen bond formation occurred due to 
the NH bonds from the drugs interacting with the OH functional groups in HA-PQ10 as 
described in Chapter 5 section 5.3.1.1. This region contains NH bonds from EFV, TDF and 
EFV, TDF and FTC mixed in one sludge Separate layers of EFV, TDF and FTC
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FTC as well as OH functional groups from TDF, FTC and HA-PQ10. The difference in peak 
absorbance between CRTT and the drugs is insignificant indicating that weak hydrogen 
interactions took place. 
 
 
Figure 6.2: FTIR spectra of CRTT in relation to EFV, TDF, FTC and HA-PQ10 
 
6.3.3. Analysis of CRTT surface morphology 
SEM imagery provided insight into the exact strand widths and pore sizes created by 3DP 
with a 0.61mm injection nozzle creating 60º and 90º inner structure patterns (Figure 6.3). 
Surface morphology of the tablet at 100x magnification is depicted in Figure 6.3(a) and a 
closer analysis of the surface at higher magnification, 500x (Figure 6.3(b)), revealed that 
CRTT contained a fibrilla structure with pores spread on it. Such a surface would be 
expected to allow permeation of the dissolution fluid therefore increasing the wettability of 
the encapsulated drugs. Besides these smaller pores evident on the strands, the inner 
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patterns selected (90º and 60º with 1.2mm distance) also created pores through gaps 
between the strands. These patterns were intentionally chosen to increase the ingress of 
fluid into the system as confirmed by results from the drug release study. The final strand 
thickness and pores created after 3DP were measured from the SEM images. The CRTT 
with inner structure pattern of 90º (Figure 6.3(c)) gave better strand thickness (0.65mm) in 
relation to the nozzle size used (0.61mm). The 3DP tablet with the 60º inner pattern yielded 
thicker strands measured to be 0.88mm thick (Figure 6.3(d)). This indicated that smudging 
occurred during printing therefore the ideal inner structure pattern for drug-loaded HA-PQ10 
was determined to be 90º between each tablet layer.  
 
 
Figure 6.3: SEM images of CRTT at (a) surface of a strand at 80x magnification, (b) surface 
of a strand at 500x magnification, (c) inner pattern alignment of strands at 90º and (d) inner 
pattern alignment of strands at 60º 
 
6.3.4. Evaluation of the CRTT matrix strength prediction in gastric and intestinal fluid 
The image tracking option was implemented to calculate the exact values and spatial 
variation of the strains subjected to CRTT based on the motions of the BioRake tines. Figure 
6.4 shows the digital images of CRTT set up in SGF and SIF with inserts of the image 
tracking as well as the Y-force graph. More strain was exerted towards the periphery of the 
tablet in both media (red areas). The higher strain values were demonstrated in SGF with 
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the highest strain of 52.8 recorded. CRTT exhibited more mechanical strength in SGF where 
it did not absorb the medium readily. This characteristic was expected since the FDC 
contains CAP which is insoluble in SGF. Once submerged in SIF, the tablet became ‘softer’ 
as evidenced by the lower strain values (maximum strain 21.3). CAP became solvated in SIF 
therefore allowing more matrix-fluid interaction. Tablets should resist mechanical stress in 
the GIT in order to prevent erratic tablet erosion. Assessment of mechanical strength was 
vital because it was a measure of CRTT’s ability to withstand the mechanical forces likely to 
be exerted on it in the gastrointestinal tract (GIT). Formulation of tablets with good resistance 
maximizes the chance of obtaining more accurate in vitro-in vivo correlation. Solid dosage 
forms are liable to losing their tensile strengths when hydrated (Ali et al., 2017). Despite the 
differences in behaviour of CRTT in SGF and SIF, the tablet maintained its tensile strength 
modulus and did not break during movement of the attached BioRakes. 
 
 
Figure 6.4: Digital Biotester images of CRTT, corresponding strains and Y-force graphs in 
(a) SGF and (b) SIF 
 
Calculation of the Young’s modulus revealed that CRTT was more elastic in SGF than SIF 
with values of 0.1167Pa (Figure 6.5) and 0.1129Pa (Figure 6.6) respectively. These values 
indicated that the nature of the tablet was amorphous overall as crystalline materials would 
have exhibited much higher Young’s modulus values as studied by Eichhorn and Young 
(2001). It can be concluded that CRTT was more elastic in SIF as the pH was more 
favourable for fluid ingress into the tablet thus making the polymeric matrix more flexible. 
CRTT elasticity had an effect on the solubility of drugs as adequate fluid absorption into the 
system increases drug wettability (Sideridou et al., 2003). 
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Figure 6.5: Stress-strain graphs of (a) CRTT submerged in SGF, (b) initial linear curve in 
SGF, (C) CRTT submerged in SIF and (d) initial liner curve in SIF 
 
6.3.5. Analysis of drug loading and the in vitro drug release profiles of 3DP CRTT and 
the conventional tablet 
The rectangular prism tablet dimensions were adjusted to accommodate the drug loading 
and the optimal size was found to be 2.3cmx0.8cmx1.2cm, constituting EFV/TDF/FTC at 
300mg/150mg/100mg loading capacities. Drug loading in each layer was 
12.5mg/6.3mg/4mg of EFV/TDF/FTC respectively. The calibration of EFV was repeated 
since the drug used was from a different to that previously used. Figure 6.7 shows the 
calibration curves used for the in vitro quantification of drugs in the study. 
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Figure 6.6: UV calibration curves of (a) EFV, (b) TDF and (c) FTC 
 
The rate of release of TDF and FTC was proportional to the rate of hydration of the tablets 
(Figure 6.8). Release in SGF was almost insignificant due to the incorporation of CAP in the 
system which is insoluble in acidic media. The small amount of drug that dissolved was the 
amount that was on the tablet surface and not covered with the CAP since the tablet was not 
coated.  Visual inspection of the media showed that the SGF had a slight tinge of yellow 
colour (due to HA) in SGF. The colour deepened to a more brown solution in SIF as a result 
of the permeation of more fluid into the tablet leading to dissolution of some of the polymers 
into the alkaline medium. Swelling of the complex into a hydrogel structure facilitated drug 
release by allowing the SIF to gain access to the entrapped drug (Harillal et al., 2013).  
 
Swelling occurs when the charge density in the drug-loaded PEC becomes low and the 
polyelectrolyte fails to maintain the complex. This process leads to subsequent dissolution, 
however in this study, the rate of release was retarded by the formation of a strong gel due 
to the macromolecular nature of polymers used (Buriuli and Verma, 2017; Sriamornsak et 
al., 2007). The conventional tablet disintegrated within 30 minutes of being placed in SGF 
and this explains the high drug release within the duration of 2 hours. The sustained release 
exhibited by CRTT was attributed to the HA-PQ10 PEC which limited movement of the 
entrapped drugs into the dissolution medium. CAP served as a diffusion barrier to water 
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access into the matrix therefore restricting the bioactives within the tablet and slowly 
releasing them over time. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7: Drug release profiles of (a) EFV, (b) TDF and (c) FTC in CRTT compared to 
Atripla® 
 
6.4. CONCLUDING REMARKS 
The HA-PQ10 matrix is applicable for formulation of a 3DP FDC loaded with both lipophilic 
and hydrophilic drugs. Extrusion-based 3DP is a versatile tool that allows the control of 
object geometries to customize them for the ‘printing ink’ as well as for the intended purpose 
of the 3DP object. Optimization of CRTT involved printing different tablet shapes and 
exploring with inner structure patterns thus 3DP renders a lot of potential for the manufacture 
of novel drug delivery systems. Through SEM analysis, the exact size of the resultant printed 
strands could be measured and this further contributed to the tablet optimization process. 
This chapter also explored how CRTT would behave in simulated gastric and intestinal 
conditions by measuring the mechanical properties as well dissolution in the respective 
fluids. At this stage, it was pertinent to conduct in vivo studies of the system to verify the in 
vitro findings. 
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CHAPTER 7  
 
IN VIVO ANALYSIS OF THE 3D-PRINTED FIXED DOSE COMBINATION TABLET 
IN LARGE WHITE PIGS 
  
The animal ethics clearance for this study was obtained from the Animal Ethics Screening 
Committee (AESC) at the University of the Witwatersrand, Johannesburg, South Africa 
(AESC clearance number: 2014/38/C). 
 
7.1. INTRODUCTION 
New drug delivery systems warrant the need to perform in vivo studies to assess their 
efficacy as well as to predict their pharmacokinetic and pharmacodynamic properties when 
used in human beings. In vitro studies are conducted under simulated in vivo conditions but 
more accurate results are obtained when systems are tested in living organisms. The 
bioavailability of drugs is affected by various factors including physicochemical, biological, 
food ingested and formulation factors (Yasuji et al., 2012). In vivo toxicity as a result of anti-
HIV therapy remains a major cause for concern and the toxicity has been found to be dose-
dependent (Pinti et al., 2006). This indicates the need to enhance the effectiveness and 
bioavailability of the anti-HIV drugs. Implementing effective, yet, convenient therapies such 
as the fixed dose combination (FDC) plan will boost the likelihood of patients adhering to the 
treatment and therefore leading to success of the treatment. 
 
Pigs are cost-effective animal models in studies that require repeated blood sampling. 
Frequent sampling enables one to attain more in-depth quantifiable indications of drug 
release and absorption of drugs from the gastrointestinal tract (GIT) into the systemic 
circulation. The anatomy of the GIT in the selected pig model resembles that of the human 
being. Rabbits and rodents, though common animal models, are not ideal due to the size of 
oral dosage forms (Jensen-Waern et al., 2009).  Previous studies have validated the safety 
and biocompatibility of humic acid (HA) and polyquaternium-10 (PQ10) (Siyawamwaya et al., 
2016), it was still pertinent to further corroborate such findings with animal studies. This was 
done to establish the efficacy of the two polymers in a 3D-Printed FDC yielding a 
polyelectrolyte complex (PEC) loaded with known first line HIV drugs (efavirenz (EFV), 
tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC). 
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7.2. MATERIALS AND METHODS 
7.2.1. Materials 
Brown humic acid sodium salt (HA), hydroxyethylcellulose ethoxylate, quaternized (PQ10 
Mw=~656.1g/moL), cellulose acetate phthalate (CAP Mw=2534.12g/moL) and diclofenac 
sodium salt were purchased from Sigma-Aldrich® (St. Louis, USA). Efavirenz (EFV), 
tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) were purchased from DB Fine 
Chemicals/Specialities (Pty) Ltd (Woodmead, Johannesburg, South Africa). A comparator 
product, Atripla®, was commercially available. UPLC grade water was purified by Milli-Q® 
gradient water purification system (Millipore SAS, Molsheim, France). All other chemicals 
used were of analytical grade.  
 
7.2.2. Habituation of pigs at the animal unit 
Upon arrival at the Central Animal Services (CAS), University of the Witwatersrand, the six 
large female white pigs were housed in the farm animal unit where a 12 hour light/dark cycle 
was maintained. Initially, they were all kept in one pen while they adapted to a new 
environment, the researchers and standard procedures. Habituation was achieved by 
brushing and feeding them with raisins. After insertion of jugular catheters, they were housed 
in separate smooth walled pens for easier monitoring. 
 
7.2.3. Experimental design and procedures on the white pigs 
For easier withdrawal of blood as well to avoid pain in the pigs, catheters (7 French gauge 
double lumen 35cm catheter (CS-28702); Arrow Deutschland GmdH, Erding, Germany) 
were inserted into the jugular veins through a subcutaneous incision (Figure 7.1(a-d)). 
Catheterization was performed by the staff at CAS under aseptic conditions. The pigs were 
anaesthetized using ketamine (11mg/kg I.M), midazolam (0.3mg/kg I.M) and topical procaine 
HCl (0.5%). An antibiotic (Buprenorphine 0.05mg/kg I.M) and an analgesic (Carpofen 
4mg/kg I.M) were also administered prior to surgery and anaesthesia was maintained by 2% 
isoflurane and 100% oxygen gas. The vital signs were monitored throughout the procedure. 
The external injection ports of the catheters were sutured to the skin to prevent disturbing 
the catheter when the pig moved (Figure 7.1(e). Functioning of the catheter was tested by 
withdrawal of a blood sample followed by flushing of the brown external ports using 
heparinized saline (1000i.u/L 0.9% saline) (Figure 7.1(f). The pigs were allowed 10 days of 
full recovery before commencement of dosing with the synthesized delivery system and 
conventional tablets (Jørgensen et al., 2010). Meanwhile, the ports were maintained by 
flushing twice daily during feeding time. An antiseptic solution was sprayed on both ports 
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before withdrawing blood using a needle and syringe. An equal amount of heparinized saline 
(5mL) was injected into the port to prevent any blockages from blood clots. 
 
 
Figure 7.1: Digital images depicting the surgical procedure followed during catheterization 
 
7.2.4. Administration of the 3DP CRTT and conventional via gastric gavage  
Five pigs (±45kg) were dosed with either CRTT or Atripla® tablets during a crossover study 
where 1 week washout period was allowed between the dosage forms. A full standard dose 
of EFV/TDF/FTC (600mg/300mg/200mg respectively) was administered. Two CRTT tablets 
(EFV=300mg, TDF=150mg and FTC=100mg in each tablet) had to be administered to meet 
the daily dosage for an adult human. One pig was used as the control for each study. A 
baseline sample was withdrawn prior to gastric administration which was conducted while 
the pigs were fasting. The animals were sedated as explained in section 7.2.3 before the 
insertion of the intragastric tube through which the formulations were administered (Figure 
7.2(a-c)). Water (50mL) was poured down the tube to ensure that the tablet was not stuck in 
the intragastric tube. The pigs were monitored in the housing unit during recovery after the 
gastric administration. 
 
The same procedure for flushing described in section 7.2.3 was also used in blood sampling 
(Figure 7.2(d)). Blood sampling was conducted at: 0, 1, 2, 3, 4, 6, 8, 12, 18 and 24 hour 
intervals and food was used to distract the pigs while blood sampling was conducted. The 
collected blood samples were put into heparinized vacutainers (Improvacuter®, Guangzhou 
Improve Medical Instruments, Guangzhou, China), centrifuged at 3000rpm for 15 minutes 
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before aspirating the plasma supernatant which was then stored in a freezer (-80ºC) for 
further analysis. 
 
 
Figure 7.2: Digital images of gastric administration of CRTT and Atripla®  
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Figure 7.3 highlights the outline of the in vivo study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.3: Flow diagram showing the outline of the in vivo study 
 
7.2.5. Drug Quantification by Ultra Performance Liquid Chromatography Analysis 
The collected blood samples were analyzed with the aid of an Ultra Performance Liquid 
Chromatography (UPLC). The Waters® AcquityTM UPLC system (Waters®, Milford, MA, 
Total number of pigs = 6 
First dosing - 
CRTT 
Second dosing - 
Atripla® 
Anaesthesia: Ketamine HCl (40mg/kg), 
Xylazine HCl (10mg/kg) and topical 
procaine HCl (0.5%). 
Blood sampling at: 0, 1, 2, 3, 4, 6, 8, 12, 
18 and 24 hour 
UPLC analysis of blood plasma to 
quantify drug concentration 
Animals returned to stock and next dosing 
conducted after 1 week 
Catheterization 
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USA) contains a binary solvent manager, sample manager and is coupled with a photodiode 
array (PDA) detector. The output signal is monitored by Empower® Pro Software (Waters®, 
Milford, MA, USA). The instrument was run using an Acquity® UPLC BEH shield RP18 
(1.7µm; 2.1x100mm) analytical column. A modified method for quantifying EFV, TDF and 
FTC to that proposed by Induri and co-workers (2016) was employed. 
 
7.2.6. Ultra Performance Liquid Chromatography Parameters 
Optimized conditions involved utilizing gradient elution conditions (Table 7.1) at 0.4mL/min 
flow rate and room temperature. Mobile Phase A (MPA) consisted of orthophosphoric acid in 
deionized water (0.1%) while Mobile Phase B (MPB) was 100% HPLC grade acetonitrile. 
Ultraviolet (UV) detection of all drugs and the internal standard, diclofenac sodium (DS), was 
optimal at a wavelength of 257nm. All samples were filtered through a 0.2µm filter (GHP 
Acrodisc® 13mm Syringe Filters, Pall Corporation, New York, USA) prior to insertion into a 
2mL ANSl48 vial. Injection volume was set at 10µL with a total run time of 3 minutes. 
 
Table 7.1: Ultra Performance Liquid Chromatography gradient elution conditions 
Elution time (min) Flow rate (mL/min) MPA (%) MPB (%) 
0.0 0.4 88 12 
0.8 0.4 15 85 
2.0 0.4 88 12 
3.0 0.4 88 12 
 
7.2.7. Preparation of Standard Calibration Curve and the Liquid-Liquid Extraction 
Process 
Standard solutions in drug-free porcine blood plasma were prepared from the stock solution 
of EFV/TDF/FTC (30mg/15mg/10mg in 100mL diluent). The diluent comprised of 70% MPA 
and 30% MPB. The plasma (0.49mL) was spiked with the standard drug solution (0.01mL) 
as well DS (0.01mL of 0.03mg/mL) before mixing with the aid of a vortex for 2 minutes. 
EFV/TDF/FTC were extracted from the blood plasma prior sample injection by adding 0.5ml 
of hexane : ethyl acetate (1:1) to an equal volume of plasma (Avery 2010). This was 
centrifuged for 3 minutes at 3000rpm. The top layer was allowed to dry before reconstitution 
with methanol (0.5ml) and this was centrifuged for another 3 minutes. A standard curve was 
obtained by plotting area under the curve (AUCdrug/AUCDS) against the specific 
concentration. The extraction method was validated by comparing the peak areas of a 
known drug concentration spiked in blank plasma (AUCplasma) with the area of the same 
concentration of standard solution (AUCstandard). Equation 7.1 was employed for the 
percentage extraction calculation (Rezk et al., 2005). 
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% 𝐸𝑥𝑡𝑟𝑎𝑐𝑡𝑖𝑜𝑛 =  
𝐴𝑈𝐶𝑝𝑙𝑎𝑠𝑚𝑎
𝐴𝑈𝐶𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑
 𝑥 100 
                  Equation 7.1 
The same procedure was followed for assessment of plasma drug concentration during the 
in vivo study. 
 
7.2.8. Determination of the pharmacokinetic profiles of drugs and 3DP CRTT IVIVC 
A Microsoft Excel add-in program written in Visual Basic for Applications (VBA), PKSolver, 
was employed to conduct pharmacokinetic analysis of the release profiles (Zhang et al., 
2010). Since the system under investigation was an oral one, compartmental analysis was 
undertaken and appropriate parameters obtained.  
 
To further optimize the FDC, WinNonLin® software (V5.3 with IVIVC Toolkit Build 
20091211139, Pharsight Software, Statistical Consultants Inc., Apex, NC, USA) was 
instituted to predict in vitro-in vivo correlation (IVIVC) of the in vitro and in vivo release data 
from all drugs. A Level A IVIVC is a mathematical model that establishes a point to point 
correlation of the in vitro dissolution and in vivo plasma drug concentration. IVIVC was 
determined by using the deconvolution and convolution processes. With deconvolution, the 
Wagner-Nelson (Wang and Nedelman, 2002) method is employed to detect an approximate 
amount of drug absorbed which together with the concentration of drug dissolved is used to 
develop the appropriate IVIVC model. The convolution method is then implemented to 
convolve the predicted amount of drug absorbed to the predicted plasma drug 
concentrations.  
 
7.3. RESULTS AND DISCUSSION 
7.3.1. Post-surgical and post-gavage evaluation of pigs 
All pigs were monitored during recovery from anaesthesia which was administered for both 
the jugular catheter insertion as well as the gastric administration of the tablets.  
Administration of both CRTT and Atripla® resulted in good recovery and resumption of 
normal activities in the pigs. No major adverse effects were observed besides the pigs 
becoming lethargic at 4 hours after administration of Atripla® tablets. This lasted for about 1 
hour after which they behaved normally. Blood sampling was successful without any sign of 
distress from the pigs. 
 
7.3.2. In vivo drug release profiles of 3DP CRTT and Atripla® 
EFV, TDF, FTC and the internal standard (DS) were eluted within 3 minutes and their 
retention times were 1.709min (EFV), 1.513min (TDF), 0.977min (FTC) and 2.513 min (DS) 
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(2.513 min) (Figure 7.4). Validation of the extraction process revealed that all the analytes 
had a percentage extraction above 80% (84.46% EFV, 93.79% TDF and 97% FTC). The use 
of methanol resulted in higher percentage extraction through the liquid-liquid extraction 
process compared to acetonitrile. 
 
 
Figure 7.4: Representative chromatogram of stock solution showing the UPLC detection and 
selectivity of EFV, TDF, FTC and DS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 141 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.5: Calibration curves for (a) EFV, (a) TDF and (c)FTC 
 
The plasma drug release profiles for CRTT and Atripla® are depicted in Figure 7.6. The 
maximum plasma drug concentrations (Cmax) for all drugs were reached after 6 hours, in 
CRTT. The lethargy that exerted inaction in the pigs 4 hours after Atripla® administration 
was likely due to the faster release of EFV, TDF and FTC. The Cmax recorded for EFV 
release from Atripla® exceeded the EFV Cmax from CRTT.  Slow release of EFV is beneficial 
given that the drug has a narrow therapeutic index and is associated with neuropsychiatric 
effects when plasma drug concentrations are increased. The therapeutic interval of EFV has 
been set at 1-4µg/mL (Ståhle et al., 2004) and the EFV plasma levels from CRTT were 
sustained within this index from 4-24 hours. CRTT successfully increased the bioavailability 
of TDF and FTC both of which had higher Cmax values than the same drugs in Atripla®. The 
CRTT release profiles suggested that drug release occurred mostly in the intestines 
regardless of the Biopharmaceutics Classification System (BCS) class of the drug. 
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Figure 7.6: In vivo  plasma drug concentrations for (a) EFV, (b) TDF and (c) FTC 
 
7.3.3. Evaluation of in vivo pharmacokinetics of EFV, TDF and FTC and their IVIVC 
analysis 
Modelling was conducted with the one compartmental algorithm with and without lag. 
Pharmacokinetics analysis revealed that release for EFV, TDF and FTC was best described 
by the one compartmental analysis with Tlag (Table 7.2, Table 7.3 and Table 7.4). This 
algorithm with the Tlag presented with the most favourable SE, SS, AIC and SC values for 
the optimized CRTT therefore providing a more accurate dose exposure-response 
relationship. The need for the absorption time lag emphasizes that the active pharmaceutical 
ingredients (APIs) are distributed in the systemic circulation after crossing the 
gastrointestinal barrier. For comparative purposes, one compartmental modelling with lag 
was also conducted for Atripla®. 
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Table 7.2: Efavirenz extravascular compartmental model with Tlag 
Parameter Units  Average value 
  CRTT Atripla® 
A  μg/mL 1.632 1.812 
Ka  1/h 0.223 1.053 
K10  1/h 0.009 0.043 
Tlag  h 1x10-6 0.000216 
t½ka  h 3.112 0.658 
t½k10  h 74.071 15.953 
V/F  (mg)/(μg/mL) 383.770 345.457 
CL/F  (mg)/(μg/mL)/h 3.591 15.010 
Tmax  h 14.854 3.158 
Cmax  μg/mL 1.361 1.514 
AUC 0-t  μg/mL*h 27.790 25.278 
AUC 0-inf  μg/mL*h 167.072 39.973 
AUMC  μg/mL*h2 18603.613 957.920 
MRT  h 111.351 23.964 
 Diagnostics  
R obs-pre  0.980 0.939 
SS  0.0813 0.287 
WSS  0.0813 0.287 
R2  0.992 0.980 
WR2  0.992 0.980 
SE  0.116 0.202 
AIC  -17.090 -5.748 
SC  -15.880 -4.156 
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Table 7.3: Tenofovir disoproxil fumarate extravascular compartmental model with Tlag 
Parameter Units  Average value 
  CRTT Atripla® 
A  μg/mL 1.451 102.443 
Ka  1/h 0.975 0.277 
K10  1/h 0.009 0.267 
Tlag  h 0.014 1x10-6 
t½ka  h 0.711 2.506 
t½k10  h 78.330 2.599 
V/F (mg)/(μg/mL) 417.241 81.441 
CL/F  (mg)/(μg/mL)/h 3.692 21.719 
Tmax h 4.879 3.682 
Cmax μg/mL 1.377 1.380 
AUC 0-t  μg/mL*h 29.891 13.659 
AUC 0-inf μg/mL*h 162.505 13.813 
AUMC μg/mL*h2 18530.713 101.730 
MRT h 114.032 7.365 
Diagnostics  
R obs-pre  0.945 0.883 
SS  0.232 0.718 
WSS  0.232 0.718 
R2  0.984 0.921 
WR2  0.984 0.921 
SE  0.182 0.320 
AIC  -8.094 4.350 
SC  -6.502 5.941 
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Table 7.4: Emtricitabine extravascular compartmental model with Tlag 
Parameter Units Average value 
  CRTT Atripla® 
A  μg/mL 18.471 19.978 
Ka 1/h 0.347 0.722 
K10  1/h 0.008 0.0472 
Tlag  h 1x10-6 1x10-6 
t½ka  h 1.996 0.960 
t½k10  h 83.295 14.687 
V/F (mg)/(μg/mL) 11.094 10.712 
CL/F (mg)/(μg/mL)/h 0.092 0.505 
Tmax  h 11.009 4.041 
Cmax μg/mL 16.450 15.430 
AUC 0-t μg/mL*h 348.658 259.273 
AUC 0-inf μg/mL*h 2166.431 395.649 
AUMC μg/mL*h2 266578.470 8930.989 
MRT h 123.050 22.573 
 Diagnostics  
R obs-pre  0.959 0.970 
SS  29.133 14.038 
WSS  29.133 14.038 
R2  0.983 0.990 
WR2  0.983 0.990 
SE  2.040 1.416 
AIC  45.091 37.059 
SC  46.682 38.651 
 
A: the zero time intercept associated with the Alpha phase (an initial phase of rapid decrease in 
plasma concentration due distribution) 
Ka: 1st order absorption rate constant 
K10: Elimination rate constant 
Tlag: Finite time taken for a drug to appear in systemic circulation following extravascular 
administration 
t½ka: Absorption half-life rate constant 
t½k10: Elimination half-life rate constants 
V/F: The volume of distribution of the absorbed fraction 
CL/F: The observed total body clearance for extravascular administration 
Tmax: Time at which the maximum concentration (Cmax) is observed 
Cmax: Maximum observed concentration occurring at Tmax 
AUC0-t: Area Under the Curve (AUC) from the dosing time to the last measurable concentration 
AUC0-inf: AUC from dosing time extrapolated to infinity 
AUMC: Area Under the Moment Curve 
MRT: Mean Residence Time is the average amount of time the drug remains in a compartment or 
system 
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3DP CRTT can be deemed capable of extending drug release over a prolonged period of 
time as indicated by the elevated MRT values for all drugs (111.351 hours for EFV, 114.032 
hours for TDF and 123.050 hours for FTC) and their respective lower elimination rate 
constants. Residence time values for Atripla® were 23.964 hours (EFV), 7.365 hours (TDF) 
and 22.573 hours (FTC). Consequently, there was a significant difference in the time taken 
to reach maximum plasma drug concentration (Tmax) in CRTT than in the comparator product 
(EFV=11.696 hours, TDF=1.197 hours and FTC=6.968 hours). The Tmax for EFV, TDF and 
FTC was higher in CRTT and these values were significantly higher than those recorded by 
Lamorde and co-workers (2012) for the same FDC. The CRTT maximum drug 
concentrations at Tmax (Cmax) were lower with the lipophilic drugs EFV and TDF and higher 
with FTC than for the same drugs in Atripla®. Overall, higher plasma drug concentrations 
were recorded for all drugs in CRTT than in Atripla® based on the AUC0-t and AUC0-inf values 
therefore implying superior therapeutic efficacy of CRTT. These results may be linked to the 
high swellability and solubility enhancing effects of CRTT with minimal tablet erosion.  
 
7.3.4. Assessment of IVIVC of EFV, TDF and FTC in CRTT 
Level A assessment of CRTT release profiles led to the development of a correlation 
between the in vitro and in vivo results. The results provided insight on the predictive 
accuracy of the in vitro drug release study employed. Deconvolution was achieved by using 
the Wagner Nelson method to calculate the concentration of the drugs absorbed using the 
linear trapezoidal rule (Figure 7.7). Although in vitro drug release studies were conducted in 
biologically relevant media, high sheer rates in physiological conditions are responsible for 
more rapid tablet disintegration (Mudie et al., 2010). These conditions cannot be accurately 
simulated during the in vitro dissolution. EFV and TDF reached maximum concentrations 
much later than was predicted from the in vitro studies. Both these APIs exhibit 
bioavailability limitations with EFV being poorly soluble (lipophilic) and TDF contains a 
diester derivative responsible for its lipophilicity, rendering it a poorly permeable drug. The 
lipophilicity of both EFV and TDF meant that these drugs were trapped in the hydrophobic 
core of amphiphilic HA of HA-PQ10 and this enhanced their dissolution and absorption 
across the intestinal membrane. Absorption of EFV and TDF was further improved when the 
pigs were fed leading to a higher amount of drug absorbed, compared to that recorded in the 
dissolution studies.  
 
TDF and FTC are subject to intracellular phosphorylation and this largely determines 
absorption of the drugs. Phosphorylation would take place in vivo therefore both TDF and 
FTC showed markedly higher concentrations than the maximum reached in vitro (Lamorde 
et al., 2012). The IVIVC results suggest that the in vitro test conducted resulted in a slower 
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initial drug release but reached the maximum concentration faster. After convolution, EFV 
release was best described using the correlation plot which yielded an 85.17% level of 
accuracy of correlation of the fraction of drug absorbed in relation to that released. TDF and 
FTC showed best correlation with the levy plot (percentage absorbed against percentage 
dissolution) with 87.32% and 96.96% accuracies respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.7: Predicted in vitro release profiles and mean observed in vivo CRTT drug release 
profiles of (a) EFV, (b) TDF and (c) FTC 
 
7.4. CONCLUDING REMARKS 
In vivo analysis of the drugs loaded in the 3DP FDC tablet confirmed successful controlled 
and targeted drug release mechanism from the delivery system. The system allowed for the 
delivery and simultaneous release of three drugs belonging to different BCS classes 
(EFV=class II, TDF=class III and FTC=class I). The maximum drug concentrations absorbed 
were superior in TDF and FTC compared to the release of the same drugs in Atripla®. 
Though EFV absorption from CRTT was lower, the release was sustained within the 
therapeutic index throughout the 24 hour test period. Administration of delivery systems 
capable of slowly releasing anti-HIV bioactives is commendable since it leads to the 
minimum side effects.  
 148 
 
7.5. REFERENCES 
 Induri, M., Mantripragada, B.R., Yejella, R.P., 2016. Development and validation of 
UPLC method for simultaneous estimation of Efavirenz and Lamivudine in 
pharmaceutical formulations. Journal of Applied Pharmaceutical Science, 6(03), 029-33. 
 Jensen-Waern, M., Andersson, M., Kruse, R., Nilsson, B., Larsson, R., Korsgren, O., 
Essén-Gustavsson, B., 2009. Effects of streptozotocin-induced diabetes in domestic pigs 
with focus on the amino acid metabolism. Laboratory Animals, 43(3), 249-54. 
 Jørgensen, H., Serena, A., Theil, P.K., Engberg, R.M., 2010. Surgical techniques for 
quantitative nutrient digestion and absorption studies in the pig. Livestock Science, 
133(1), 57-60. 
 Lamorde, M., Byakika-Kibwika, P., Tamale, W.S., Kiweewa, F., Ryan, M., Amara, A., 
Tjia, J., Back, D., Khoo, S., Boffito, M., Kityo, C., 2012. Effect of food on the steady-state 
pharmacokinetics of tenofovir and emtricitabine plus efavirenz in Ugandan adults. AIDS 
Research and Treatment.  
 Mudie, D.M., Amidon, G.L., Amidon, G.E., 2010. Physiological parameters for oral 
delivery and in vitro testing. Molecular Pharmaceutics, 7(5), 1388-405. 
 Pinti, M., Salomoni, P., Cossarizza, A., 2006. Anti-HIV drugs and the mitochondria. 
Biochimica et Biophysica Acta (BBA)-Bioenergetics, 1757(5), 700-7. 
 Rezk, N.L., Crutchley, R.D., Kashuba, A.D., 2005. Simultaneous quantification of 
emtricitabine and tenofovir in human plasma using high-performance liquid 
chromatography after solid phase extraction. Journal of Chromatography B, 822(1), 201-
8. 
 Siyawamwaya, M., Choonara, Y.E., Kumar, P., Kondiah, P.P.D., du Toit, L.C., Pillay, V., 
2016. A humic acid-polyquaternium-10 stoichiometric self-assembled fibrilla 
polyelectrolyte complex: Effect of pH on synthesis, characterization, and drug release. 
International Journal of Polymeric Material and Polymeric Biomaterials, 65(11), 550-60. 
 Ståhle, L., Moberg, L., Svensson, J.O., Sönnerborg, A., 2004. Efavirenz plasma 
concentrations in HIV-infected patients: inter-and intraindividual variability and clinical 
effects. Therapeutic Drug Monitoring, 26(3), 267-70. 
 Wang, Y., Nedelman, J., 2002. Bias in the Wagner-Nelson estimate of the fraction of 
drug absorbed. Pharmaceutical Research, 19(4), 470-476. 
 Yasuji, T., Kondo, H., Sako, K., 2012. The effect of food on the oral bioavailability of 
drugs: a review of current developments and pharmaceutical technologies for 
pharmacokinetic control. Therapeutic Delivery, 3(1), 81-90. 
 149 
 
 Zhang, Y., Huo, M., Zhou, J., Xie, S., 2010. PKSolver: An add-in program for 
pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Computer 
Methods and Programs in Biomedicine, 99(3), 306-14. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 150 
 
CHAPTER 8  
 
CONCLUSIONS, RECOMMENDATIONS AND FUTURE OUTLOOK 
  
8.1. CONCLUSIONS 
It is highly beneficial to design systems that not only enhance the effectiveness of bioactives, 
but also seeks to make the treatment plan successful by reducing the pill burden. Complex 
dosing regimens usually result in poor patient compliance leading to the onset of drug 
resistance. 
 
This study validated that complexation between humic acid and polyquaternium-10 is 
possible using the complexation-precipitation (C-P) technique yielding an amorphous 
polyelectrolyte complex. Drug loading with a BCS class II drug, EFV, was successfully 
achieved and the C-P method was extended to extrusion-spheronization (E-S) yielding 
impressive solubility, permeability and biocompatibility results which were preferable to those 
obtained from C-P. Similarly, encapsulation of RTV into the extruded and spheronized HA-
PQ10 produced spheroidal extrudates accompanied by solubility and permeability 
enhancement compared to the comparator product.  
 
The third technique implemented was 3DP of drug-loaded HA-PQ10 into an oral tablet with 
an extrusion-based Bioplotter®. With this technology, a higher drug loading (50%) was 
attained. Characterization of the EFV-loaded 3DP tablet revealed that the swelling and drug 
release kinetics of the 3DP tablet were superior to those synthesized by direct compression. 
The larger and more numerous pores on the 3DP tablet allowed sufficient fluid-matrix 
interaction which enhanced the wettability of the encapsulated drug. These differences were 
attributed to the differences in tableting techniques implemented thus rendering 3DP a 
cutting edge and promising technique for novel formulations.   
 
The optimal 3DP tablet was a fixed dose combination (FDC) of efavirenz (EFV), tenofovir 
(TDF) and emtricitabine (FTC) which swelled significantly in simulated intestinal fluid than 
gastric fluid. The pH responsiveness of the FDC was attributed to the presence of cellulose 
acetate phthalate (CAP). A versatile drug delivery system, capable of encapsulating and 
enhancing bioavailability of drugs from all BCS classes, was successfully 3D-Printed into a 
tablet with higher drug loading than the spheronized extrudates. In vivo studies further 
corroborated the potential for bioavailability enhancement from the FDC. EFV, TDF and FTC 
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were released in a sustained manner. TDF and FTC had higher plasma concentrations than 
the conventional FDC, Atripla®. 
  
3DP successfully minimized problems associated with lower drug loading, as well as drug 
and polymer wastage experienced with the benchtop extrusion process. The shape and size 
of the formulation could be predetermined and customized. Drug release properties were 
modified by changing the inner structure pattern to ‘enlarge’ the tablet porosity. The loading 
of EFV, TDF and FTC, which belong in different BCS classes, was successful with each 
drug exhibiting high intestinal absorption properties. 
 
8.2. RECOMMENDATIONS AND FUTURE OUTLOOK 
This thesis reports on how a pH responsive tablet was successfully fabricated from the novel 
HA-PQ10 PEC.  The 3D-Printed tablet from cost-effective and biocompatible materials gave 
impressive outcomes however minor improvements could be made following modifications to 
the system:  
 TDF and FTC had higher maximum drug concentrations reached than from the 
conventional, after more research, dose reduction could be considered. 
 The pig model provided gainful insight into the in vivo performance of the 3DP tablet, 
however, more analysis would need to be conducted in a human model to obtain 
accurate indications of how the system would work for anti-HIV drug administration. 
 The sludge for printing can be further modified to allow individual drugs to be printed 
in different layers whilst avoiding synthesis of sizable formulations. This would be 
beneficial in synthesizing FDCs of incompatible drugs, modifying their release 
kinetics. 
 The research reported in this thesis provides techniques that are applicable to other 
areas of drug delivery. The novel HA-PQ10 PEC can be applied for other drug 
delivery systems, other than the oral route due to swellability and maintenance of 
structural integrity subsequently prolonging their drug release profiles. 
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APPENDICES 
 
9.1. APPENDIX A 
9.1.1. Research Publications 
9.1.1.1. Review Paper 
Published in ISI rated journal (International Journal of Polymeric Materials and Polymeric 
Biomaterials) 
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9.1.1.2. Research Paper 1 
Published in ISI rated journal (International Journal of Polymeric Materials and Polymeric 
Biomaterials) 
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9.1.1.3. Research Paper 2 
Published in ISI rated journal (AAPS PharmSciTech) 
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9.2. APPENDIX B 
9.2.1. Abstracts of Research Outputs at Conference Proceedings 
 
9.2.1.1. The Academy of Pharmaceutical Sciences of the Pharmaceutical Society of 
South Africa (APSSA) Conference, Cedar Woods of Sandton, Conference Centre, 
Johannesburg, South Africa, 2015. (Poster Presentation). 
 
Humic acid/polyquaternium-10 novel stoichiometric self-assembled fibrous polyelectrolyte 
complex 
Margaret Siyawamwaya, Viness Pillay, Yahya E. Choonara, Pradeep Kumar, Pierre P.D 
Kondiah and Lisa C. Du Toit. 
Department of Pharmacy and Pharmacology, Faculty of Health Sciences, University of the 
Witwatersrand, 7 York Road, Parktown, 2193, Johannesburg, South Africa. 
 
The formation of a novel polyelectrolyte complex (PEC) between humic acid (HA) and 
polyquaternium-10 (PQ-10) was investigated and validated. The solution mixing method was utilized 
to investigate the impact of the formation of a PEC at pH 6.0, 7.0 and 8.0. The stoichiometric self-
assembly between the polymers occurred when 140 mg of HA reacted with 141 mg of PQ-10. 
Attenuated Total Reflectance-Fourier Transform Infrared (ATR-FTIR), powder X-ray diffraction (XRD), 
scanning electron microscopy (SEM), differential scanning calorimetry (DSC) and thermogravimetric 
analysis (TGA) were pertinent methods employed for characterization. The drug release potential of 
the complex was investigated after a drug falling in Biopharmaceutics Classification System (BCS) 
class II was loaded into the complexes. The complexation ability of the two polymers can be attributed 
to their complementary charges that facilitated spontaneous formation of the electrostatic bonds 
between amino groups in PQ-10 and carboxylic groups in HA leading to the formation of a self-
assembled “fibrilla” architecture. The % drug loading for the PECs at pH 6.0, 7.0 and 8.0 were 
23.91%, 14.27% and 11.9% respectively. The complex is applicable for the delivery of lipophilic drugs 
such as EFV through entrapping them in the hydrophobic core of HA. The study conclusively revealed 
that ionic interactions occurred between HA and PQ-10 leading to the formation of a new “fibrilla” 
complex that can be implemented for targeted drug release purposes.  
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9.2.1.2. The 7th Cross Faculty Post Graduate Symposium, University of the 
Witwatersrand, Johannesburg, South Africa, 2016. (Poster Presentation). 
 
Humic acid/polyquaternium-10 novel stoichiometric self-assembled fibrous polyelectrolyte 
complex: synthesis, characterization and drug release 
Margaret Siyawamwaya, Viness Pillay, Yahya E. Choonara, Pradeep Kumar, Pierre P.D 
Kondiah and Lisa C. Du Toit. 
Department of Pharmacy and Pharmacology, Faculty of Health Sciences, University of the 
Witwatersrand, 7 York Road, Parktown, 2193, Johannesburg, South Africa. 
 
The formation of a novel polyelectrolyte complex (PEC) between humic acid (HA) and 
polyquaternium-10 (PQ-10) was investigated and validated. The solution mixing method was utilized 
to investigate the formation of a PEC at pH 6.0, 7.0 and 8.0. The stoichiometric self-assembly 
between the polymers occurred when 140 mg of HA reacted with 141 mg of PQ-10. Attenuated Total 
Reflectance-Fourier Transform Infrared (ATR-FTIR), powder X-ray diffraction (XRD), scanning 
electron microscopy (SEM), differential scanning calorimetry (DSC) and thermogravimetric analysis 
(TGA) were pertinent methods employed for characterization. The drug release potential of the 
complex was investigated after a drug falling in Biopharmaceutics Classification System (BCS) class II 
was loaded into the complexes. The % drug loading for the PECs at pH 6.0, 7.0 and 8.0 were 
23.91%, 14.27% and 11.9% respectively. The study conclusively revealed that ionic interactions 
occurred between the HA and PQ-10 leading to the formation of a new “fibrilla” complex that can be 
utilized for the enhancement of bioavailability of drugs as well as for their targeted release purposes.  
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9.2.1.3. The Faculty of Health Sciences Research Day, University of the 
Witwatersrand, Johannesburg, South Africa, 2016. (Poster Presentation). 
 
The use of a novel polyelectrolyte complex to enhance the aqueous solubility of a BCS class 
II anti-HIV drug 
Margaret Siyawamwaya, Viness Pillay, Yahya E. Choonara, Pradeep Kumar, Pierre P.D 
Kondiah and Lisa C. Du Toit. 
Department of Pharmacy and Pharmacology, Faculty of Health Sciences, University of the 
Witwatersrand, 7 York Road, Parktown, 2193, Johannesburg, South Africa. 
 
Poor in vivo bioavailability of drugs in Biopharmaceutics Classification System (BCS) class II remains 
a cause for concern in anti-HIV therapy. It is imperative to enhance the bioavailability of these drugs 
in order to circumvent the need for large doses which leads to toxicity in the body. A novel 
polyelectrolyte complex was utilized to improve the solubility and therefore, the bioavailability, of a 
poorly water soluble anti-HIV drug, efavirenz, which has a bioavailability of 40-45%. Solid dispersions 
of the drug in the polyelectrolyte complex were synthesized. Characterization of the drug and 
polymeric complex were undertaken with the aid of Attenuated Total Reflectance-Fourier Transform 
Infrared (ATR-FTIR), scanning electron microscopy (SEM) and differential scanning calorimetry 
(DSC). Human colorectal adenocarcinoma (Caco2) cell line viability test was conducted to determine 
the biocompatibility of the system. Any cytotoxicity caused by the efavirenz loaded complex over the 
24 hour test period was measured and quantified. In order to determine any increase in solubility and 
therefore bioavailability of the drug entrapped in the complex, a saturation solubility study was carried 
out. The complexation ability of the two polymers was attributed to their complementary charges that 
resulted in the formation of the electrostatic bonds between the polymers. Efavirenz was successfully 
dispersed and entrapped in the polyelectrolyte complex. The study conclusively revealed that the 
solubility of efavirenz loaded into the optimized polyelectrolyte complex was superior by 14.16% to 
that of the comparator product tested in simulated human gastrointestinal fluid. 
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9.2.1.4. The International AAPS Annual Meeting and Exposition, Colorado Convention 
Centre, Denver, Colorado, USA, 2016. (Poster Presentation). 
 
3D Printing of a Novel Humic Acid and Polyquaternium-10 Polyelectrolyte Complex for Oral 
Controlled Drug Release Application 
Margaret Siyawamwaya, Viness Pillay, Yahya E. Choonara, Pradeep Kumar, Pierre P.D 
Kondiah and Lisa C. Du Toit. 
Department of Pharmacy and Pharmacology, Faculty of Health Sciences, University of the 
Witwatersrand, 7 York Road, Parktown, 2193, Johannesburg, South Africa. 
 
3D printing is revolutionizing the design of drug delivery systems. The purpose of this study was to 
utilize 3D printing to fabricate a novel humic acid-polyquaternium-10 polyelectrolyte complex (HA/PQ-
10 PEC) to increase the bioavailability of efavirenz. Optimal 3D printing parameters for the HA/PQ-10 
PEC were identified. By using the 3D Bioplotter®, the stability of the amorphous solid dispersion 
system and efavirenz loading was enhanced. The in vitro drug release properties could be altered by 
changing the porosity of the tablet via varying the printing design. 3D printing of the HA/PQ-10 PEC 
was achieved by initially allowing the native polymers to complex thus forming a printable sludge that 
was extruded from the low temperature sample holder of the 3D Bioplotter® (EnvisionTEC GmbH, 
Gladbeck, Germany). Microcrystalline cellulose (MCC) was added as a binder to the HA/PQ-10 PEC 
sludge to facilitate solidification after extrusion. Swelling of the PEC was evaluated by placing the pre-
weighed efavirenz tablets in 900mL of simulated intestinal fluid (SIF)(pH 6.8). 
The USP apparatus II paddle stirrer (Erweka DT 700, Erweka GmbH, Heusenstamm, Germany) 
(50rpm) was utilized and temperature was maintained at 37°C. Tablets were reweighed periodically 
over 24 hours to determine the extent of swelling. Other pertinent tests undertaken included 
measurement of the viscosity of the optimal printable sludge by rheological analysis (ThermoHaake 
MARS Modular Advanced Rheometer, Thermo Electron, Karlsruhe, Germany). The mechanical 
strength of the 3D printed tablets was measured using a BioTester 5000 test system (CellScale 
Biomaterials Testing, ON, Canada). Drug release studies were conducted to further corroborate the 
controlled release properties of the drug-loaded 3D printed HA/PQ-10 PEC. The HA/PQ-10 PEC was 
successfully printed in 3D at 25ºC. Suitable operation parameters were a speed of 20mm/s and a 
pressure of 2.5 bars. It was pertinent to first form a highly viscous sludge of the PQ-10 before adding 
the HA powder. Complexation occurred immediately. The tablet swelled in SIF to a maximum of 
353.3% after 4 hours and the swelling slowly decreased over the 24 hour test period. Rheological 
studies revealed an elevated viscosity of the PEC sludge (45 950mPa.s) compared to that for the 
initial PQ-10 paste (2904mPa.s). This increase in viscosity was attributed to the HA/PQ-10 electro-
association leading to complexation. These results validate the potential of the drug delivery system 
to control drug release over 24 hours The results obtained indicate that the novel HA/PQ-10 PEC can 
undergo 3D printing with potential for application in controlled drug release systems. Findings of this 
study also suggest that highly soluble drugs from BCS class I and III may also be loaded into the 
HA/PQ-10 PEC for controlled release due to the synthesis of a swellable system. 
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9.3. APPENDIX C 
9.3.1. Animal Ethics Approval 
 
